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A B S T R A C T
Background
Tuberculous meningitis (TBM) is the main form of tuberculosis that affects the central nervous system and is associated with high
rates of death and disability. Most international guidelines recommend longer antituberculous treatment (ATT) regimens for TBM
than for pulmonary tuberculosis disease to prevent relapse. However, longer regimens are associated with poor adherence, which could
contribute to increased relapse, development of drug resistance, and increased costs to patients and healthcare systems.
Objectives
To compare the effects of short-course (six months) regimens versus prolonged-course regimens for people with tuberculous meningitis
(TBM).
Search methods
We searched the following databases up to 31 March 2016: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane
Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; EMBASE; LILACS; INDMED;
and the South Asian Database of Controlled Clinical Trials. We searched the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) and ClinicalTrials.gov for ongoing trials. We also checked article reference lists and contacted
researchers in the field.
Selection criteria
We included randomized controlled trials (RCTs) and prospective cohort studies of adults and children with TBM treated with
antituberculous regimens that included rifampicin for six months or longer than six months. The primary outcome was relapse, and
included studies required a minimum of six months follow-up after completion of treatment.
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Data collection and analysis
Two review authors (SJ and HR) independently assessed the literature search results for eligibility, and performed data extraction and
’Risk of bias’ assessments of the included studies. We contacted study authors for additional information when necessary. Most data
came from single arm cohort studies without a direct comparison so we pooled the findings for each group of cohorts and presented them
separately using a complete-case analysis. We assessed the quality of the evidence narratively, as using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach was inappropriate with no direct comparisons between short- and
prolonged-course regimens.
Main results
Four RCTs and 12 prospective cohort studies met our inclusion criteria, and included a total of 1881 participants with TBM. None of
the included RCTs directly compared six months versus longer regimens, so we analysed all data as individual cohorts to obtain relapse
rates in each set of cohorts.
We included seven cohorts of participants treated for six months, with a total of 458 participants. Three studies were conducted in
Thailand, two in South Africa, and one each in Ecuador and Papua New Guinea between the 1980s and 2009. We included 12 cohorts
of participants treated for longer than six months (ranging from eight to 16 months), with a total of 1423 participants. Four studies
were conducted in India, three in Thailand and one each in China, South Africa, Romania, Turkey and Vietnam, between the late
1970s and 2011.
The proportion of participants classified as having stage III disease (severe) was higher in the cohorts treated for six months (33.2%
versus 16.9%), but the proportion with known concurrent HIV was higher in the cohorts treated for longer (0/458 versus 122/1423).
Although there were variations in the treatment regimens, most cohorts received isoniazid, rifampicin, and pyrazinamide during the
intensive phase.
Investigators achieved follow-up beyond 18 months after completing treatment in three out of the seven cohorts treated for six months,
and five out of the 12 cohorts treated for eight to 16 months. All studies had potential sources of bias in their estimation of the relapse
rate, and comparisons between the cohorts could be confounded.
Relapse was an uncommon event across both groups of cohorts (3/369 (0.8%) with six months treatment versus 7/915 (0.8%) with
longer), with only one death attributed to relapse in each group.
Overall, the proportion of participants who died was higher in the cohorts treated for longer than six months (447/1423 (31.4%)
versus 58/458 (12.7%)). However, most deaths occurred during the first six months in both treatment cohorts, which suggested that
the difference in death rate was not directly related to duration of ATT but was due to confounding. Clinical cure was higher in the
group of cohorts treated for six months (408/458 (89.1%) versus longer than six months (984/1336 (73.7%)), consistent with the
observations for deaths.
Few participants defaulted from treatment with six months treatment (4/370 (1.1%)) versus longer treatment (8/355 (2.3%)), and
adherence was not well reported.
Authors’ conclusions
In all cohorts most deaths occurred in the first six months; and relapse was uncommon in all participants irrespective of the regimen.
Further inferences are probably inappropriate given this is observational data and confounding is likely. These data are almost all from
participants who are HIV-negative, and thus the inferences will not apply to the efficacy and safety of the six months regimens in HIV-
positive people. Well-designed RCTs, or large prospective cohort studies, comparing six months with longer treatment regimens with
long follow-up periods established at initiation of ATT are needed to resolve the uncertainty regarding the safety and efficacy of six
months regimens for TBM.
P L A I N L A N G U A G E S U M M A R Y
Six months therapy for patients with tuberculous meningitis
What is tuberculous meningitis and why is the duration of treatment important?
Tuberculous meningitis (TBM) is a severe form of tuberculosis, which affects the membranes that cover the brain and spine. It is
associated with high rates of death and disability. While there are standardized international recommendations for treating people
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with pulmonary tuberculosis (tuberculosis of the lungs) for six months with antituberculous therapy, there is a wide range of differing
recommendations and practices for treating people with TBM worldwide. Some specialists recommend nine months, 12 months, or
even longer treatment for TBM in order to prevent relapse of the disease. Longer regimens have potential disadvantages: they are
associated with poor adherence to treatment, which could contribute to increased relapse and development of drug resistance; and
increased costs to patients and healthcare systems.
What the evidence shows
This Cochrane review assessed the effects of six months regimens for treating people with TBM, compared with longer regimens.
Cochrane researchers examined the available evidence up to 31 March 2016. They did not find any trial that directly compared people
with TBM treated for six months with people with TBM treated for longer. They included seven studies with 458 participants that
evaluated six months of treatment, and 12 studies with 1423 participants that evaluated longer treatment. Although the treatment
regimens in the included studies varied, most participants received standard first-line antituberculous drugs, and were followed up for
more than a year after the end of treatment. The studies included adults and children with TBM, but few participants were HIV-
positive.
Relapse was an uncommon event across both groups of studies, with only one death attributed to relapse in each group. Most deaths
occurred during the first six months of treatment in both groups of studies, which showed that treatment duration did not have a direct
impact on the risk of death in these studies. There was a higher death rate in participants treated for longer than six months, and this
probably reflects the differences between the participants in the two groups of studies. Few participants defaulted from treatment, and
adherence was not clearly documented.
They found no evidence of high relapse rates in people treated for six months, and relapse was uncommon in all patients irrespective
of regimen. There may be differences between the participants treated for six months and longer than six months that could have led
to bias (confounding factors), so further research would help determine if shorter regimens are safe. Most of the data were in patients
without HIV, and so these inferences do not apply to patients who are HIV-positive.
B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is caused by infection with one of several my-
cobacterial species that belong to the Mycobacterium tuberculosis
complex. TB is estimated to be the leading infectious cause of
death worldwide alongside HIV, and approximately one-third of
the world’s population is thought to have latent TB. TB is as-
sociated with poverty. Low- and middle-income countries carry
the greatest burden of the disease, and more than three-quarters
of cases are reported in South-East Asia, the Western Pacific, and
Africa (WHO 2015). Tuberculous meningitis (TBM) is a severe
form of TB, which affects the meninges that cover the brain and
spine. TBM is themain form of TB that affects the central nervous
system (CNS), which accounts for approximately 1% of all cases
of active TB, and 5% to 10% of extrapulmonary TB cases (TB
involving organs other than the lungs) (Thwaites 2009; Török
2015). TBM prevalence is higher in populations with high over-
all TB prevalence. The World Health Organization (WHO) re-
ported 0.8 million new extrapulmonary TB cases worldwide in
2013 out of 5.4 million people with a first episode of TB (WHO
2014). TBMmainly affects children and immunosuppressed peo-
ple (Principi 2012).
TBM is a major contributor to the death and disability associated
with TB. Death occurs in around 30% of people with TBM and
50% of people who survive TBM suffer from neurological deficits
that cause disability despite antituberculous treatment (ATT) (
Principi 2012). Early diagnosis and prompt treatment with ATT
and corticosteroids are themain determinants of outcome in TBM
(Prasad 2016; Thwaites 2013).
TBM is diagnosed clinically by recognition of meningitis together
with findings suggestive of M. tuberculosis infection (Principi
2012). A “bacteriologically confirmed TBM case” implies confir-
mation of the diagnosis by identification of M. tuberculosis in the
person’s cerebrospinal fluid (CSF) by microscopy, cell culture, or
molecular methods. A case diagnosed as TBM by a health worker
without laboratory confirmation is defined as a “clinically diag-
nosed TBM case” (WHO 2013). The disease severity at presenta-
tion is classified into three stages according to the British Medical
Research Council (MRC) (MRC 1948), based on the Glasgow
Coma Scale (GCS) (Teasdale 1974) and neurological signs.
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• Stage I: non-specific signs and symptoms but no
neurological focal signs and GCS of 15.
• Stage II: minor neurological focal signs such as cranial nerve
palsies or GCS of 11 to 14.
• Stage III: severe neurological deficits such as paresis or GCS
equal to or less than 10.
Such classification facilitates comparison between findings from
different studies and is useful to predict prognosis.
Description of the intervention
Without treatment, TBMleads to death.To effectively treat people
with TBM, ATT must eliminate active TB bacilli to prevent neu-
rological sequelae and death, eliminate dormant bacilli to prevent
relapse, and prevent the emergence of drug resistance (Woodfield
2008). In contrast to pulmonary TB, there are no standardized
international recommendations for treating people with TBM.
There is a wide range of differing recommendations and practices
for treating people with TBM worldwide (Appendix 1). This is
partly due to the limited existing evidence regarding the optimal
choice and dose of antituberculous drugs, as well as the most ap-
propriate duration of treatment for people with TBM. Most data
on treating TBM have been extrapolated from pulmonary TB
(Heemskerk 2011).
Regarding treatment duration, two main concerns have led to the
perception that treatment longer than the six months regimen for
pulmonary TB is needed for people with TBM to ensure microbi-
ological cure and prevent relapse. Firstly, the blood-brain barrier
hinders the penetration of antituberculous drugs to reach adequate
drug concentration in the infected site, meaning that it may take
longer to eradicate viable bacilli in the person’s CNS (Thwaites
2013). The second argument concerns relapse rates. In 2013, 0.3
million cases of TB relapse after previous cure of the disease were
reported (WHO 2014). Although relapse rates of 5% are generally
considered acceptable for pulmonary TB regimens, this may not
be the case for TBM, in which relapse can lead to severe neurodis-
ability and death (Donald 2010a). Furthermore, reliable parame-
ters for monitoring response to treatment in TBM are lacking, in
contrast to pulmonary TB where sputum microscopy and culture
are used. Consequently, some specialists recommend 12 months
treatment for drug-sensitive TBM, consisting of a two months in-
tensive phase with isoniazid, rifampicin, pyrazinamide, and either
ethambutol or streptomycin, followed by a 10 months continua-
tion phase with isoniazid and rifampicin (Török 2015).
All international guidelines, including the WHO guidelines
(WHO 2010a), recommend the use of isoniazid, rifampicin, and
pyrazinamide, usually with a fourth drug such as ethambutol or
streptomycin, as first-line antituberculous drugs in people with
TBM. Isoniazid is highly active against rapidly replicating my-
cobacteria and has good CSF penetration. Rifampicin kills both
rapidly replicating and slow or non-replicating bacilli, while pyraz-
inamide has strong bactericidal effect against intracellular my-
cobacteria. Thus, both rifampicin and pyrazinamide are critical
drugs to sterilize lesions by killing dormant bacteria and those in
remote sites such as the CSF, which is essential to reduce the risk
of relapse (Donald 2010b; Thwaites 2005a). The introduction
of rifampicin allowed the shortening of pulmonary TB treatment
(Zumla 2014). Although rifampicin has poor CSF penetration,
its importance in TBM treatment has being emphasized in a trial
in which mortality rate was higher among participants with ri-
fampicin-resistant TBM (Thwaites 2005b).
How the intervention might work
There is uncertainty about the effectiveness of short-course regi-
mens of sixmonths ATT in people with TBM. Some study authors
report that six months were adequate for treating TBM (Donald
1998; van Toorn 2014), while prolonged regimens have disad-
vantages. Prolonged regimens may increase the risk of drug-re-
lated adverse events and are associated with poor adherence to
treatment and default. Poor adherence increases the risk of re-
lapse leading to potential neurological disability and death, and
facilitates the development of drug-resistant bacterial strains (van
Loenhout-Rooyackers 2001). Finally, long regimens lead to greater
expenditure of resources and greater workload for TB control pro-
grammes. Short-course regimens may not be long enough to elim-
inate dormant bacilli from the CNS, and may lead to higher re-
lapse rates. Higher relapse rates may increase neurodisability and
death after completion of ATT (Figure 1).
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Figure 1. Possible disadvantages of prolonged and short-course antituberculous regimens for treating
people with TBM.
Relapse is the most daunting possible consequence of using short
treatment regimens. There is uncertainty around the lag time be-
tween completion of treatment and relapse. However, most re-
lapses seem to occur within the first six months after completing
ATT (Jullien 2015). Thus, at least six months of follow-up are re-
quired to adequately assess this outcome, and longer follow-up pe-
riods are desirable for detecting all cases of relapse. Defaulters may
be at increased risk of relapse due to inadequate dosing with ATT,
particularly during the intensive phase of treatment, although di-
rect evidence for this association is lacking in people with TBM
(Conde 2009). The number of deaths and neurological deficits
are reduced by early diagnosis and prompt ATT. Indeed, most of
the deaths associated with TBM will occur during the first weeks
of disease (Yarami 1998). In preliminary work for this Cochrane
Review, Jullien 2015 attributed deaths occurring after six months
of treatment mainly to complications of TBM and comorbidity,
such as secondary infection. Few deaths were associated with re-
lapse. Finally, longer regimens expose patients to the risk of adverse
effects of antituberculous drugs for longer.
Why it is important to do this review
Themost appropriate duration of treatment for people with TBM
is uncertain. Although several studies have reported safe outcomes
in adults and children with TBM treated with six months regi-
mens (Donald 1998; van Toorn 2014), there are concerns about
whether six months regimens would be sufficient to sterilize CSF
and thus prevent relapse. Most international guidelines recom-
mend prolonged-course ATT of nine to 12 months for people
with drug-sensitive TBM. In practice, more than four antituber-
culous drugs are sometimes used, and regimens may be prolonged
up to 24 months for fear of relapse. Treatment is also prolonged in
people for whom supervision and follow-up are doubtful (Principi
2012). On the one hand, TBM treatment duration must be long
enough to eliminate dormant bacilli to prevent relapse. On the
other hand, treatment should be as short as possible to avoid dis-
advantages related to prolonged regimens. Reducing the duration
of TBM therapy from prolonged-course regimens to short-course
regimens could have several benefits, including reduced drug toxi-
city and improved adherence to treatment, with fewer consequent
relapses and lower risk of developing drug-resistant strains. Addi-
tionally, short-course regimens would reduce the use of resources
and workloads in TB control programmes, which are often over-
burdened in settings where TB incidence is high (Conde 2009;
van Loenhout-Rooyackers 2001).
A study that reviewed treatment duration for people with TBM by
comparing case series of adults and children, showed similar com-
pletion and relapse rates between six months regimens including
at least isoniazid, rifampicin, and pyrazinamide and longer regi-
mens (van Loenhout-Rooyackers 2001). In this review, we have
included more recent studies, and performed ’Risk of bias’ assess-
ments and appraised the quality of the evidence.
This review was prompted as part of work with the Central TB
Division, Ministry of Health and Family Welfare in India, and
the All India Institute of Medical Sciences in New Delhi in prepa-
ration for the Indian Extra-Pulmonary TB (INDEX-TB) guide-
lines (INDEX-TB 2016). There was uncertainty and debate as to
whether six to nine months of treatment is as safe as longer regi-
mens for treating people with TBM (Jullien 2015), with varying
views on what the literature showed. As we knew there were no
randomized controlled trials (RCTs), we sought to summarize and
critically appraise evidence from observational studies. The initial
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systematic review found several observational studies that reported
low numbers of relapse with short regimens, but did not include
all the available evidence for longer regimens. In this Cochrane
Review, we examined the effects of six months (short-course) and
longer than sixmonths (prolonged-course) regimens onTBMout-
comes.
O B J E C T I V E S
To compare the effects of short-course (six months) regimens
versus prolonged-course regimens for people with tuberculous
meningitis (TBM).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), quasi-RCTs, and prospec-
tive cohort studies. As our preliminary work (Jullien 2015) sug-
gested a lack of studies that directly compared short-course and
prolonged-course treatment, we included prospective cohort stud-
ies in which all participants were treated with the same duration
of antituberculous treatment (ATT).
Types of participants
Adults and children with a diagnosis of presumed drug sensitive
tuberculous meningitis (TBM) as defined by the study authors,
from all settings and countries.
Types of interventions
Short-course regimens
ATT regimens of six months that included rifampicin.
Prolonged-course regimens
ATT regimens of more than six months that included rifampicin.
Types of outcome measures
Primary outcomes
• Relapse: the number of participants in each treatment
group who had new symptoms and signs of TBM after resolution
of disease and completion of ATT. We included studies with a
minimum of six months follow-up after completion of ATTa .
Secondary outcomes
• Death from any cause.
• Death after six months of ATT. We were interested in this
outcome in order to discriminate the number of deaths that may
have been related to duration of treatment.
• Clinical cure: the number of participants in each treatment
group who completed treatment according to the original
treatment plan without evidence of treatment failure at the end
of treatment (WHO 2013)b.
• Default: the number of participants in each treatment
group who discontinued ATT before the end of treatment, or
participants whose treatment was interrupted for eight weeks or
more consecutively (WHO 2013).
• Poor adherence: the number of participants in each
treatment group who did not adhere to the prescribed treatment
regimen, as reported by study authors, but who did not meet the
definition of default given above.
aLong follow-up periods are required to reliably detect all cases
of relapse. We chose to include studies with a minimum of six
months follow-up as we considered studies with shorter follow-up
periods would be likely to miss cases of relapse.
bThe World Health Organization (WHO)’s definitions for TB
outcomes are primarily based on the assessment of pulmonary TB
patients, so sputum smear and culture status are important fac-
tors in defining outcomes. Generally, repeating cerebrospinal fluid
(CSF) sampling and culture at the end of ATT in TBM partici-
pants is not done routinely, therefore CSF smear/culture status is
not part of the definition of cure or successful treatment in prac-
tice. Our definition of ’clinical cure’ is broadly equivalent to the
definition of ’treatment completed’ in the WHO’s nomenclature.
We considered the outcomes for this Cochrane Review carefully.
Although treatment failure is an important outcome in TBM,
there is currently no accepted definition of TBM treatment failure.
In this review, we defined treatment failure as referring to partici-
pants who failed to improve with ATT, or deteriorated following
initial improvement while on ATT. Importantly, this definition
excluded participants who deteriorate after completing ATT; we
classified these participants as relapses for the purposes of this re-
view. In our preliminary work for the TB-INDEX guidelines, we
included treatment failure as a secondary outcome (INDEX-TB
2016; Jullien 2015).During thiswork, it became apparent that this
outcome was not directly related to the duration of treatment, as
by definition it can occur at any point during ATT. Furthermore,
treatment failure was not well defined or described in many of the
included studies, was not reported consistently, and participants
were described as having treatment failure usually received longer
treatment. Thus, we decided not to include treatment failure as
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a primary or secondary outcome in this review, although we did
provide the information in the ’Results’ section for completeness.
For our inclusion criteria, we also considered length of follow-up
carefully. Long follow-up periods are required to reliably detect all
cases of relapse. Therefore, we excluded studies with short follow-
up to limit detection bias, as this could lead to underestimation
of the number of relapses, which was the primary outcome of this
review.
Adverse events
• All adverse effects related to the ATT.
• Drug toxicity leading to the discontinuation or
modification of the treatment regimen
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and on-
going).
Electronic searches
We searched the following databases for relevant studies us-
ing the search terms and strategy detailed in Appendix 2: the
Cochrane Infectious Diseases Group (CIDG) Specialized Regis-
ter; the Cochrane Central Register of Controlled Trials (CEN-
TRAL), published in the Cochrane Library issue 3 2016; MED-
LINE (Pubmed, 1966 to 31 March 2016); EMBASE (OVID,
1980 to 31March 2016); LILACS (1982 to 31March 2016); IN-
DMED (http://indmed.nic.in/, 31 March 2016); and the South
Asian Database of Controlled Clinical Trials. We also searched the
WHO International Clinical Trials Registry Platform (ICTRP;
http://www.who.int/ictrp/en/) and ClinicalTrials.gov for ongoing
trials (both accessed on 31 March 2016).
Searching other resources
We checked the reference lists of all studies identified by the above
methods for other potentially relevant studies. We contacted re-
searchers at the National Institute for Research in Tuberculosis,
Chennai, to identify unpublished studies (grey literature).
Data collection and analysis
Selection of studies
Two review authors (SJ and HR) independently screened the titles
and abstracts of the studies identified by the literature searches to
identify studies that met eligibility criteria, and removed duplicate
reports. We retrieved the full-text articles of the studies we iden-
tified as potentially eligible. SJ and HR independently assessed
the full-text articles for study eligibility using an eligibility form
based on the predefined inclusion and exclusion criteria, and re-
solved any disagreements by discussion. Where eligibility was un-
clear we attempted to contact the study authors for clarification.
We excluded studies that did not meet the inclusion criteria and
listed them and their reasons for exclusion in the ’Characteristics
of excluded studies’ table. We constructed a study flow diagram
to illustrate this process.
Data extraction and management
One review author (SJ) piloted the data extraction form on two
studies. Based on the results of the pilot, wemodified and finalized
the data extraction form. Two review authors (SJ and HR) inde-
pendently extracted data from the included studies according to
the agreed data extraction tool. We compared the data extracted
by the two review authors to identify any possible errors. We re-
solved any discrepancies through discussion and by referring to
the original articles. We extracted the following data.
• Country, when the study was conducted, study design,
inclusion and exclusion criteria applied, and the number of
participants recruited.
• Participant characteristics: age, gender, epidemiological data
such as known contact with TB patient, duration of symptoms
at presentation, clinical severity of the disease according to the
British Medical Research Council (MRC) scale, comorbidity
(HIV, other immunosuppression disease and other diseases), and
diagnostic methods used (for example, CSF testing,
neuroimaging, chest X-ray, purified protein derivative (PPD)
skin test) along with number of bacteriologically confirmed and
clinically-diagnosed TBM cases.
• Intervention data: description of drugs, dose, route of
administration in both the intensive and continuation phase,
and duration of ATT for both phases. Administration of other
drugs or therapeutic procedures.
• Outcome data.
For the primary outcome we extracted the following data.
• Relapse:
◦ number of relapse cases, stratified by age and HIV
status, if available;
◦ clinical severity of relapse;
◦ clinical severity at original diagnosis;
◦ method of diagnosing relapse;
◦ time between end of treatment and relapse.
For the secondary outcomes we extracted the following data.
• Death from any cause:
◦ number of deaths, stratified by clinical severity, age,
HIV status, if available.
• Death after six months of ATT treatment:
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◦ number of deaths after six months, stratified by
clinical severity, age and HIV status if available;
◦ time from start of ATT until death;
◦ cause of death, if specified.
• Clinical cure:
◦ number of cases cured at end of treatment;
◦ number of cases cured stratified by clinical severity,
age, HIV status if available.
• Default:
◦ number of defaulters, stratified by clinical severity, age
and HIV status if available;
◦ method of monitoring adherence during treatment
(clinical history, direct observation, tablet counting).
• Poor adherence:
◦ number of participants not receiving prescribed ATT
regimen but not meeting the definition of default;
◦ method of monitoring adherence during treatment
(clinical history, direct observation, tablet counting).
In addition, we extracted data on treatment failure (number of par-
ticipants in each treatment group who failed to improve with ATT,
or deteriorated following initial improvement while on ATT), on
neurological sequelae (number of participants in each treatment
group with neurological sequelae as described by the original study
authors), and on follow-up (length of follow-up after complet-
ing ATT, the way participants were followed-up, and number and
characteristics of losses to follow-up).
For each established outcome, we extracted the number of par-
ticipants assigned and the numbers analysed in each treatment
group. For dichotomous outcomes, we extracted the number of
participants experiencing the event. For count data outcomes, we
extracted the number of events in the intervention and control
group. From our preliminary work, we knew that relapse and de-
fault are relatively uncommon. Therefore we did not attempt a
time-to-event analysis for these outcomes as the results are likely
to be misleading.
For the purposes of analysis in this review, we categorized treat-
ment groups to six months or more than six months based on the
duration of treatment they were scheduled to receive.
Assessment of risk of bias in included studies
Based on our preliminary work, we anticipated there would be
no studies with a direct comparison between short and prolonged
ATT.We treated the included studies as observational cohort stud-
ies for the purpose of analysis in our review. The Cochrane ’Risk
of bias’ assessment tool, Higgins 2011, and the Downs and Black
checklist for assessment of methodological quality, Downs 1998,
are inadequate to assess the quality of single-arm observational co-
hort studies. Therefore, we devised a ’Risk of bias’ assessment tool
to appraise the reliability of the outcome data from each study,
based on the domains included in the ’Risk Of Bias In Non-
randomized Studies - of Interventions’ (ROBINS-I) tool (Sterne
2016), which applies to non-randomized, observational cohort
studies. As no direct comparison is made between cohorts treated
with six and more than six months of ATT, we did not assess
participant selection and allocation. At least two review authors
independently assessed each included study for potential sources
of bias that could have affected the reliability of the outcome data,
and resolved any discrepancy through discussion. We classified our
judgments as either low, high, or unclear risk of bias based on the
following criteria.
• Detection bias for outcomes that occurred during the
follow-up period, after completing ATT (relapse, death after six
months of ATT):
◦ low risk: the study authors attempted to see all
participants (for example, by giving them a clinic appointment, a
telephone call, or home visit) at least once at 18 months of
follow-up after the end of ATT or beyond;
◦ unclear risk: poorly described method of follow-up, or
follow-up between six and 18 months;
◦ high risk: passive follow-up or follow-up with for less
than six months.
• Detection bias for outcomes that occurred during ATT
(death, clinical cure, default, adherence to treatment):
◦ low risk: all participants had clear methods of follow-
up during ATT, through regular visits, hospital-based treatment
or Directly Observed Therapy (DOT) programmes;
◦ unclear risk: unclear method of follow-up during ATT;
◦ high risk: passive follow-up, not hospital-based.
• Attrition bias for outcomes occurring during the follow-up
period, after completing ATT (relapse, death after six months of
ATT):
◦ low risk: less than 5% of participants lost to follow-up
at the end of the follow-up period;
◦ unclear risk: between 5 and 10% of participants lost to
follow-up at the end of the follow-up period;
◦ high risk: more than 10% of participants lost to
follow-up at the end of the follow-up period.
• Attrition bias for outcomes occurring during ATT (death,
clinical cure, default, adherence to treatment):
◦ low risk: less than 5% of participants lost to follow-up
during ATT;
◦ unclear risk: between 5 and -10% of participants lost
to follow-up during ATT;
◦ high risk: more than 10% of participants lost to
follow-up during ATT.
• Performance bias for all outcomes: ATT received for longer
than planned could reduce the probability of relapse if clinicians
gave prolonged ATT to the participants they judged were at
higher risk of relapse. Thus we considered:
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◦ low risk: less than 5% of participants had duration of
treatment prolonged, with reasons given;
◦ unclear: between 5 and 10% of participants had
duration of treatment prolonged, or no reasons given;
◦ high risk: more than 10% of participants had duration
of treatment prolonged.
• Confounding bias for all outcomes:
◦ factors that may have affected the main outcomes but
were unrelated to the duration of treatment, including poor
adherence to ATT (which could lead to relapse and treatment
failure), and co-interventions such as steroids and surgical
treatment.
We summarized the results of the assessment for the group of
cohorts that received six months ATT and the group of cohorts
that received prolonged ATT regimens, in ’Risk of bias’ graphs
and tables, with supporting evidence from the study reports (and
the ’Characteristics of included studies’ tables).
Measures of treatment effect
We stated in our protocol, Jullien 2016, that we would calculate
the risk ratio (RR) for dichotomous outcomes and the rate ratio
for count data outcomes, and that we would present the effect esti-
mates with 95% confidence intervals (CIs). This was not possible,
as we did not find any trials that directly compared short versus
prolonged course regimens. Therefore, we presented the findings
separately for each group of cohorts.
Dealing with missing data
Where data from the study reports were insufficient, unclear, or
missing, we attempted to contact the study authors for additional
information. For all included studies, we performed a complete-
case analysis, whichmeans that we only analysed the available data.
Assessment of heterogeneity
We assessed clinical and methodological diversities by looking at
the variability in participants, interventions, and risk of bias of the
included cohorts.
Assessment of reporting biases
We planned to construct funnel plots to assess publication bias,
but this was not possible as no comparative trials met the inclusion
criteria of this review.
Data synthesis
Although we planned to conduct meta-analyses, this was not pos-
sible. Instead we synthesized results narratively and in tables. We
attempted to assess the quality of the evidence using the Grading
of Recommendations Assessment, Development and Evaluation
(GRADE) principles (Guyatt 2011), but this was not possible due
to the lack of direct comparison between short- and prolonged-
course regimens. Instead, we constructed a modified ’Summary of
findings’ table to summarize findings of both groups of cohorts,
and assessed the quality of the evidence narratively. We used Re-
view Manager (RevMan 2014) to gather and synthesise our find-
ings.
Subgroup analysis and investigation of heterogeneity
We could not conduct formal subgroup analyses. Instead we ex-
plored heterogeneity between trials narratively by considering dif-
ferences between study populations and intervention, such as: age
group of participants, clinical severity of the disease at presenta-
tion, HIV status, time of the study, and length of follow-up.
Sensitivity analysis
We did not perform a sensitivity analysis as we were unable to
conduct meta-analyses.
R E S U L T S
Description of studies
Results of the search
We conducted the literature search up to the 31 March 2016
and identified 1541 studies. We identified five additional records
through other resources. By screening titles, abstracts, and key-
words, we selected 154 records and attempted to retrieve the full-
text articles of these studies. By contacting the first author of
one of these potentially eligible studies for clarification, we were
granted access to the database of a prospective observational co-
hort of participants with tuberculous meningitis (TBM), which
met our inclusion criteria (Alvarez-Uria 2012). Although some
of the participants included in our analysis have also been pre-
sented in Alvarez-Uria 2013 and Alvarez-Uria 2015, all the data
we present in this review come from the larger database provided
by the study author. Overall, 18 studies presented in 21 records
met the inclusion criteria of this review (see the ’Characteristics
of included studies’ table). We had insufficient information to de-
cide inclusion or exclusion of 11 studies (see the ’Characteristics
of studies awaiting classification’ table). We presented the reasons
for excluding the remaining 122 reports in the ’Characteristics of
excluded studies’ table. We illustrated this process in the study
flow diagram (Figure 2).
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Figure 2. Study flow diagram.
Included studies
We included 17 published studies and one unpublished ongo-
ing cohort. Of the published studies, four were randomized con-
trolled trials (RCTs) and 13 were non-randomized prospective co-
hort studies. None of the included RCTs compared six months
antituberculous treatment (ATT) versus ATT given for more than
six months for TBM, so we analysed all as single cohorts. Overall,
we identified seven cohorts treated for six months, and 12 cohorts
treated for longer than six months. Any comparisons between reg-
imens of six months and regimens of greater than six months are
entirely observational.
Cohorts treated for six months
See Table 1 for a full description of the included cohorts.
Setting and time
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The seven cohorts were from single tertiary centres in Thai-
land (Chotmongkol 1991; Chotmongkol 1996; Jacobs 1992),
South Africa (Donald 1998; van Toorn 2014), Ecuador (Alarcón
1990), and Papua New Guinea (Biddulph 1990). Four stud-
ies were conducted in the 1980s (Alarcón 1990; Biddulph
1990; Chotmongkol 1991; Jacobs 1992), two in the 1990s
(Chotmongkol 1996; Donald 1998), and one between 2006 and
2009 (van Toorn 2014).
Participants
The seven cohorts included 109 adults (three studies) and 349
children (five studies) diagnosedwith TBM.Only van Toorn 2014
reported HIV status, and none of the seven cohorts reported data
on malnutrition. Six studies used the British Medical Research
Council (MRC) criteria to assess clinical severity (MRC 1948),
but only five of them (256 participants) reported disaggregated
data: stage I (mild): 30 participants; stage II (moderate): 141 par-
ticipants; and stage III (severe): 85 participants.
ATT regimens
In all seven studies the intensive phase included at least two
months of isoniazid, rifampicin, and pyrazinamide. Four stud-
ies also gave streptomycin (Biddulph 1990; Chotmongkol 1991;
Chotmongkol 1996; Jacobs 1992), and two gave ethionamide
(Donald 1998; van Toorn 2014). Five studies gave a two months
intensive phase with three or four drugs, followed by a fourmonths
continuation phase with isoniazid and rifampicin only (Alarcón
1990; Biddulph 1990; Chotmongkol 1991; Chotmongkol 1996;
Jacobs 1992), while the two cohorts from South Africa gave four
drugs for the whole six months (Donald 1998; van Toorn 2014).
Drugs were given orally except streptomycin, which was given in-
tramuscularly. There was some variation between studies in the
dosages used (see the ’Characteristics of included studies’ table).
Dosages were given as a single daily administration, except in
Biddulph 1990, in which antituberculous drugs were given twice
weekly during the continuation phase. Drugs were given under
Directly Observed Therapy (DOT) in Donald 1998 and under
trial conditions in Chotmongkol 1996. In van Toorn 2014, half
of the participants were hospital-based during ATT and the other
half were home-based. In the remaining four studies, drugs were
self administered under condition of being recruited in a prospec-
tive observational cohort with the purpose of describing TBM
outcomes (Alarcón 1990; Biddulph 1990; Chotmongkol 1991;
Jacobs 1992).
Corticosteroids
Overall, 344 participants from the seven cohorts received corti-
costeroids. Different regimens were given to either all participants
or only to those with moderate and severe presentation of TBM
or with neurological complications, or as part of a RCT to assess
the use of corticosteroids (Chotmongkol 1996), during the first
four to eight weeks of ATT.
Diagnosis: clinical, radiological, and microbiological
characteristics
Diagnosis of TBMwas based on characteristic clinical features (see
Table 2), typical cerebrospinal fluid (CSF) findings (elevated cell
count with predominance of lymphocytes, low glucose content,
and elevation of protein content), and the presence of acid-fast
bacilli inCSF evidenced bymicroscopy examinationor culture (see
Table 3). Only one cohort reported 5/28 participants with a pre-
vious history of TB (Alarcón 1990). Four cohorts reported known
contact with an infectious TB patient (Alarcón 1990; Biddulph
1990; Donald 1998; Jacobs 1992). The diagnosis of TBM was
bacteriologically confirmed in 56 participants and clinically based
in 198 participants among the 254 participants with disaggregated
data. Only one study reported performing drug sensitivity testing
(Donald 1998).
Cohorts treated for longer than six months
See Table 4 for a full description of the included cohorts.
Setting and time
The 12 cohorts were from different geographical settings: India
(Iype 2014; Ramachandran 1989; Ramachandran 1997; Sharma
2013a), Thailand (Jacobs 1992; Phuapradit 1987), South Africa
(van Toorn 2014), China (Lau 2005), Ecuador (Alarcón 1990),
Romania (Anastasatu 1993), Turkey (Do anay 1995), and Viet-
nam (Török 2011a). Do anay 1995 was conducted in uni-
versity hospitals, Lau 2005 was performed in tertiary and sec-
ondary hospitals and chest clinics, and the remaining studies were
conducted in tertiary hospitals. Five studies were multicentric
(Do anay 1995; Lau 2005; Ramachandran 1989; Ramachandran
1997; Török 2011a). The earliest study was started in 1977
(Ramachandran 1989), followed by three studies conducted in
the 1980s (Alarcón 1990; Jacobs 1992; Phuapradit 1987), four
in the 1990s (Anastasatu 1993; Do anay 1995; Lau 2005;
Ramachandran 1997), and four between 2001 and 2011 (Iype
2014; Sharma 2013a; Török 2011a; van Toorn 2014).
Participants
The 12 cohorts included 893 adults (six studies) and 530 children
(seven studies) diagnosedwith TBM.Three cohorts included 122/
736 HIV-positive people (Lau 2005; Török 2011a; van Toorn
2014); Iype 2014 and Sharma 2013a excluded people with HIV,
and the remaining seven cohorts did not report the HIV sta-
tus of the participants. Ramachandran 1989 and Ramachandran
1997 reported data on severe malnutrition and included 147/395
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children with severe malnutrition according to the growth stan-
dards from the Indian Council of Medical Research. Eleven stud-
ies used the MRC criteria to assess clinical severity, with disaggre-
gated data in nine cohorts: stage I (mild): 371 participants; stage
II (moderate): 743 participants; and stage III (severe): 231 partici-
pants (Alarcón 1990;Do anay 1995; Iype 2014; Jacobs 1992; Lau
2005; Phuapradit 1987; Ramachandran 1989; Ramachandran
1997; Sharma 2013a; Török 2011a; van Toorn 2014).
ATT regimens
Twelve cohorts assessed the effects of more than 20 regimens of
between eight and 16 months of duration. All of them comprised
at least isoniazid and rifampicin (except two participants in Jacobs
1992), with up to five antituberculous drugs.
Drugs were given orally except streptomycin, which was given in-
tramuscularly. The cohorts used different drug dosages (see the
’Characteristics of included studies). Intermitent regimens (twice
or thrice weekly) were administered in three studies through-
out the course of treatment (Iype 2014; Ramachandran 1997;
Sharma 2013a), and in two studies during the intensive or con-
tinuation phase only (Anastasatu 1993; Ramachandran 1989).
The remaining studies gave single daily doses. In Iype 2014 and
Sharma 2013a, drugs were given under DOT; while in Anastasatu
1993, Ramachandran 1997, and Török 2011a, participants re-
ceived ATT under trial conditions. In van Toorn 2014, half of the
participants were hospital-based during ATT and the other half
were home-based. In the remaining studies, drugs were self-ad-
ministered under the condition of being recruited to a prospective
observational cohort with the purpose of describing TBM out-
comes.
Corticosteroids
All studies considered corticosteroids, except Anastasatu 1993 in
which authors did not report whether participants received cor-
ticosteroids or not. Overall, 1001 participants received corticos-
teroids. Different regimens were given to either all participants or
only to those with moderate and severe presentation of TBM or
with neurological complications, or as part of RCTs to assess the
use of corticosteroids (Török 2011a), during the first four to eight
weeks of ATT.
Diagnosis: clinical, radiological, and microbiological
characteristics
Similarly to the cohorts of participants receiving six months of
ATT, diagnosis of TBM was based on characteristic clinical fea-
tures (see Table 5), typical CSF findings, and presence of acid-fast
bacilli in CSF evidenced by microscopy examination or culture
(see Table 6). Three participants out of 72 presented a previous
history of TB inDo anay 1995. Five studies reported known con-
tact with an infectious TB patient (Iype 2014; Jacobs 1992; Lau
2005; Ramachandran 1989; Ramachandran 1997). The diagnosis
of TBM was bacteriologically confirmed in 470 participants, clin-
ically-based in 794 participants among the 1264 participants with
disaggregated data fromeight studies. Four studies performeddrug
sensitivity testing (Ramachandran 1989; Ramachandran 1997;
Török 2011a; Visudhiphan 1989).
Outcomes
Although some studies used different definitions of relapse, de-
fault, clinical cure, and poor adherence, we collected and presented
the data according to the definitions we established in our proto-
col, Jullien 2016 (see the ’Types of outcome measures’ section).
Primary outcome
All included studies reported relapse.
Secondary outcomes and adverse events
All studies reported death from any cause and clinical cure. We
were able to extract data on death after six months of ATT in
all the cohorts receiving six months of ATT and in eight cohorts
receiving prolonged ATT.We extracted data on default in five and
six cohorts of participants treated for six months and more than
six months respectively. One cohort study of six months ATT and
two cohort studies of more than six months ATT reported poor
adherence.
Authors of the included studies did not report adverse events uni-
formly. Some studies collected all adverse events while some oth-
ers reported only the cases requiring discontinuation of ATT due
to drug toxicity, or adverse effects secondary to corticosteroids.
Overall, 13 studies reported adverse events related to ATT, and
14 studies reported drug toxicity leading to the discontinuation
or modification of the treatment regimen.
Additional cohort
All participants in the Alvarez-Uria 2012 cohort come from the
Vicente Ferrer HIV Cohort Study (VFHCS), which is a long-term
prospective cohort study of all HIV-positive patients who have
attended Rural Development Trust (RDT) hospitals in the district
of Anantapur, India. Therefore such data reflect a cohort of partic-
ipants in a ’real-world’ setting. We presented these data separately
as it would be misleading to pool findings from this cohort with
the other cohorts. We reported the findings of all consecutive par-
ticipants diagnosed with TBM between 23 December 2010 and
30 September 2014, which corresponded to 217 participants co-
infected with HIV and TBM. There were three children (aged 8,
9 and 13 years) and 214 adults older than 18 years, with a mean
age of 38 years. Data on clinical severity were not reported.
Local policy stated that participants without previous TB should
receive six months of treatment while participants with previous
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TB should be treated for eight months. However, some clinicians
treat patients with TBM for longer, independently of the condi-
tion of the patient according to the main investigator. Thereby,
20 participants were treated for six months (including one partic-
ipant with previous TB) and 75 were treated for between seven to
16.7 months (including 19 participants with previous TB). The
remaining 122 participants either died before the sixth month
of ATT or received interrupted treatment, and the study authors
therefore classified them as defaulters. Authors reported data on
relapse, death, clinical cure and default, but did not reported data
on poor adherence and adverse events.
Excluded studies
We have listed the reasons for excluding 122 studies in the
’Characteristics of excluded studies’ section.
Risk of bias in included studies
See Figure 3 for a summary of the ’Risk of bias’ assessment of
both group of cohorts receiving six months and more than six
months of ATT. The ’Risk of bias’ tables provide further details
for supporting evidence in the ’Characteristics of included studies’
table.
Figure 3. ’Risk of bias’ summary for the cohorts treated for six months (left) and the cohorts treated for
longer than six months.
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Cohorts treated for six months
Detection bias
Three of the seven cohorts conducted routine follow-up at greater
than 18 months after completion of treatment, and we classified
them as at low risk of detection bias for relapse and death after six
months (Alarcón 1990; Biddulph 1990; van Toorn 2014). Five
cohorts presented a clear method of follow-up during treatment
and were at low risk of detection bias for death during treatment,
clinical cure, default, and adherence (Alarcón 1990; Biddulph
1990; Chotmongkol 1996; Donald 1998; van Toorn 2014).
Attrition bias
Three cohorts followed up more than 95% of survivors, and
we classified them as at low risk of attrition bias for relapse,
and death after treatment (Alarcón 1990; Chotmongkol 1991;
Chotmongkol 1996). Five cohorts had less than 5% loss to follow-
up during treatment and were at low risk of attrition bias for death
during treatment, clinical cure, default, and adherence (Alarcón
1990; Chotmongkol 1991; Chotmongkol 1996; Donald 1998;
van Toorn 2014).
Performance bias
In four cohorts, more than 95% of the participants received the
planned six months treatment, with few participants receiving
prolonged treatment for specific reasons stated by the study authors
(for example, modified and prolonged ATT due to severe adverse
event), and we considered them as at low risk of performance bias
(Alarcón 1990; Chotmongkol 1991; Chotmongkol 1996; Donald
1998).
Confounding bias
In all the cohorts, we identified factors that may affect the main
outcomes but that are not related to the duration of ATT, such as
poor adherence and administration of corticosteroids. It is unclear
how these factors would affect the findings and have classified
them as unclear risk of confounding bias.
Cohorts treated for longer than six months
Detection bias
Five of the 12 cohorts conducted routine follow-up at greater
than 18 months after completion of treatment and we classified
them as at low risk of detection bias for relapse and death after
six months of treatment (Anastasatu 1993; Ramachandran 1989;
Ramachandran 1997; Török 2011a; van Toorn 2014). Seven co-
horts presented a clear method of follow-up during treatment
and were at low risk of detection bias for death, clinical cure,
default, and adherence (Iype 2014; Lau 2005; Phuapradit 1987;
Ramachandran 1989; Ramachandran 1997; Török 2011a; van
Toorn 2014).
Attrition bias
Six cohorts followed-upmore than95%of survivors andwe judged
them as at low risk of attrition bias for relapse and death after
six months of treatment (Iype 2014; Lau 2005; Phuapradit 1987;
Ramachandran 1989; Ramachandran 1997; Visudhiphan 1989).
Four cohorts had less than 5% loss to follow-up during treatment
and we considered them as at low risk of attrition bias for death
during treatment, clinical cure, default, and adherence (Iype 2014;
Sharma 2013a; Török 2011a; van Toorn 2014).
Performance bias
In three cohorts, it is very likely that all participants received the
planned duration of treatment, with only one participant in one
cohort receiving longer treatment due to severe adverse event, and
we considered them as at low risk of performance bias (Anastasatu
1993; Phuapradit 1987; Visudhiphan 1989).
Confounding bias
In all the cohorts, we identified factors that may have affected the
main outcomes but that were not related to the duration of ATT,
such as poor adherence and administration of corticosteroids. It is
unclear how these factors would affect the findings and we have
classified them as at unclear risk of confounding bias.
Additional cohort
We have presented our ’Risk of bias’ assessment of the cohort
reported by Alvarez-Uria 2012 in the corresponding ’Risk of bias
table’ (see the ’Characteristics of included studies’ table). There
was high risk of detection bias and unclear risk of attrition bias for
outcomes that occurred during the follow-upperiod,which ranged
from one to 51 months. For outcomes that occurred during ATT,
the risk of detection and attrition biases was low. We considered
there was a high risk of performance bias as participants were
treated from six to 16.7months based on the decision of clinicians.
Effects of interventions
See Figure 4 for the ’Summary of findings’ table. We summarized
the findings of the Alvarez-Uria 2012 cohort separately in Table
7.
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Figure 4. ’Summary of findings’ table.
We have provided more details in Table 8 and Table 9 for cohorts
treated for six months, and in Table 10 and Table 11 for cohorts
treated for longer than six months.
Relapse
Six months ATT
Up to the end of follow-up, 3/369 participants (0.8%) from seven
cohorts had relapsed. These three participants were from three
different studies (Alarcón 1990; Biddulph 1990; Donald 1998),
had received different regimens, and relapsed between three weeks
and three months after completing ATT. Their HIV status is un-
known. They consisted of one adult (34 years of age), who died,
and two children (one year and 11 years), who both recovered. In
Biddulph 1990, 5/7 children who had relapsed of TB infection
from any organ in the whole cohort had missed doses, but au-
thors did not report whether the case of TBM relapse was one of
these five children. The child who relapsed in Donald 1998 had
ethionamide stopped and the dosages of isoniazid, rifampicin, and
pyrazinamide halved due to poor appetite and nausea after three
months of treatment.
More than six months ATT
In 11 cohorts, 7/915 (0.8%) had relapsed during the follow-up
period. These participants arise from three different studies (Iype
2014; Ramachandran 1997; Török 2011a), and they all received
nine-month ATTwith different regimens. They consisted of three
children and four adolescents or adults. The HIV status was neg-
ative for one participant as Iype 2014 excluded HIV-positive peo-
ple, and unknown for the remaining six participants: three in
which the HIV status was not reported (Ramachandran 1997),
and three in Török 2011a, in which there were 98/545 HIV-pos-
itive people, but the status of those who relapsed was not spec-
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ified. They all recovered except one child who died. This child
had culture-positive CSF with fully sensitive M. tuberculosis on
drug sensitivity testing at initial diagnosis and again at relapse, was
retreated for nine months, and died 10 months after completing
the second ATT regimen, despite having normal CSF analysis and
negative CSF cultures.
Additional cohort
None of the 18 participants treated for six months and followed
up for 30.5 months on average presented relapse. From the 71
participants treated for longer than six months and followed-up
for a mean of 25 months, seven relapsed with fatal outcome in
two cases. Time to relapse was between five days and 31 months.
We have presented the profile of all participants who relapsed after
completing ATT in Table 12.
Death from any cause
Six months ATT
Overall, 58/458 participants (12.7%) who received or planned to
receive six months ATT regimen across the seven cohorts, died
from any cause. The proportion of death in each cohort ranges
from 9/159 (5.7%) in vanToorn 2014 to 9/28 (32.1%) in Alarcón
1990. Alarcón 1990 is the cohort with higher proportion of par-
ticipants with severe TBM at presentation (14/28; 50%), and the
nine participants who died had severe disease. The van Toorn 2014
cohort receiving six months of ATT did not include any HIV-pos-
itive participant and is the most recent study, conducted between
2006 and 2009, while the other cohorts were conducted between
1984 and 1994.
More than six months ATT
Among participants who received or planned to receive more than
six months ATT, 465/1423 participants (32.7%) died from any
cause among the 12 cohorts, ranging from0%(0/44) inAnastasatu
1993 to 45.7% (249/545) and 50% (4/8) in Török 2011a and
Jacobs 1992 respectively. In Anastasatu 1993, the absence of death
in uncertain as there were five participants without outcome re-
ported. In Török 2011a, 18% of the participants were HIV-pos-
itive, which may explain the higher proportion of deaths in this
cohort.
Additional cohort
Overall, 131/217 (60.4%) participants died; 71.8% of them oc-
curred during the first six months of ATT, and 13.7% in default-
ers.
Death after six months of ATT
Six months ATT
In participants that received six months regimens, death after six
months of ATT coincides with death after completing treatment.
All seven cohorts reported the timing of death and it was therefore
possible to disaggregate the data to report the number of deaths
that occurred after six months of treatment. Overall, 8/458 par-
ticipants (1.7%) died after completing six months of ATT, which
corresponded to 13.8% of the total number of deaths from any
cause. Of these eight deaths, one was attributed to relapse, six to
complications of TBM related to severe neurological sequelae, and
there was no cause reported for the remaining death (see Table
13).
More than six months ATT
Amont eight cohorts of participants receiving more than six
months ATT, there were 39/662 participants (5.9%) who died af-
ter six months of ATT, corresponding to 8.7% of the total number
of participants who died from any cause. One of these deaths was
attributed to relapse, while 33 were due to complications of TBM
related to severe neurological sequelae or non TB causes, and there
were five deaths of unknown cause (see Table 13). The two cohorts
with higher number of participants dying after six months of ATT
were Ramachandran 1989 (19/180 deaths) and Ramachandran
1997 (12/215), which are two cohorts with long follow-up (42
to 84 months, and 51 months). In addition, the Török 2011a
cohort reported 50/296 deaths after completing the nine-month
treatment, meaning that there were at least 50 participants who
died after six months of ATT. The authors of the original paper
could not determine howmany of these deaths could be attributed
to relapse. Finally, Lau 2005 reported three deaths during the sec-
ond year from the start of ATT, attributable to causes no related
to TBM. There is a lack of reporting to say how many of the 23
deaths reported during the first year occurred after the six months
of ATT.
Additional cohort
Among the survivors who completed at least six months of ATT,
19/89 (21.3%) participants died after six months of treatment: 3/
18 (16.7%) were treated for six months and 16/71 (22.5%) were
treated for longer than six months of ATT. Only two of these
deaths were attributed to relapse in participants who were treated
for 9.1 months and 10 months.
Clinical cure
Six months ATT
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In participants that received six months ATT, 408/458 (89.1%,
seven cohorts) achieved clinical cure at the end of ATT. These
findings were homogeneous across five cohorts. Alarcón 1990 pre-
sented the lowest proportion of cases who achieved clinical cure
(20/28; 71.4%), and van Toorn 2014 the highest proportion (153/
159; 96%), which is consistent with the findings exposed in deaths
of any cause outcome.
More than six months ATT
In participants that receivedmore than sixmonths ATT, 989/1371
(72.1%, 12 studies) had achieved clinical cure at the end of ATT.
There was high heterogeneity between the studies. The lowest
proportions of participants with clinical cure are reported at 50%
(4/8) in Jacobs 1992 and at 62.8% (336/535) in Török 2011a,
which included 18% of HIV-positive participants. The highest
clinical cure rates were in Anastasatu 1993 with 100% clinical
cure (by complete-case analysis, as authors did not report the final
outcome for five participants), and van Toorn 2014 with 96%
(24/25) in participants either HIV-positive or with M. tuberculosis
with monoresistance to isoniazid.
Additional cohort
Overall, 94/217 (43.3%) participants achieved clinical cure at the
end of ATT, which comprised of 19 participants treated for six
months and 75 participants who were treated for longer.
Default
Six months ATT
We were able to extract data on the number of participants who
met our definition of default from five of the seven cohorts. There
were 4/370 (1.1%) cases of default. The four cases came from the
same cohort (Chotmongkol 1991), in which the study authors
reported that these participants received 2, 2, 3, and 4 months
of ATT respectively, and correspondence via letter after a mean
period of 16.5 months indicated that all had fully recovered.
More than six months ATT
Six of the 12 cohorts reported data on default. There were 8/355
(2.3%) cases of default in this group: seven of them during the
first six months of ATT, and the remaining one at an unclear time
from the start of ATT.
Additional cohort
Overall, there were 30/217 (13.8%) defaulters. It is not possible
to classify these participants according to the duration of treat-
ment that they were originally planned to receive, from the data
available.
Poor adherence
One cohort that only received six months ATT reported poor
adherence for 3/159participants (1.9%; van Toorn 2014), and two
cohorts that received prolonged ATT reported on this outcome,
with no cases reported cases with poor adherence (Lau 2005; van
Toorn 2014).
All adverse effects related to the ATT
We have described the adverse events as reported in the included
studies (see Table 14). We are aware that some adverse events
may be attributed to co-intervention such as corticosteroids, or to
complications of the TBM itself.
Six months ATT
Three cohorts reported disaggregated data on adverse effects re-
lated to ATT. There was inconsistency in the way the three cohorts
reported the adverse events. Chotmongkol 1991 only reported one
case of severe adverse event (severe hepatitis) among 29 partici-
pants, while Alarcón 1990 and Donald 1998 reported 24 and 32
adverse events respectively among 28 and 95 participants, which
comprised a more comprehensive list of adverse events, ranging
from mild and transient elevation of transaminases to severe ele-
vation of transaminases and uric acid. van Toorn 2014 reported
adverse events for all participants that received six and more than
six months of treatment. Biddulph 1990 reported all adverse ef-
fects for the whole cohort of participants with TB from any organ,
without disaggregated data for those with TBM.
More than six months ATT
Nine cohorts reported a comprehensive list of adverse effects re-
lated to treatment, although there was inconsistency in the meth-
ods the study authors used to detect adverse events. In some stud-
ies investigators actively looked for adverse events, while in other
studies investigators only reported on participants who reported
symptoms.
Drug toxicity leading to the discontinuation or
modification of the treatment regimen
Six months ATT
There were 13/197 (6.6%) participants from four cohorts who had
their ATT interrupted due to hepatotoxicity or significant nausea
and vomiting (Alarcón 1990; Chotmongkol 1991; Donald 1998;
Jacobs 1992). In van Toorn 2014, drug toxicity led to discontinu-
ation of ATT in 17/184, without disaggregated data between par-
ticipants receiving six and more than six months of ATT.
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More than six months ATT
There were 216/1299 (16.6%) participants from 10 cohorts who
had their ATT discontinued or modified due to a range of adverse
events (see Table 14). There was inconsistency across the cohorts
on how these participants were managed.
Additional TB outcomes reported by studies
Six months ATT
None of the cohorts reported treatment failure.
Four cohorts reported 123/358 participants with neurodisability
after treatment completion. There is high inconsistency across
studies regarding the neurological sequelae reported and in the
way of diagnosing them.
More than six months ATT
Three cohorts reported data on treatment failure. In Do anay
1995, one participant is reported to died due to treatment failure
after five months of therapy, and ATT was modified in another
participant due to “inadequate clinical response”. In Iype 2014,
four participants developed treatment failure (three during the
fourth month of therapy, and one with isoniazid resistance open
case of pulmonary TB during the nine month of therapy). Török
2011a reported 89participantswith “onset of new focal neurologic
signs or a fall in the Glasgow coma score of two points or more for
two or more days after more than seven days of clinical stability or
improvement at any time after randomization”, after a median of
41 days in the dexamethasone group and 38 days in the placebo
group from starting treatment. Although the study authors defined
these cases as relapse, they did not meet our definition of relapse
as they deteriorated during ATT; we classified them as treatment
failure. Lack of an agreed definition of treatment failure in TBM,
and differences in monitoring of participants during therapy, are
likely to have led to the marked discrepancy in reporting of this
outcome between studies.
Nine cohorts reported 352/1304 participants with neurodisability
at the end of treatment. There is high inconsistency across studies
in the neurological sequelae reported and in the way of diagnosing
them.
D I S C U S S I O N
Summary of main results
The seven cohorts treated for sixmonths included 458 participants
from Thailand, South Africa, Ecuador, and Papua New Guinea,
and only one study was conducted after the year 2000. The 12
cohorts treated for longer (eight to 16 months) included 1423
participants from India, Thailand, South Africa, China, Roma-
nia, Turkey, and Vietnam, with four conducted between 2001 and
2011. The proportion of participants classified as having stage III
disease (severe) was higher in the cohorts treated for six months,
but the proportion with known concurrent HIV was higher in the
cohorts that were treated for longer. The diagnosis was confirmed
on culture in 56/254 (22%) participants treated for six months
versus 470/1264 (37%) treated for longer (in studies where this
was clearly stated). Although there were variations in the treat-
ment regimens, most cohorts received isoniazid, rifampicin, and
pyrazinamide during the intensive phase.
Three out of the seven cohorts treated for six months and five
of the 12 cohorts treated for longer achieved follow-up beyond
18 months after completing treatment. All studies had potential
sources of bias in their estimation of the relapse rate, and compar-
isons between the cohorts could be confounded.
Relapse was an uncommon event in both groups of cohorts of
participants treated for six months and longer than six months,
and only one death was attributed to relapse in each group.
Overall, the proportion of participants who died was higher in
the cohorts treated for longer than six months, but most deaths
occurred during the first six months regardless of treatment du-
ration. This difference is not due to the treatment duration, but
rather indicates that there is likely to be substantial clinical hetero-
geneity between the six months cohorts and the longer treatment
cohorts. The disease severity is unlikely to be themain cause of this
difference in the mortality rate in these cohorts, as the proportion
of participants with severe tuberculous meningitis (TBM) (grade
III) was higher in the cohorts treated for six months. The reason
for the higher mortality rate in the group of cohorts treated for
longer than six months is likely multifactorial. Delay in starting
antituberculous treatment (ATT), drug resistance, drug-induced
hepatitis, adherence to ATT, quality of supportive care, HIV sta-
tus, and drug regimens could all contribute to this difference be-
tween the groups of cohorts.
As there was a higher proportion of deaths during ATT in the
longer treatment cohorts, the proportion of participants that
achieved clinical cure was higher in the group of cohorts treated
for six months.
Few participants defaulted from treatment in both groups of co-
horts, and adherence was poorly reported.
Most of the study authors reported on adverse events, but the level
of detail in reporting varied significantly, and we were unable to
draw any clear conclusions about rates of adverse events between
the two groups of cohorts.
The main difference between the Alvarez-Uria 2012 cohort and
the rest of the included cohorts was that all participants in the
Alvarez-Uria 2012 trial were HIV-positive, and that they were
managed in a “real-world” setting, contrary to the other cohorts
in which participants were under trial or study conditions. The
relapse rate was higher, with no cases among the 18 survivors
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who completed six months of ATT, and seven cases among the
71 survivors treated for longer than six months. In this cohort, it
would be misleading to compare participants treated for six and
more than six months, as we do not know whether the baseline
characteristics of the participants were comparable. The mortality
rate was high (131/217, 60.4%), and 71.8%of the deaths occurred
during the first six months of treatment, similarly to the rest of
the cohorts included in the review. The proportion of defaulters
was higher than in the rest of the included studies (13.8%). This
could represent a more accurate picture of the real proportion of
defaulters among HIV-positive people in an operational setting
who must take a high number of prescribed drugs.
Overall completeness and applicability of
evidence
This Cochrane review includes adults and children from a variety
of geographical settings, including countries in South-East Asia
and Africa with a high tuberculosis (TB) burden (WHO 2015).
Only one cohort in the group of studies treating for six months
reported theHIV status of the participants, and in this studyHIV-
positive people were all treated for nine months (van Toorn 2014).
Five cohorts where participants received more than six months
mentioned HIV status: two cohorts explicitly excluded HIV-pos-
itive people (Iype 2014; Sharma 2013a), and three cohorts in-
cluded 122/376 HIV-positive people (Lau 2005; Török 2011a;
van Toorn 2014). In addition, the cohort from Alvarez-Uria 2012
reported 217 participants co-infected with HIV. Further evidence
relating to the duration of ATT inHIV-positive people with TBM
is needed.
Six of the seven cohorts treated for six months and 11 of the 12
cohorts treated for longer than six months presented the three
stages of clinical severity, with around half of participants in stage
II in all cohorts. Results from this review are therefore applicable
for all stages of clinical severity of the disease at presentation.
In this review, we have restricted the inclusion of studies to those
that included ATT regimens that contained rifampicin. All six
months course regimens contained at least isoniazid, rifampicin,
and pyrazinamide during the intensive phase, and 1250/1423 par-
ticipants treated for longer also received these three drugs, which
reflect the current first-line regimens. The range of single daily
doses used is mostly concordant with current recommendations.
We also restricted study inclusion to studies that reported partic-
ipants with drug-sensitive TBM. van Toorn 2014 excluded chil-
dren withmultidrug-resistant TBM.However, this study included
those with isoniazid-monoresistance. For these participants, the
planned treatment consisted in a fluoroquinolone and terizidone
in addition to the standard ATT for nine months. We decided to
include this study as data on isoniazid-monoresistant cases (three
children) were disaggregated. Across all studies, most cases did not
have a M. tuberculosis-positive culture. Thus, the drug-sensitivity
patternwas unavailable andwe cannot be sure that some cases were
not caused by drug-resistant strains. However, if any, this would
have affected few cases, as prevalence of drug-resistant strains was
lower in the period when most of the studies were conducted.
Hence, results from this review are not applicable to drug-resistant
TBM.
Adjunctive treatment with corticosteroids is currently recom-
mended in all cases of TBM to reduce death (Prasad 2016). Most
of the recruited participants received corticosteroids, which means
that applicability of the results is unlikely to be affected by this co-
intervention.
Quality of the evidence
We derived the results from single-arm studies and not direct ran-
domized comparisons, although some were arms within random-
ized controlled trials (RCTs) performed for other purposes. As
such, participant characteristics, comorbidities, the severity of the
disease, differences in ATT regimens, drug resistance, drug-related
adverse events, quality of supportive care, and method of follow-
up could be different between the two groups, and making causal
inferences on the basis of potentially confounded cohorts is prob-
lematic. Because of this substantial clinical and methodological
heterogeneity between the studies, we did not attempt to per-
form a meta-analysis or perform a Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) assessment.
Nevertheless, relapse rates were low after treatment completion in
both groups.
Potential biases in the review process
We attempted to limit bias by following the rigorous methods pro-
vided by theCochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). TheCochrane InfectiousDiseasesGroup In-
formation Specialist performed the literature search without lan-
guage restrictions, and as such it is unlikely that we missed any
large studies. We attempted to identify unpublished studies by
contacting relevant researchers in this area, but only one study
author replied. Thus, we cannot rule out the possibility that we
missed some unpublished data. Also, we were unable to assess pub-
lication bias because no study directly compares six versus longer
than six months of ATT. We attempted to limit bias in the selec-
tion process, data extraction, and assessment of the quality of the
included studies by conducting these processes independently and
by comparing results between at least two review authors.
Agreements and disagreements with other
studies or reviews
The findings of this Cochrane Review are similar to those of a
systematic review conducted by van Loenhout-Rooyackers 2001,
who concluded, based on the results of 11 included studies, that
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six months regimens with at least isoniazid, rifampicin, and pyraz-
inamide were sufficient for participants with fully drug sensi-
tive TBM. This review was similar to our review in that the
included studies were all non-randomized observational studies.
Completion of treatment was 81% in participants that received six
months regimens and 85% in those that received longer regimens.
There were 2/131 and 0/591 participants with relapse in the six
months regimen group and longer ATT group respectively. An-
other systematic review, which belongs to a series that addressed
the scientific evidence behind the World Health Organization
(WHO)’s recommendations, reviewed the most appropriate ATT
for TBM and drew similar conclusions regarding length of treat-
ment, based on four prospective and retrospective observational
cohorts (Woodfield 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite potential confounding, there is no evidence of higher re-
lapse in people treated for only six months: relapse was an un-
common event regardless of the duration of treatment, and there
was no higher proportion of deaths among those treated for six
months. These data are almost all from participants who are HIV-
negative, and thus it is inappropriate tomake inferences from these
data about the safety and efficacy of the six month regimen to
HIV-positive people. The quality of the evidence is limited by a
lack of studies including a direct comparison between six months
and more than six months regimens.
Implications for research
Notably, no randomized controlled trials (RCTs) have compared
six months standard first-line ATT with longer regimens, despite
the significant uncertainty around best practice and the conse-
quent variations in practice and guidelines. This could be because
of resource constraints and competing research priorities, but it
might also be due to prevailing perceptions that six months ATT
is simply inadequate in this life-threatening form of TB disease.
We originally conducted this review to inform a guideline devel-
opment process in India on extrapulmonary TB, the Indian Ex-
tra-Pulmonary TB (INDEX-TB) Guidelines (INDEX-TB 2016).
During the guideline development process, several experts com-
mented that they were concerned about the ethics of conducting
a RCT that compared six months ATT with longer regimens in
people with TBM, citing their experiences of patients treated for
six months who have relapsed. They felt it would be unsafe and
unethical to randomize patients to receive six months of ATT.
The results of this Cochrane review suggest that relapse is an un-
common event whether participants are treated for six months or
longer, and so randomization of participants to a six months reg-
imen would not be unethical in a well-conducted trial. An ade-
quately powered,multicentre RCTconducted in low- andmiddle-
income countries where TB prevalence is high, that compares six
versus nine or 12-month regimens using the same first-line drugs
in standardized doses would help answer this question. Such trials
should involve HIV-positive and HIV-negative adults and chil-
dren, and should be powered to allow subgroup analyses between
age group, HIV status, nutritional status, and disease severity at
presentation. An alternative to conducting an RCT would be to
set up large, prospective cohort studies that compare six months
and prolonged treatment regimens, where duration of treatment
is clearly decided at initiation of ATT. This would have the ad-
vantage of more closely reflecting the outcomes that are achievable
in everyday practice, rather in the carefully controlled conditions
of a trial, and may be more feasible than an RCT. RCTs have the
advantage of being better equipped to deal with the problems of
confounding and bias in patient selection that we have identified
in the studies included in this review than cohort designs.
On the other hand, shortening the overall duration of TBM treat-
ment to achieve outcomes at least as good as the 12 months regi-
mens may be possible through different regimens, such as increas-
ing the length of the intensive phase, changing the doses, or the
frequency of administration of the first-line drugs currently used,
or adding or substituting second-line drugs. These different op-
tions need to be addressed. Few trials have been conducted eval-
uating high doses of rifampicin and use of fluoroquinolones for
TBM (Heemskerk 2016; Ruslami 2013; Thwaites 2011). How-
ever, these trials assessed survival as main outcome and did not fol-
low-up participants after completion of ATT for relapse.Whether
these new regimens would allow shortening of the overall treat-
ment duration is unknown. Most research focuses on pulmonary
TB. Several trials assessing new regimens are being developed or
are in progress (Zumla 2015). For drug-sensitive pulmonary TB,
a systematic review assessed fluoroquinolones as substitute or ad-
ditional agents in ATT regimens, and concluded that there is in-
sufficient evidence on whether this would reduce death or relapse
(Ziganshina 2013).When extrapolation of results is contemplated
from pulmonary TB to TBM, pharmacodynamics of the antitu-
berculous regimen should be taken into account, to ensure ad-
equate effects of antituberculous agents in the site of infection.
Analyses on cerebrospinal (CSF) concentrations of drugs may be
required. Thus, additional studies are needed to elucidate the role
of fluoroquinolones in TBM treatment, and to further address
alternative regimens that would allow shortening of the overall
length of ATT.
Finally, we noted that there was a lack of homogeneity in the in-
cluded studies when reporting outcomes and follow-up. Efforts
towards using standardized definitions for relapse and default, at
least 12 months follow-up after completing ATT and better re-
porting on outcomes including adverse events should be encour-
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aged for future studies to facilitate comparability between them
and allow meta-analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alarcón 1990
Methods Study objective: to review the clinical and therapeutic characteristics of the short course
of antituberculous treatment (ATT) in tuberculous meningitis (TBM)
Study design: prospective observational study.
Length of follow-up: 24 to 36 months from start of ATT in survivors
Follow-up method: after hospital discharge, programmed visit in their neurological de-
partment once a month for receiving antituberculous drugs, detailed neurological exam-
ination and cerebrospinal fluid (CSF) examination if indicated. CSF examination was
performed at the beginning of the treatment, 48 h later, and 15, 30, 60, 90, 180, 360 and
720 days after initiating the treatment. Neurological sequelae were assessed 18 months
after concluding the treatment
Losses to follow-up: none.
Participants Number: 28; mean age 29.1 years (range 11 months to 70 years); 75% male
Target treatment groups: children and adults with TBM.
Inclusion criteria: CSF analysis (differential cell count, protein and glucose levels, acid-
fast bacilli (AFB), culture in Lowenstein-Jensen medium, adenosine deaminase (ADA)
, enzyme-linked immunosorbent assay (ELISA) for Bacillus Calmette-Guérin (BCG)
antibodies). Participants were classified into the following groups
• Definite TBM: diagnosis based on an autopsy finding, or on positive CSF AFB
smear and culture, or on both.
• Probable TBM: negative CSF AFB smear and culture, but at least 1 of a positive
AFB smear or positive culture of M. tuberculosis from another tissue or body fluids,
positive ELISA, or positive ADA in CSF; and at least two of the following tests positive:
purified protein derivative (PPD) test, chest X-ray, computerized tomography (CT)
scan, and a history of previous tuberculosis (TB) or contact with someone with TB.
Exclusion criteria: participants who received a treatment with isoniazid previously and
had followed an adequate course of the drug
Bacteriologically confirmed TBM cases: 22/28.
Site of TB other than central nervous system (CNS): 17 with abnormal chest X-ray
including 7miliary pattern. 5 positive smear/cultures fromurine, 3 positive smear/cultures
from sputum, 2 positive smear/cultures from gastric aspirate, 1 positive culture from
perirenal abscess, and 1 positive culture from lymph node biopsy
Other clinical features: none described.
Clinical severity of the disease: 4 in stage I; 10 in stage II; 14 in stage III
HIV status: not reported
Duration of symptoms for less than 3weeks prior to admission in 18/28; time to treatment
initiation between 1 hour and 7 days after admission
Interventions Short-course ATT: 6months - 2months isoniazid, rifampicin and pyrazinamide, followed
by 4 months isoniazid and rifampicin (2HRZ/4HR), daily dosage, orally
• Isoniazid: 10 mg/kg (6 months).
• Rifampicin: 15 mg/kg (6 months).
• Pyrazinamide: 30 mg/kg (2 months).
Prolonged-course ATT: none.
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Alarcón 1990 (Continued)
Other interventions
• Prednisone (1 to 3 mg/kg/day) given to 19 cases (indicated for participants with
impairment of consciousness, focal neurology abnormalities, and a CSF pressure greater
than 300 mmH2O).
• Pyridoxine (50 to 100 mg/day) given to all participants.
• Ventriculoperitoneal shunting in 3 participants.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
• All adverse effects related to the ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
Notes Country: Ecuador.
Setting:Department ofNeurology in oneHospital of the capital (EugenioEspejoHospital,
Quito)
Study dates: from March 1986 to January 1989.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk The trial followed up participants at specific
points during the follow-up period, with
physical and CSF examinations, although
no details are given if participants did not
attend the planned visits. All 19 survivors
had CSF examination at 18 months after
completing ATT
Detection bias
Clinical cure and default
Low risk After hospital discharge, participants had
visits programmed once a month for receiv-
ing antituberculous drugs, detailed neuro-
logical examination and CSF examination
if indicated
Attrition bias
Relapse
Low risk No losses of follow-up during the follow-up
period of 18 to 30 months
Attrition bias
Clinical cure and default
Low risk No losses of follow-up during the treatment
duration.
Performance bias Low risk All participants received 6 months ATT.
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Alarcón 1990 (Continued)
Confounding bias Unclear risk Adherence to treatment is not reported.
Prednisolone was given to 19/29 partici-
pants on the basis of disease severity but it
is unclear how this would affect the results
Alvarez-Uria 2012
Methods We contacted the first author for disaggregated data for TBM and to clarify how long
participants were followed-up. Instead, the study author provided us access to a larger
database of cohort of participants with TBM. Some of these participants were included in
Alvarez-Uria 2012, which describes the setting. Some of the participants included in our
analysis have also been presented in Alvarez-Uria 2013 and Alvarez-Uria 2015. However,
all the data we present in this review come from the larger database provided by the study
author
Study objective: Rural Development Trust (RDT) is a non-governmental organization
that provides freemedical care toHIV-positive participants in a resource-poor rural setting
of India (district of Anantapur). The Vicente Ferrer HIV Cohort Study (VFHCS) is a
long-term prospective cohort study of all HIV-infected participants who have attended
RDT hospitals. Data are collected prospectively since September 2009 to describe the
epidemiology of HIV and its related conditions in the investigators area, and to study
the effectiveness of health interventions in a ’real-world’ setting (implementation and
operational research)
Study design: prospective observational study.
Length of follow-up among survivors who completed ATT: mean 28.8 months after
completing ATT (range 2.8 to 51.3 months)
Follow-up method: participants are followed up monthly during the duration of ATT,
and every month or 2 months after completing ATT
Losses to follow-up: 2 participants were lost to follow-up right after completing ATT (1
participant in the 6 months group, 1 in the 8 months group)
Participants Number: 217; mean age 38 years (3 children of 8, 9, and 13 years, otherwise range 18 to
70 years); 72% male
Target treatment groups: HIV-positive participants with TBM co-infection
Inclusion criteria: participants were diagnosed with TBM following the criteria defined
in Marais 2010.
Exclusion criteria: other CSF infection identified by positive cryptococcal antigen in CSF
or positive culture for pyogenic bacteria
Bacteriologically confirmed TBM cases: not reported.
Site of TB other than CNS: not reported.
Other clinical features: not reported.
Clinical severity of the disease: not reported.
HIV status: all participants were HIV-positive.
Duration of symptoms and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months to participants without previous TB
From23December 2010until 28 January 2012: standard regimen (category I) of 2HRZE/
4HR, oral, once daily
• Isoniazid: 300 mg (6 months).
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Alvarez-Uria 2012 (Continued)
• Rifampicin: 450 mg (6 months).
• Pyrazinamide: 1500 mg/kg (2 months).
• Ethambutol: 800 mg (2 months).
From 29 January 2012: new ATT regimen during admission, oral, once daily
• Isoniazid: 600 mg.
• Rifampicin: 900 mg.
• Pyrazinamide: 1500 mg/kg.
• Levofloxacin: 750 mg.
• Ethionamide: 750 mg.
After discharge, participants were treated with standard regimen (category I)
Prolonged-course ATT: 8 months to participants previously exposed to ATT
From23December 2010until 28 January 2012: standard regimen (category II) 2HRZES/
1HRZE/5HRE, oral, once daily
• Isoniazid: 300 mg (8 months).
• Rifampicin: 450 mg (8 months).
• Ethambutol: 800 mg (8 months).
• Pyrazinamide: 1500 mg/kg (3 months).
• Streptomcin: 750 mg (2 months).
From 29 January 2012: new ATT regimen during admission, oral, once daily
• Isoniazid: 600 mg.
• Rifampicin: 900 mg.
• Pyrazinamide: 1500 mg/kg.
• Levofloxacin: 750 mg.
• Ethionamide: 750 mg.
After discharge, participants were treated with standard regimen (category II)
The participants who relapsed were given category II regimen
Other interventions
• Corticoids: the typical regimen given to all participants consisted of intravenous
dexamethasone (16 mg every 6 hours for 3 to 4 days, then 8 mg every 8 hours for 3 to 4
days), followed by oral prednisolone (40 mg once daily) before hospital discharge. After
discharge, prednisolone was reduced 10 mg every 2 weeks, so corticosteroids were
stopped after 8 weeks of hospital discharge.
• Pyridoxine 50 mg/day to all participants.
• Sodium heparin (5000 IU subcutaneous every 12 hours) to all participants during
the hospital admission.
• Valproate acid to participants with seizures.
Outcomes Outcomes included in this review
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Default.
• Clinical cure (defined as treatment completed by the investigators).
Outcomes not included in this review: none.
Notes Country: India.
Setting: RDT hospitals in the district of Anantapur.
Study dates: cases of TBM diagnosed from 23 December 2010 to 30 September 2014.
Execution of the search from the database: 2 February 2016
Study sponsor: none.
34Six months therapy for tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Alvarez-Uria 2012 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
High risk After completing ATT, participants visited
the clinic every 1 or 2 months, as part of
the follow-up of the large HIV cohort. The
length of follow-up in survivors who com-
pleted ATT ranges from 1 to 51 months
Detection bias
Clinical cure and default
Low risk Participantswere followed-upmonthly dur-
ing ATT.
Attrition bias
Relapse
Unclear risk Among the survivors who completed ATT,
there were 5/94 participants with no day of
follow-up after completing the therapy (5.
3%)
Attrition bias
Clinical cure and default
Low risk No participant was reported lost of follow-
up during the duration of the treatment
Performance bias High risk According to local guidelines, participants
without previous TB would be treated for
6 months and those with previous TB for 8
months. However, participants were treated
up to 16.7 months according to clinician
decision, with considerable variation in du-
ration of treatment within the cohort
Confounding bias Unclear risk Adherence to treatment is not reported.
All participants received corticosteroids. All
participants are HIV-positive. We do not
know the antiretroviral treatment given and
how this may have interacted with the out-
comes
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Anastasatu 1993
Methods Study objective: to review the results of 9 months ATT in children with severe forms of
TB, 5 years after completing ATT
Study design: randomized controlled trial (RCT) that compared 9 months versus 12
months ATT regimens
Length of follow-up: 5 years after completing ATT.
Follow-up method: periodic follow-up in the paediatric department of the Institute of
Pneumo-physiology “M.Nasta”
Losses to follow-up: 5/44
Participants Number: 44 TBM; age and gender not reported.
Target treatment groups: children between 0 and 14 years with severe forms of TB,
including TBM, granulomas, and caseous forms (pneumonia and bronchopneumonia)
Inclusion criteria: no further details provided.
Exclusion criteria: none reported.
Bacteriologically confirmed TBM cases: positive culture in 30/60 cases of severe forms of
TB, without disaggregated data for TBM
Site of TB other than CNS in participants with TBM: no abnormal findings in chest X-
ray, no other details reported
Other clinical features: none reported.
Clinical severity of the disease: not reported.
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: none.
Prolonged-course ATT
• Experimental group: 9 months - 3HRZ/6HR2 (given to 19 participants with
TBM).
• Control group: 12 months - 3HR/3HR2/6H2 (given to 25 participants with
TBM).
• Drug dosages:
◦ in the first 3 months:
⋄ isoniazid: 10 mg/kg/day (both groups);
⋄ rifampicin: 10 mg/kg/day (both groups);
⋄ pyrazinamide: 20 to 25 mg/kg/day (experimental groups);
⋄ streptomycin twice weekly is included in the administered drugs for
both groups. However, this drug is not described earlier in the methods;
◦ Thereafter, twice weekly:
⋄ isoniazid: 15 mg/kg (6 months in experimental group, 9 months in
control group);
⋄ rifampicin: 15 mg/kg (6 months in experimental group, 3 months in
control group).
Other interventions: none reported.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
Outcomes not included in this review
• Neurological sequelae at 5 years of follow-up.
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Anastasatu 1993 (Continued)
• Radiologic aspect at 5 years of follow-up.
• Bacteriological status at 5 years of follow-up.
Notes Country: Romania.
Setting: PaediatricDepartment of the Institute of Pneumo-physiology Institute “M.Nasta”
Study dates: not reported.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk The study gave outcomes at 5 years of fol-
low-up for all participants not lost to fol-
low-up, with findings reported in radiolog-
ical and bacteriological outcomes
Detection bias
Clinical cure and default
Unclear risk The study authors reported that partici-
pants were followed-up periodically. How-
ever, the follow-upmethods duringATTare
unclear
Attrition bias
Relapse
Unclear risk It is unclear when the 5/44 participants lost
to follow-up left the trial and what their
outcomes were
Attrition bias
Clinical cure and default
Unclear risk It is unclear when the 5/44 participants lost
to follow-up left the trial and what their
outcomes were
Performance bias Low risk Investigators did not report whether or not
participants received prolonged ATT.How-
ever, this is unlikely, as the aim of this RCT
was to compare 9 versus 12 months of treat-
ment
Confounding bias Unclear risk Adherence to treatment and co-interven-
tion are not reported.
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Biddulph 1990
Methods Study objective: to review the results of 6 months ATT in childhood TB
Study design: prospective observational study.
Length of follow-up: up to 24 months after completing ATT.
Follow-up method
• During ATT: all participants were managed in hospital for the first 2 months of
chemotherapy, then discharged to an outpatient clinic for the last 4 months of
treatment. They attended the clinic twice weekly to receive chemotherapy under
supervision and were checked once monthly at the hospital paediatric TB follow-up
clinic. A paediatric TB sister attempted to track down defaulters.
• After completing ATT: visit every 3 months for the following 2 years, in the
paediatric TB follow-up clinic.
Losses to follow-up: no disaggregated data for TBM.
Participants Number: 639 children with TB, including 43 children with CNS TB. 58% of the 639
TB participants were less than 5 years old and 54% were male, without disaggregated data
provided for the CNS TB cases
Target treatment groups: children with TB.
Inclusion criteria: TB diagnosis was made on clinical, bacteriologic or histologic evidence
• Clinical diagnosis required suggestive history and clinical findings, supported by
either a significant Mantoux response or a confirmed household contact of TB, or
characteristic findings on chest X-ray, CSF, pleural fluid, or ultrasound of the abdomen
and a good response to ATT, in the absence of a more likely diagnosis.
• Suggestive features of CNS TB were one or more of the following: meningeal signs,
impaired state of consciousness, cranial nerve palsies, hemiparesis, ataxia, or papilledema
in the absence of a more likely diagnosis (e.g. purulent or cryptococcal meningitis).
Childrenwith neurological signs who had gross papilledema did not have lumbar puncture
performed, hence the use of the term CNS TB by the investigators rather than TBM. In a
number of these children, it was not possible to distinguish between TBM, tuberculoma
or TB encephalopathy
Thus, among the 43 children with CNS TB, there were as follows
• 31 TBM, with predominance of lymphocytes, reduced glucose and raised protein
concentrations in CSF.
• 11 children with gross papilloedema and thus without lumbar puncture.
• 1 child with spinal subarachnoiditis, with high CSF protein concentration and
partial block shown on myelography.
Exclusion criteria: none reported.
Bacteriologically confirmed TBM cases: 5.
Site of TB other than CNS: 14 abnormal chest X-ray among the 43 children with CNS
TB
Other clinical features: 1 spinal arachnoiditis.
Clinical severity of the disease: not reported.
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months - 2HRZS/4(HR)2 .
• First 2 months: single daily dosages:
◦ isoniazid: 10 to 15 mg/kg, max 300 mg;
◦ rifampicin: 10 to 15 mg/kg, max 600 mg;
◦ pyrazinamide: 25 to 35 mg/kg, max 1500 mg;
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Biddulph 1990 (Continued)
◦ streptomycin: 20 to 30 mg/kg, max 750 mg.
• Following 4 months: twice a week:
◦ isoniazid: 15 to 20 mg/kg, max 900 mg;
◦ rifampicin: 10 to 15 mg/kg, max 600 mg.
Children who lived to far from an outpatient clinic were given 3 months HRZS, followed
by 3 months of daily Isoniazid 10 to 15 mg/kg. Follow-up of these children was not
possible
Prolonged-course ATT: none.
Other interventions
• Corticosteroids to all children with CNS TB.
• Pyridoxine (25 mg) if isoniazid dose was more than 300 mg.
• Ventriculo-peritoneal shunt.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Default (no disaggregated data for TBM).
• All adverse effects related to ATT (no disaggregated data for TBM).
• Drug toxicity leading to discontinuation of regimen (no disaggregated data for
TBM).
Outcomes not included in this review: none.
Notes Country: Papua New Guinea.
Setting: Port Moresby General Hospital.
Study dates: from November 1984 to November 1986.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk Survivors had programmed visits every 3
months for the following 2 years
Detection bias
Clinical cure and default
Low risk All participants were managed in hospital
for the first 2months of treatment, then dis-
charged to an outpatient clinic for the last
4 months of treatment. They attended the
clinic twice weekly to receive chemotherapy
under supervision and were checked once
monthly at the hospital paediatric TB fol-
low-up clinic. A paediatric TB nurse at-
tempted to track down defaulters
Attrition bias
Relapse
High risk There are no disaggregated data for TBM.
However, 70/373 attended the full 24-
month follow-up
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Attrition bias
Clinical cure and default
Unclear risk There are no disaggregated data for TBM.
Performance bias Unclear risk Whether participants received ATT longer
than the planned 6 months is not reported
Confounding bias Unclear risk Study authors did not report on adherence
to treatment. All participants received cor-
ticosteroids
Chotmongkol 1991
Methods Study objective: to review the results of 6 months ATT in adults with TBM
Study design: prospective observational study.
Length of follow-up: mean 16.3 months after completion of therapy (range 4 to 33)
Follow-up method: unclear. Correspondance by letters described in 4 participants
Losses to follow-up: the study authors reported 4 participants were lost to follow-up
and excluded them from the results. However, the study authors reported that these
participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via
letter after a mean period of 16.5 months after treatment indicated that all fully recovered
Participants Number: 29; mean age 35 years (range 16 to 61); gender not reported
Target treatment groups: adults with TBM.
Inclusion criteria: based on the characteristic clinical features and typical CSF findings
(lymphocytic meningitis with low glucose and elevation of protein content)
Exclusion criteria: none mentioned.
Bacteriologically confirmed TBM cases: 6/29
Site of TB other than CNS: 10 participants with abnormal chest X-ray, 1 peritonitis, 1
osteomyelitis, 1 laryngitis
Other clinical features: 4 participants with tuberculoma, 7 with communicating hydro-
cephalus, 3 with spinal arachnoiditis
Clinical severity of the disease: 7 in stage I; 12 in stage II; 10 in stage III (Gordon and
Parsons classification, Gordon 1972).
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months - 2HRZS/4HR, single daily dosage
• Isoniazid: 300 mg orally (6 months).
• Rifampicin: 600 mg orally (450 mg if participant weight < 45 kg) (6 months).
• Pyrazinamide: 1500 mg orally (2 months).
• Streptomycin 750 mg intramuscular (2 months) (26 cases).
• Ethambutol 800 mg was used as a replacement if streptomycin could not be taken.
One participant had severe hepatitis due to isoniazid; treatment was continued with
rifampicin and ethambutol for 18 months
Prolonged-course ATT: none
Other interventions
• Prednisolone (45 to 60 mg/day, gradually tapered off over 2 to 4 weeks) given to 9
participants with mental change, high CSF protein content or spinal arachnoiditis.
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• Repeated lumbar puncture for participants with CSF pressure over 200 mmH2O.
• Ventriculo-peritoneal shunt for participants with persistent high CSF pressure after
3 to 4 weeks of daily lumbar puncture (8 participants).
• Immediate ventriculostomy to participants who had severe mental change with
hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
Notes Country: Thailand.
Setting: Department of Medicine, Srinagarind Hospital, Khon Kaen
Study dates: from January 1988 to June 1990.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
High risk The study authors reported correspondence
by letters for 4 participants. However, they
did not describe the methods of follow-up
for the rest of participants. Participants were
followed-up for ameanof 16.3months after
completion of ATT, ranging from 4 to 33
Detection bias
Clinical cure and default
Unclear risk The study authors did not describe the
methods of follow-up during ATT
Attrition bias
Relapse
Low risk No losses of follow-up during the follow-up
period.
Attrition bias
Clinical cure and default
Low risk No losses of follow-up during the duration
of the treatment.
Performance bias Low risk 1/25 (4%) participant received more than
6 months ATT, due to modified treatment
for adverse events
Confounding bias Unclear risk The study authors did not report on adher-
ence to treatment. Prednisolone was given
to 9/29 participants on the basis of disease
severity but it is unclear how this would af-
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fect the results
Chotmongkol 1996
Methods Study objective: to determine whether corticosteroid is beneficial to participants with
TBM
Study design: randomized double-blind controlled trial of antituberculous therapy with
corticoids versus antituberculous therapy with placebo. Treated as prospective observa-
tional data for the purposes of this review
Length of follow-up: mean 30 months after completion of therapy (range 16 to 45)
Follow-up method: assessment and record of physical examination and adverse events
every week during hospitalization, every 1 or 2 months until the 6 months study period
was completed, and at 3rd , 6th, 9th, and 12th months after completing antitubercular
therapy.
Losses to follow-up: 0/59.
Participants Number: 59;mean age 42 and39years in the prednisolone andplacebo groups respectively
(range 16 to 86); 54.2% male
Target treatment groups: adults over 15 years with TBM.
Inclusion criteria: diagnosis of TBM was based on the following
• Characteristic clinical features.
• Typical CSF findings: lymphocytic meningitis with low glucose level, elevation of
protein content, sterile routine bacterial and fungal culture, a negative latex agglutination
test for bacterial and cryptococcal antigen and a negative cytologic study for malignancy.
Exclusion criteria: positive serologic test for syphilis or HIV
Bacteriologically confirmed TBM cases: 5 positive culture and 1 positive AFB stain (un-
clear whether specimen with positive stain was also culture positive)
Site of TB other than CNS: 23 lung (including 4 miliary patter), 3 lymph node, 1 spine,
1 larynx, 1 peritoneum, and 1 intestine
Other clinical features: 26 hydrocephalus (including 3 with tuberculoma), 2 tuberculoma
alone, 7 spinal arachnoiditis, 1 TB spondylitis
Clinical severity of the disease: 9 in stage I; 40 in stage II; 10 in stage III
HIV status: HIV-positive people excluded.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months - 2HRZS/4HR, single daily dosage
• Isoniazid: 300 mg orally (6 months).
• Rifampicin: 600 mg orally (450 mg if participant weight < 50 kg) (6 months).
• Pyrazinamide: 1500 mg orally (2 months).
• Streptomycin 750 mg intramuscular (2 months).
Prolonged-course ATT: none.
Other interventions
• Steroid therapy: participants were randomized to receive placebo (30 participants)
or prednisolone (29 participants; 60 mg/day orally during 2 weeks, then dose gradually
tapered off over 5 weeks).
• Repeated lumbar puncture for participants with CSF pressure over 200 mmH2O.
• Ventriculo-peritoneal shunt for participants with persistent high CSF pressure after
4 weeks of daily lumbar puncture (9 participants).
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• Immediate ventriculostomy to participants who had severe mental change with
hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
Outcomes not included in this review
• Neurological sequelae.
• Ventricular shunting.
• Time until disappearance of headache after treatment.
• Time until normal body temperature after treatment.
Notes Country: Thailand.
Setting: Srinagarind Hospital in Khon Kaen.
Study dates: from July 1990 to December 1992.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk The study aimed to follow participants ev-
ery 3 months after completing ATT dur-
ing the first year. Participants were, in real-
ity, followed for a mean of 30 months after
completion of therapy (range 16 to 45)
Detection bias
Clinical cure and default
Low risk Close follow-up of participants duringATT,
under trial conditions
Attrition bias
Relapse
Low risk No losses of follow-up during the follow-up
period.
Attrition bias
Clinical cure and default
Low risk No losses of follow-up during the duration
of the treatment.
Performance bias Low risk Investigators reported that no participants
received prolonged treatment
Confounding bias Unclear risk Adherence to treatment is not reported. 29/
59 participants were randomized to receive
either prednisolone or placebo, but it is un-
clear how this would affect the results
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Methods Study objective: to describe the results of 6 months intensive ATT in children with
complicated forms of TBM
Study design: prospective observational study.
Length of follow-up: 12 months after completion of therapy.
Follow-up method: after the first month of treatment, children were transferred to a
regional TB hospital for completion of 6 months of treatment under direct supervision.
After completion of chemotherapy, parents were requested to take the child to the relevant
clinic once monthly for the first year. Clinic personnel then reported the child’s clinical
condition to the study authors in writing following this monthly visit. When children
failed to attend, a home visit was undertaken
Losses to follow-up: 12/95
• 5 children, because they moved to a rural remote area immediately after discharge.
• 7 children moved during the follow-up period.
Participants Number: 95; median age 17 months for 39 participants in stage III, 38 months for 52
participants in stage II and 37 months for 4 participants in stage I. Gender not reported
Target treatment groups: children with TBM.
Inclusion criteria: “the children were evaluated according to a long-standing protocol,
and the majority were entered in studies evaluating different methods of managing the
various complications of TBM”
Exclusion criteria: not reported.
Bacteriologically confirmed TBM cases: 18 positive culture of M. tuberculosis from CSF;
31 positive culture of M. tuberculosis from gastric aspirate (7 of them also had positive
culture from CSF)
Site of TB other than CNS: 41 abnormal chest X-ray, other sites not reported
Other clinical features: 6 children with 1 or more tuberculomata, 82 hydrocephalus
Clinical severity of the disease: 4 in stage I; 52 in stage II; 39 in stage III
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months - 6HRZEth, single daily dosage, which were increased
appropriately as the children gained in weight
• Isoniazid: 20 mg/kg (6 months).
• Rifampicin: 20 mg/kg (6 months).
• Pyrazinamide: 40 mg/kg (6 months).
• Ethionamide: 20 mg/kg (6 months).
3 children were inadvertently started again on ATT by regional medical staff after com-
pleting 6 months ATT
Prolonged-course ATT: none.
Other interventions
• Prednisone (4 mg/kg/day) in 40 or 44 (unclear as both numbers are stated in the
text) children as part of a randomized prospective evaluation of the use of steroids in
TBM.
• Daily acetazolamide and furosemide during the first month of ATT.
• Ventriculo-peritoneal shunt to 27 children (21 with non-communicating
hydrocephalus and 6 with unsatisfactory response to medical management).
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
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• Death after 6 months of ATT.
• Clinical cure.
• Default.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
Notes Country: South Africa.
Setting: Department of Paediatrics and Child Health of a tertiary care institution (Tyger-
berg Hospital) in the Western Cape Province
Study dates: from 1 January 1991 to 31 August 1994.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk Methods of follow-up are clear, with
monthly visits to the clinic during the first
year after completingATT. A home visit was
undertaken when children failed to attend.
Follow-upwas planned for 1 year after com-
pleting ATT, with no details given on the
real follow-up of the participants
Detection bias
Clinical cure and default
Low risk Children received ATT in the study hospi-
tal after the first month of treatment, and
were transferred afterwards to a regional TB
hospital for completion of 6 months treat-
ment under direct supervision
Attrition bias
Relapse
High risk 12/82 (14.6%) participants were lost to fol-
low-up after completing ATT
Attrition bias
Clinical cure and default
Low risk No losses of follow-up during the duration
of the treatment.
Performance bias Low risk 3/82 (3.7%) survivors were inadvertently
started again on ATT by regional medical
staff after completing 6 months ATT
Confounding bias Unclear risk Adherence to treatment not reported. 40
or 44 (unclear as both numbers are stated
in the text) children received prednisone as
part of a randomized prospective evaluation
of the use of steroids in TBM. Ventriculo-
peritoneal shunt to 27 children. It is unclear
how these co-interventions would affect the
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results
Do anay 1995
Methods Study objective: to evaluate the results of therapy in participants with TBM at 4 centres
in Turkey
Study design: prospective comparative study between 2 ATT regimens (8 months treat-
ment in 3 centres, 12 to 16 months treatment in 1 centre), with data collected during the
same period of time
Length of follow-up: median 10 (range 6 to 24) and 13 (range 4 to 36) months after
completion of therapy in 48 participants in the 8 months and the 12 to 16 months
treatment groups respectively
Follow-up method: not reported.
Losses to follow-up: 10participants duringATT, 7 additional participants after completing
ATT
Participants Number: 72; mean age 30.4 years (range 16 to 65 years); 55.6% male
Target treatment group: adults over 15 years with TBM.
Inclusion criteria: the diagnosis of TBM was based on
• Clinical findings of subacute and chronic meningitis (meningeal symptoms lasting
for > 4 days).
• CSF findings (clear or xanthochromatic, elevated cell count with predominance of
lymphocytes, glucose level < 400 mg/L, protein level > 1 g/L).
• Demonstration of AFB in CSF by microscopy examination,or culture, or both.
• Evidence of any associated extrameningeal tuberculous lesion.
Exclusion criteria: participants dying in the first 5 days of admission. Exclusion criteria
for receiving 8 months therapy: if participants were given a different ATT regimen for >
1 week; if therapy lapsed for 10 days during treatment period; participants treated for TB
in the previous 2 years
Bacteriologically confirmed TBM cases: not reported.
Site of TB other than CNS: 22 pulmonary TB (PTB), 5 miliary TB, 4 spondylitis, 1 TB
lymphadenitis
Other clinical features: 1 intracerebral tuberculoma, 3 hydrocephalus
Clinical severity of the disease: 7 in stage I; 34 in stage II; 31 in stage III
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: none.
Prolonged-course ATT:
• 8 months - 2HRZS/6HR. 37 participants:
◦ isoniazid: 300 mg/day (8 months);
◦ rifampicin: 600 mg/day (8 months);
◦ pyrazinamide: 1500 mg/day (2 months);
◦ streptomycin: 1 g/day (1 month, thereafter on alternate days, to a total of 45
g).
Duration of therapy was prolonged in 1 participant until 9 months and in 1 participant
until 10 months. Treatment was modified in 1 participant because of inadequate clinical
response
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• 12 to 16 months: 4 drugs for 4 to 6 months, followed by 2 to 3 drugs until overall
duration of treatment of 12 to 16 months. 35 participants:
◦ regimens used: 19 participants: HRZE; 6 participants: HRES; 6 participants:
HRZS; 3 participants: HRZES; 1 participant: HRE; protainamide was also given to 3
participants;
◦ duration of treatment: 25 participants for 12 months; 2 participants for 15
months; 3 participants for 16 months.
Other interventions:
• Steroid therapy in 48 participants:
◦ 8 months group: prednisolone given to participants in stage III;
◦ 12 to 16 months group: prednisolone or dexamethasone given if
papilloedema, cranial nerve palsies, clouding of consciousness or coma, or both.
• Pyridoxine (100 mg/day) to all participants.
• Ventriculo-peritoneal shunt in the 3 participants who developed hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
• All adverse effects related to the ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Treatment failure.
• Residual sequelae (including neurological sequelae).
Notes Country: Turkey.
Setting: 4 university clinics (Kayseri, Sivas, Diyarbakir, and Istanbul)
Study dates: from January 1989 to April 1993.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
High risk The study authors followed-up the partici-
pants for between 4 and 36months, but did
not report the method of follow-up
Detection bias
Clinical cure and default
Unclear risk The study authors did not report the meth-
ods of follow-up during treatment
Attrition bias
Relapse
High risk 7/55 (12.7%) participants were lost to fol-
low-up after completing ATT
Attrition bias
Clinical cure and default
High risk 10/72 (13.9%) participants were lost to fol-
low-up during ATT
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Performance bias High risk In the 8 months regimen group, treatment
was prolonged in 2 participants up to 9
and 10 months respectively, with no rea-
sons given. Treatment was modified in an-
other participant due to inadequate clinical
response. Overall in the 8 months group,
3/25 (12%) survivors had their treatment
modified. In the long course therapy group,
there was no strict upper definition; partic-
ipants were treated for between 12 and 16
months
Confounding bias Unclear risk Adherence to treatment not reported. Pred-
nisolone was given to some participants on
the basis of disease severity but it is unclear
how this would affect the results
Iype 2014
Methods Study objective: to assess all-cause mortality and 9-months morbidity of participants with
TBM on intermittent thrice-a-week directly observed ATT
Study design: prospective observational study.
Length of follow-up from start of ATT: median of 396 days (interquartile interval 274 to
544) for the whole cohort; 425 days (interquartile interval 373 to 565) among survivors
Follow-up method: participants came to the Revised National TB Control Programme
(RNTCP) clinic (opened 6 days/week) once a month during the duration of treatment
and thereafter once every 3 months until the 31st of December 2012 (12 months after the
end of the recruitment period). In addition to this caregivers were encouraged to contact
the principal investigator by cell phone in case of any medical illness or life events
Losses to follow-up: 2 participants (both excluded for analysis)
Participants Number: 47 recruited, 43 analysed (2 deaths within 5 days and 2 losses to follow-up);
median age 36 years (range 14 to 61); 51% males
Target treatment group: adults with TBM.
Inclusion criteria: TBM diagnosis was based on consensus TBM criteria, and categorized
into definite, probable and possible TBM
Exclusion criteria: patients below the age of 13 years; withThwaites index of above 4;with a
setting for bacterial meningitis like bacterial sinusitis, otitis media, CSF, rhinorrhoea; with
history of head injury and nasal or aural bleeding; with pre-existing renal or liver disease;
immunocompromised including those with retroviral positive status; with premorbid
visual impairment, deafness and mental retardation since it would affect the morbidity
assessment; and patients who died within 5 days of initiation of RNTCP regimen
Bacteriologically confirmed TBM cases: 2/43.
Site of TB other than CNS: 11 with abnormal chest X-ray, 1 with TB pyelonephritis, and
1 with lymph nodes TB
Other clinical features: 5 tuberculoma, 9 hydrocephalus, 3 spinal arachnoiditis
Clinical severity of the disease: 15 in stage I; 24 in stage II; 4 in stage III
HIV status: HIV status tested for all participants; HIV-positive people excluded
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Duration of symptoms prior to admission: median 17 days (interquartile interval 8 to 62)
; time to treatment initiation: median 25 days (interquartile interval 15 to 65)
Interventions Short-course ATT: none.
Prolonged-course ATT: all drugs were given thrice weekly under directly observed therapy
(DOTS)
Category I: 9 months - 2(HRZS)3 /7(HR)3 for 41 participants
• Isoniazid: 10 mg/kg (9 months).
• Rifampicin: 10 mg/kg (9 months).
• Pyrazinamide: 35 mg/kg (2 months).
• Streptomycin: 750 mg (2 months).
Category II: 10 months - 2(HREZS)3 /1(HREZ)3 /7(HR)3 for 2 participants previously
exposed to ATT.
• Isoniazid: 10 mg/kg (9 months).
• Rifampicin: 10 mg/kg (9 months).
• Pyrazinamide: 35 mg/kg (2 months).
• Streptomycin: 750 mg (2 months).
Treatment was stopped at 4 months in 1 participant, at 6 months in 3 participants, and
at 7 months in 2 participants (5 due to the RNTCP DOTS providers, 1 after 124 days
due to induced drug hepatitis)
1 participant received 12 months for tuberculoma; 1 participant received 15 months for
spinal arachnoiditis
Other interventions: steroids during the 4 first weeks to all participants
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Clinical cure.
• Default.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Reported outcomes not included in this review
• Treatment failure.
• Neurological sequelae.
Notes Country: India.
Setting: Departments of Community Medicine and Neurology, Government Medical
College Hospital, Thiruvananthapuram, Kerala, a tertiary care referral centre in South
India
Study dates: from 1 January 2010 to 31 December 2011.
Study sponsor: the State Board of Medical Research, Government of Kerala
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
High risk Participants were followed-up once every 3
months in the RNTCP clinic until up to 12
months after the end of the recruitment pe-
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riod. Participants were therefore followed-
up for a median of 5.2 months after com-
pleting ATT, with an interquartile range
from 3.4 to 9.8 months
Detection bias
Clinical cure and default
Low risk Participants received ATT under DOT and
were visited monthly in the RNTCP clinic
during the duration of treatment
Attrition bias
Relapse
Low risk No losses of follow-up after completing
ATT.
Attrition bias
Clinical cure and default
Low risk 2/47 (4.2%) participants were lost to fol-
low-up during ATT.
Performance bias Unclear risk 2/35 (5.7%) participants received pro-
longed ATT: 12 months in a participant
for the complete disappearance of tubercu-
loma, and 15months in another participant
with spinal arachnoiditis
Confounding bias Unclear risk Adherence to treatment not reported. Cor-
ticosteroids given to all participants
Jacobs 1992
Methods Study objective: to evaluate the outcomes of participants with TBM treated with 12, 9
and 6 months ATT regimens
Study design: prospective comparative study. Data are reported for 3 successive cohorts
in the same centre over time. The first cohort received a 12-month regimen with 2/4
participants receiving rifampicin, the second a 9 months regimen with all participants
receiving rifampicin, and the third received a 6 months regimen with all participants
receiving rifampicin and pyrazinamide
Length of follow-up: only reported for children receiving the 6 months regimen; at least
6 months after treatment in 27/38 survivors, less than six months after treatment in 7/38
Follow-up method: not reported.
Losses to follow-up: unclear. Authors first mentioned that 2 participants were lost of
follow-up, it is unclear which treatment group theywere in but it seems theywere excluded
from the analysis. Four children were lost to follow-up after completion of ATT
Participants Number: 53; 8 cases aged 0 to 6 months, 21 cases aged 7 to 24 months, 7 cases aged 2 to
5 years, and 17 cases aged more than 5 years; 51% male
Target treatment groups: children with TBM.
Inclusion criteria
• Characteristic CSF findings (pleocytosis with mononuclear predominance,
decrease in glucose content initially or during the course of disease, elevated protein
content), and 2 or more of the following:
◦ positive tuberculin skin test (≥ 10 mm induration);
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◦ radiographic evidence of PTB that included parenchymal or hilar lymph node
involvement;
◦ history of contact with a known TB patient;
◦ presence of M. tuberculosis in CSF.
Exclusion criteria: none reported.
Bacteriologically confirmed TBM cases: 5 positive CSF cultures and 2 positive CSF acid-
fast stains (unknown whether specimen with positive stain was also culture positive)
Site of TB other than CNS: “positive” chest X-ray in 35/53 participants; other sites not
reported
Other clinical features: 7 hydrocephalus
Clinical severity of the disease: 8 in stage I; 29 in stage II; 16 in stage III
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT
• 6 months - 2HRZS/4HR. 45 participants. Daily dosage:
◦ isoniazid: 15 mg/kg (6 months);
◦ rifampicin: 20 mg/kg (6 months);
◦ pyrazinamide: 30 mg/kg (2 months);
◦ streptomycin: 40 mg/kg (2 months).
Prolonged-course ATT
• 9 months - 2HRS/7HR. 4 participants. Daily dosage:
◦ isoniazid: 15 mg/kg (9 months);
◦ rifampicin: 20 mg/kg (9 months);
◦ streptomycin: 40 mg/kg (2 months).
• 12 months - 2HSE/10HE or 2RSE/10RE. 4 participants. Daily dosage:
◦ isoniazid: 15 mg/kg;
◦ rifampicin: 20 mg/kg;
◦ streptomycin: 40 mg/kg;
◦ ethambutol: 25 mg/kg.
Other interventions
• Dexamethasone (0.3 to 0.5 mg/kg/day) for 1 week, then prednisolone (2 mg/kg/
day) for 3 to 4 weeks with tapering dosages to all children with stage II and III (45
children).
• Ventriculostomy to children who had CSF pressure > 200 mmH2O and whose
condition was severe or progressed rapidly.
• Ventriculo-peritoneal shunt to children with obstructive or persistent
hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Clinical cure.
• Default.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
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Notes Country: Thailand.
Setting: Bangkok Children’s Hospital.
Study dates: from 1984 to 1990.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
High risk The study authors did not report the follow-
upmethods. 27/38 survivorswere followed-
up for at least 6 months, and 7/38 were fol-
lowed-up for less than 6 months after com-
pleting ATT. For the 4 survivors who re-
ceived more than 6 months treatment, the
study authors did not describe the length of
follow-up after completing ATT
Detection bias
Clinical cure and default
Unclear risk The study authors did not report the follow-
up methods.
Attrition bias
Relapse
High risk 4/38 (10.5%) participants were lost to fol-
low-up after completing ATT
Attrition bias
Clinical cure and default
Unclear risk There were 2 participants lost to follow-up,
it is unclear which treatment group they
were in but it seems theywere excluded from
the analysis
Performance bias Unclear risk The study authors did not report whether
participants received prolonged ATT
Confounding bias Unclear risk The study authors did not report on ad-
herence to treatment. Corticosteroids were
given to 45/53 participants on the basis of
disease severity but it is unclear how this
would affect the results
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Methods Study objective: to investigate the presentation, diagnosis, treatment, and outcome of
TBM, and to evaluate predictors of poor outcome
Study design: prospective observational study.
Length of follow-up: at least 3 years from the date of diagnosis
Follow-up method: once the participants were discharged, follow-up in the outpatient
clinics of the general hospitals, or in the Department of Health chest clinics. The Death
Registry for occurrence of deaths, and causes of death were also checked and recorded
Losses to follow-up: 10 participants who moved from Hong Kong
Participants Number: 166; mean age 42.9 years (range 3 to 100); 51.2% male
Target treatment group: all TBM participants within the catchment area of the hospitals
participating in the Hong Kong Tuberculous Meningitis Study Group (HKTBMSG)
Inclusion criteria: 3 degrees of certainty of diagnosis of TBM were used
• Definite: positive culture of M. tuberculosis from CSF.
• Presumptive: positive smear of acid-fast bacilli from CSF.
• Probable: low CSF sugar of < 2.8 mmol/L and/or high CSF protein of > 0.45 g/L,
plus a clinical response to ATT reflected by defervescence associated with clinical
improvement 5 to 7 days after initiation of treatment.
Exclusion criteria: none mentioned.
Bacteriologically confirmed TBM cases: 68/166.
Site of TB other than CNS: 12 disseminated TB, 21 co-existing PTB
Other clinical features: 15 cerebral tuberculoma, 25 hydrocephalus
Clinical severity of the disease: 94 in stage I; 68 in stage II; 4 in stage III at admission; 91
in stage I; 69 in stage II; 6 in stage III when starting ATT
HIV status: 2 HIV-positive.
Duration of symptoms (fever, malaise, or headache) prior to admission: mean 11.26 days;
time to treatment initiation: mean 5.22 days
Interventions Short-course ATT: no disaggregated data.
Prolonged-course ATT
• Different regimens were used: HRZES in 66 participants; HRZE in 63; HRZS in
24; HRZ in 8; HRE in 2; SHRE in 1; HZE in 1; and HR 1.
• Duration of ATT: mean 11.53 months; at least 12 months in 114/166
participants. One participant received 36 months due to brainstem tuberculoma.
Other interventions: steroids were prescribed according to the decisions of the clinicians,
and were given to 105/166 participants mainly due to routine/usual practice and deteri-
orating clinical condition
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Clinical cure.
• Poor adherence.
• Default.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen (“no severe drug reaction”).
Outcomes not included in this review
• Survival with disability, classified as mild, moderate, and severe.
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Notes Country: China (Hong Kong at the time of the trial).
Setting: the catchment area of the hospitals participating in the HKTBMSG: 9 general
hospitals until 31 March 1995; 9 additional regional hospitals and the chest clinics of the
Department of Health from 31 March 1995
Study dates: from 1 April 1993 to 31 March 2000.
Study sponsor: none mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk All participants were followed-up for at least
3 years from the date of diagnosis, until
death, or until they left the study site, in
the outpatient clinics of the general hospi-
tals or chest clinics. However, because we
don’t know how long each participant was
treated for, it is unclear how many par-
ticipants could be followed for at least 18
months
Detection bias
Clinical cure and default
Low risk All participants were followed-up in outpa-
tient chest clinics under DOT
Attrition bias
Relapse
Low risk No losses of follow-up during the follow-up
period.
Attrition bias
Clinical cure and default
Unclear risk 10/166 (6.0%) were lost to follow-up dur-
ing ATT.
Performance bias High risk Participants received individualized treat-
ment regimens according to the decisions of
the clinicians
Confounding bias Unclear risk Adherence to treatment is reported. Corti-
costeroids were prescribed to 105/166 par-
ticipants according to the decisions of the
clinicians, but it is unclear how this would
affect the results
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Methods Study objective: to review the results of 9-month ATT in adults with TBM
Study design: prospective observational study.
Length of follow-up:mean 19.8months after completion of ATT (range 12 to 29months)
in the 21 survivors who completed the follow-up period
Follow-up method
• During ATT: after discharge, observed monthly until completion of ATT.
• After ATT: assessed every 3 to 6 months.
Losses to follow-up: during ATT, 4 cases dropped out during the early stage of treatment
(1/4 stage I, 2/18 stage II, 1/6 stage III), out of whom 3 presented poor compliance
and one presented erythema multiforme from pyrazinamide. After completing ATT, 1
additional case lost to follow-up
Participants Number: 28; mean age 32 years (range 17 to 76 years); gender not reported
Target treatment groups: adults with TBM.
Inclusion criteria: adults with TBM, diagnostic algorithm not described
Exclusion criteria: none reported.
Bacteriologically confirmed TBM cases: 12/28.
Site of TB other than CNS: 18 active PTB including 8 miliary TB, 4 caseating cervical
lymphadenitis, 2 otitis media, and 1 epididymoorchitis
Other clinical features: 1 tuberculoma, 1 spinal arachnoiditis, 1 optochiasmic arachnoidi-
tis, 10 communicating hydrocephalus
Clinical severity of the disease: 4 in stage I; 18 in stage II; 6 in stage III
HIV status: not reported.
Duration of symptoms prior to admission: range 3 days to 3 months; time to treatment
initiation: study authors reported “all patients were treated immediately”
Interventions Short-course ATT: none.
Prolonged-course ATT: 9 months - 2HRZS/7HR, single daily dosage
• Isoniazid: 300 mg orally (9 months).
• Rifampicin: 600 mg orally (450 mg if < 45 kg) (9 months).
• Pyrazinamide: 1500 mg orally (2 months).
• Streptomycin 750 to 1000 mg intramuscular (2 months).
Other interventions
• Prednisolone (60 mg/day) to 10 participants with hydrocephalus, arteritis, spinal
and optochiasmic arachnoiditis.
• Repeated lumbar puncture in 7 participants with hydrocephalus.
• Ventriculo-peritoneal shunting in the 3 participants (grade III) with hydrocephalus
who were comatose with decerebrate rigidity.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
• Poor adherence.
• All adverse effects related to the ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
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• Treatment failure.
• Neurological sequelae.
Notes Country: Thailand.
Setting: Department of Medicine, Ramathibodi Hospital, Bangkok
Study dates: 1983 and 1984.
Study sponsor: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk Participants were assessed every 3 to 6
months for a mean duration of follow-up
of 19.8 months after completion of ATT,
ranging from 12 to 29 months
Detection bias
Clinical cure and default
Low risk After discharge, participants were followed-
up monthly until completion of ATT
Attrition bias
Relapse
Low risk 1/23 (4.3%) participant was lost to follow-
up after completing ATT
Attrition bias
Clinical cure and default
High risk 3/28 (10.7%) participants were lost to fol-
low-up during ATT.
Performance bias Low risk 1/23 (4.3%) participant received longer
ATT due to adverse event
Confounding bias Unclear risk Adherence to treatment not reported. Pred-
nisolone was given to 10/28 participants,
but it is unclear how this would affect the
results
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Methods Study objective: to evolve suitable regimens for the treatment of TBM in children
Study design: series of 3 consecutive prospective observational studies
Length of follow-up: between 4.5 and 8 years from start of ATT
Follow-up method: “patients were hospitalised for the first 2 months of treatment. Those
who were discharged during the first 2 months attended as outpatients daily for chemo-
therapy until they completed 2 months. After 2 months, the participants attended twice
or once a week (or once in 15 days if they lived outside Madras) to collect a supply of
drugs. Their medication was fully supervised on the days they attended. Progress was
assessed mainly by monthly clinical examination including a detailed neurological exam-
ination and, if indicated, a CSF examination.” In the long-term follow-up study (1989),
participants were called back to be seen in clinic (98/119), or completed a questionnaire
that was posted to them (2/119)
Losses to follow-up: 6 at 12 months. 2 additional cases in the long-term follow-up study
Participants Number: 180 recruited; mean age 2.8 years (range 1 to 10 years); 53% male
Target treatment groups: children aged between 1 and 12 years with TBM
Inclusion criteria: the diagnosis ofTBMwas based on clinical symptoms and signs (notably
fever, vomiting, irritability, apathy, refusal to play, anorexia, constipation, well-marked
meningeal signs, impaired consciousness, coma, and widespread paralysis) and on the
CSF findings
Exclusion criteria: children who had received more than 4 weeks of ATT, and evidence of
renal or liver disease
Bacteriologically confirmed TBM cases: 83/180. All cultures were sensitive to rifampicin.
Resistance to streptomycin (1), isoniazid (3), ethambutol (1), and streptomycin and iso-
niazid (9)
Site of TB other than CNS: 99 abnormal chest X-ray suggestive of PTB, 2 spinal TB
Other clinical features: 14 hydrocephalus, 28 optic disc pallor or optic atrophy, 4 cortical
blindness
Clinical severity of the disease: 24 in stage I; 139 in stage II; 17 in stage III
HIV status: not reported.
Severe malnutrition: 34% according to the growth standards from the Indian Council of
Medical Research
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: none.
Prolonged-course ATT: 12 months
Regimen I: 2SHR/4S2EH/6EH; 77 participants
• Isoniazid, 12 months, daily.
• Rifampicin, 2 month, daily.
• Streptomycin, daily the first 2 months; then twice a week for 4 additional months.
• Ethambutol, from the 3rd month until end of treatment, daily.
Regimen II: 2SHRZ/10 EH; 29 participants
• Isoniazid, 12 months, daily.
• Rifampicin, 2 months, daily.
• Streptomycin, 2 months, daily.
• Pyrazinamide, 2 months, daily.
• Ethambutol, from the 3rd month until the end of treatment, daily.
Regimen III: 2R2SHZ/10EH; 74 participants
• Isoniazid, 12 months, daily.
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• Rifampicin, twice a week for 2 months.
• Streptomycin, 2 months, daily.
• Pyrazinamide, 2 months, daily.
• Ethambutol, from the 3rd month until the end of treatment, daily.
Longer treatment than 12 months in 23 participants
• 13 to 18 months in 12 participants.
• 19 to 24 months in 10 participants.
• 36 months in 1 participant.
Reasons for longer treatment
• CSF abnormality, surgery, or neurological complications.
• Persistence of abnormality on chest radiography.
• Spinal TB.
• Severe respiratory infection in 1 participant with severe sequelae (the participant
died in the twenty-first month).
• Detection of PTB in one of the parents of 1 participant.
Doses of anti-tubercular drugs
• Isoniazid: 20 mg/kg in daily dosage in the first 20 participants. Then reduced to 12
mg/kg due to a substantial number of jaundice.
• Rifampicin: 12 mg/kg.
• Pyrazinamide: 30 mg/kg.
• Streptomycin: 40 mg/kg.
• Ethambutol: 17.5 mg/kg.
Other interventions
• Steroids to all participants. For those in stage II and III, intramuscular
dexamethasone (2 to 4 mg/6 to 8 hours) for the first 3 or 4 days followed by oral
prednisolone (1 to 2 mg/kg).
• Supportive therapy (intravenous fluids, anti-oedema measures, anti-convulsants
and vitamins).
• Ventriculo-peritoneal shunt in 7 cases for hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Complete recovery without sequelae.
• Neurological sequelae.
Notes Country: India.
Setting: Tuberculosis Research Centre, Institute of Child Health and Hospital for Chil-
dren, Chennai
Study dates: from October 1977 to April 1981.
Study sponsor: none reported.
Risk of bias
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Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk All survivors who completed 12-month
ATT were assessed monthly up to 24
months. The follow-up assessments in-
cluded neurological examination, CSF ex-
amination, and chestX-ray. Afterwards, sur-
vivors were called back to be seen in clinic
(98/119), or completed a questionnaire that
was posted to them (2/119). They were fol-
lowed-up for between 42 to 84 months af-
ter completing ATT
Detection bias
Clinical cure and default
Low risk Participants were hospitalized for the first 2
months of treatment and those who were
discharged during the first 2 months at-
tended as outpatients daily for chemother-
apy until they completed 2 months. After
2 months, the participants attended twice
or once a week (or once in 15 days if they
lived outside Madras) to collect a supply
of drugs. Progress was assessed mainly by
monthly clinical examination including a
detailed neurological examination and, if
indicated, a CSF examination
Attrition bias
Relapse
Low risk 2/119 (1.7%) participants were lost to fol-
low-up after completing treatment
Attrition bias
Clinical cure and default
Unclear risk 14/180 (7.8%) participants were lost to fol-
low-up during ATT
Performance bias High risk 23/119 (19.3%) received prolonged ATT
for various reasons: CSF abnormality,
surgery. or neurological complications; per-
sistence of abnormality on chest radiogra-
phy; spinal TB; severe respiratory infection
in 1 participant with severe sequelae; and
detection of PTB in one of the parents of 1
participant
Confounding bias Unclear risk Adherence to treatment was not assessed or
reported. Corticosteroids were given to all
participants, and 7 participants had ven-
triculo-peritoneal shunt for hydrocephalus.
Three different regimenswere used. It is un-
clear how this would affect the results
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Methods Study objective: to assess the results of two 9 months intensive regimens with 5 drugs in
the initial phase followed by 2 bactericidal drugs during the follow-up phase in children
with TBM
Study design: RCT that compared 2 ATT regimens of 9 months duration. Treated as
prospective observational data for the purposes of this review
Length of follow-up: 60 months from start of ATT.
Follow-up method: participants were hospitalized for a minimum period of 2 months or
more, if necessary. However, those who showed very good improvement were discharged
at request before completing the intensive phase of 2 months treatment and asked to
attend daily until they completed 2months of treatment. After 2 months, the participants
attended twice or once a week (or once in 15 days if they lived outside Chennai city) to
collect drugs. They were given the drugs under supervision on the days they attended.
The progress was assessed by monthly examination until completion of ATT. In the long-
term follow-up study, participants were followed-up once a month till 24 months, once
in 3 months till 36 months, and thereafter once in 6 weeks till 60 months
Losses to follow-up
• 29 participants were discharged against medical advice. Among them, 10 died
within 4 days of discharge and the study authors included them in the analysis as they
assumed they had died of TBM; 10 died at a later point and were not included in the
analysis; and 9 were alive at the end of ATT, but not followed-up during the long-term
follow-up study.
• 10 participants received modified treatment and were not followed-up during the
long-term follow-up study.
• No losses to follow-up among the 128 participants who completed the 9-month
ATT and 5-year follow-up.
Participants Number: 215; 56% aged less than 3 years (2 years in abstract) and 75% less than 5 years
(range 1 to 12 years); “approximately” 50% male
Target treatment groups: children aged 1 to 12 years with TBM
Inclusion criteria: the diagnosis of TBM was based on clinical symptoms and signs (like
fever, vomiting, irritability, apathy, anorexia, constipation, refusal to play, in the initial
stages followed by presence of meningeal signs and impaired consciousness, coma, and
widespread paralysis) and theCSFfindings (CSFprotein value ofmore than40mg/dLplus
cell count more than 10/mm3 (predominantly lymphocytes) was taken as confirmatory).
Exclusion criteria: children who had receivedmore than 4 weeks of ATT, evidence of renal
or liver disease, and children with optic atrophy or pallor of optic discs
Bacteriologically confirmed TBM cases: 101/215
Site of TB other than CNS: 111 abnormal chest X-ray suggestive of PTB
Other clinical features: 74 suspected hydrocephalus (68 confirmed with CT scan), 5 mild
pallor of optic disc, and 7 optic atrophy with blindness
Clinical severity of the disease on admission: 45 in stage I; 160 in stage II; 10 in stage III
HIV status: not reported.
Severe malnutrition: 40% according to the growth standards from the Indian Council of
Medical research
Duration of symptoms prior to admission: 1 to 14 days in 53 participants, 2 to 4 weeks
in 108 participants, 1 to 3 months in 24 participants. Time to treatment initiation not
reported
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Interventions Short-course ATT: none.
Prolonged-course ATT: 9 months
1. Regimen I: 2S7H7E7R3Z3 /7R2H2 ; 89/185 participants for analysis
First 2 months
• Streptomycin, isoniazid and ethambutol, daily.
• Rifampicin and pyrazinamide thrice a week.
Following 7 months
• Rifampicin and isoniazid thrice a week.
2. Regimen II: 2S7H7E7R2Z2 /7R2H2; 96/185 participants for analysis
First 2 months
• Streptomycin, isoniazid, and ethambutol, daily.
• Rifampicin and pyrazinamide twice a week.
Following 7 months
• Rifampicin and isoniazid thrice a week.
Treatment was modified in 10 participants (unknown reason; excluded from analysis)
Doses of antituberculous drugs
• Isoniazid: 12 mg/kg.
• Rifampicin: 12 mg/kg.
• Pyrazinamide: 30 mg/kg in the thrice weekly regimen; 40 mg/kg in the twice
weekly regimen.
• Streptomycin: 40 mg/kg.
• Ethambutol: 20 mg/kg for 2 weeks, followed by 15 mg/kg for the next 6 weeks. 20
mg/kg in daily dosage in the first 20 participants. Then reduced to 12 mg/kg due to a
substantial number of jaundice.
Other interventions
• Steroids to all participants. For those seriously ill, intramuscular dexamethasone (2
to 4 mg/6 to 8 hours) for the first 3 or 4 days followed by oral prednisolone (1 to 2 mg/
kg).
• Supportive therapy (intravenous fluids, anti-oedema measures, anti-convulsants
and vitamins).
• Ventriculo-peritoneal shunt in 38 cases for hydrocephalus.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Complete recovery without sequelae.
• Neurological sequelae.
Notes Country: India.
Setting: The Tuberculosis Research Centre in collaboration with the Institute of Child
Health and Hospital for Children, Chennai
Study dates: not reported.
Study sponsor: none reported.
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Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk All the participants who completed 9-
month ATT were followed-up once a
month until 24 months, once in 3 months
until 36 months and thereafter once in 6
weeks until 60 months. AT all these visits,
a complete neurological examination was
done, and CSF examination repeated until
normal
Detection bias
Clinical cure and default
Low risk Participants were hospitalized for a mini-
mum period of 2 months or more, if neces-
sary. After 2 months, they attended twice or
once a week (or once in 15 days if they lived
outsideChennai city) to collect drugs, given
under supervision. The progress was as-
sessed by monthly examination until com-
pletion of ATT
Attrition bias
Relapse
Low risk None of the 137 survivors after completing
ATT were lost to follow-up during the fol-
low-up period
Attrition bias
Clinical cure and default
High risk 29/215 (13.5%) participants were lost to
follow-up during treatment
Performance bias Unclear risk 10 participants receivedmodified treatment
for unknown reason. It is unclear whether
this was prolonged, shortened or stopped.
The study authors excluded these 10 partic-
ipants from the analysis
Confounding bias Unclear risk Adherence to treatment was not assessed or
reported. Corticosteroids were given to all
participants, and 38 participants had ven-
triculo-peritoneal shunt for hydrocephalus.
Two different regimens were used. It is un-
clear how this would affect the results
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Methods Study objective: to assess effectiveness of RevisedNational TBControl Program (RNTCP-
DOTS) regimes among TBM participants
Study design: prospective observational study.
Length of follow-up: 6 months after completing ATT.
Follow-up method: participants were followed-up monthly. No data are given on the way
they were followed-up
Losses to follow-up: 0/42.
Participants Number: 42; range age 16 to 78 years; 54.8% males.
Target treatment group: adults with TBM.
Inclusion criteria: the diagnosis of TBM was made when participants with meningitis
(CSF pleocytosis) were admitted with symptoms lasting 1 week or more, with negative
CSF Gram’s and India ink stains, negative CSF culture for pyogenic bacteria, plus one or
more of the following
• CT scan consistent with TBM (hydrocephalus, basal meningeal enhancement, ring
enhancing lesion).
• Chest X
ray consistent with active pulmonary TB.
• Good response to antituberculous chemotherapy.
Exclusion criteria: children, participants with HIV, and participants with bacterial menin-
gitis
Bacteriologically confirmed TBM cases: 4/42
Site of TB other than CNS: 9 with abnormal chest X-ray and 2 axillary lymph node TB
Other clinical features: cases of hydrocephalus with no disaggregated data
Clinical severity of the disease: 21 in stage III with no disaggregated data between stage I
and II
HIV status: HIV positive people were excluded.
Duration of symptoms prior to admission: less than 10 days; time to treatment initiation:
not reported
Interventions Short-course ATT: none.
Prolonged-course ATT: 9 months - 2(HREZ)3 /7(HR)3
All drugs were given thrice weekly under DOTS (all participants started with DOTS;
78% actually received DOTS)
Dosages not reported.
Other interventions: steroids during the 6 first weeks to all participants
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Clinical cure.
• Default.
• All adverse effects related to ATT.
Reported outcomes not included in this review
• Neurological sequelae.
Notes Country: India.
Setting:Department ofNeurology,NEIGRIHMS,NorthEastern IndiraGandhiRegional
Institute of Medical Sciences (An Autonomous Institute, Ministry of Health and Family
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Welfare, Govt of India, Shillong, India)
Study dates: from September 2008 to March 2011.
Study sponsor: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk Participants were followed-up monthly for
6 months. Methods of follow-up are not
described
Detection bias
Clinical cure and default
Unclear risk All drugs were given thrice weekly under
DOTS, but “finally 78% received actual
DOTS”
Attrition bias
Relapse
Unclear risk No losses of follow-up are described during
the follow-up period, but the study authors
did not specifically state that all participants
were followed for the full period
Attrition bias
Clinical cure and default
Low risk The study authors stated that 35 partici-
pants completed ATT, and 7 died. No losses
of follow-up during were reported the dura-
tion of the treatment, but the study authors
did not specifically state that none occurred
Performance bias Unclear risk It was not reported whether participants re-
ceived longer ATT than the planned treat-
ment
Confounding bias Unclear risk Adherence to treatment was not reported.
All participants received corticosteroids
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Methods Study objective: to determine whether adjunctive dexamethasone was associated with
reduced mortality or neurological disability 5 years after entry into the original RCT
Study design: randomized double-blind placebo-controlled trial of antitubercular therapy
with dexamethasone versus antitubercular therapy with placebo. Treated as prospective
observational data for the purposes of this review
Length of follow-up: median of 5.2 years (interquartile range 4.7 to 5.5 years) after
randomization
Follow-up method: during ATT, participants were assessed at 1, 2, 6, and 9 months
after randomization. At each point, disability was assessed and scored. Participants were
contacted by letter or telephone, or both, and attended clinic for assessment 5 years after
randomization into the original study. If the participant had died prior to the follow-up
assessment, the date and cause of death was requested from the relatives. Participants were
assessed using a standard questionnaire and neurological examination. Four survivors who
were unable to attend the hospital gave verbal consent and were assessed by telephone
interview
Losses to follow-up: 50 participants. 5 were lost to follow-up after 1 month, 3 after 2
months, 1 after 3 months, 1 after 4 months, and 40 were lost during the follow-up period
between 9 months and 5 years
Participants Number: 545 participants randomized in the original study and 495 followed up to 5
years; median age 35 years (range 15 to 88); 61% male
Target treatment groups: adults and adolescents over 14 years with TBM
Inclusion criteria
• Clinical evidence of meningitis was defined as the combination of nuchal rigidity
and CSF abnormalities.
TBM was defined as follows.
• Definite: acid-fast bacilli on CSF smear.
• Probable: one or more of the following: suspected active PTB on chest radiography,
acid-fast bacilli found in any specimen other than the CSF, and clinical evidence of
other extra-pulmonary TB (EPTB).
• Possible: at least 4 of the following: a history of TB, predominance of lymphocytes
in the CSF, a duration of illness of more than 5 days, a ratio of CSF glucose to plasma
glucose of less than 0.5, altered consciousness, yellow CSF, or focal neurologic signs.
Participants were reclassified on discharge as having definite TBM if acid-fast bacilli were
seen or M. tuberculosis was cultured from the CSF, or as not having TBM if another
diagnosis was confirmed by microbiological or histopathological evaluation
Exclusion criteria
• Corticosteroids contraindicated.
• Patients who received more than 1 dose of any corticosteroid or more than 30 days
of ATT immediately before study entry.
• Consent withheld.
Bacteriologically confirmed TBM cases: 187/545 with positive culture from CSF or an-
other site
Site of TB other thanCNS: 214 active non-miliary PTB on chest radiography, 155 miliary
TB, 114 at another site (other than lung or CNS)
Other clinical features: not reported.
Clinical severity of the disease: 176 in stage I; 247 in stage II; 122 in stage III
HIV status: 436 HIV-negative; 98 HIV-positive; 11 not tested
Duration of symptoms prior to admission: median 15 days; time to treatment initiation
not reported
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Interventions Short-course ATT: none.
Prolonged-course ATT: 9 months.
• 3RHZS/6RHZ (HIV-negative participants; 399).
• 3RHZE/6RHZ (HIV-positive participants; 98).
• 3RHZES/6RHZ (previously treated participants; 43).
• HZE (2 participants).
• SE (1 participant).
Daily doses
• Isoniazid: 5 mg/kg, oral (9 months).
• Rifampicin: 10 mg/kg, oral (9 months).
• Pyrazinamide: 25 mg/kg (maximum dose 2g), oral (9 months).
• Streptomycin: 20 mg/kg (maximum dose 1g), intramuscular (3 months).
• Ethambutol: 20 mg/kg (maximum dose 1.2 g), oral (3 months).
Drugs were administered by nasogastric tube to participants who were unable to swallow
Other interventions
• Participants were randomized to receive dexamethasone (0.3 to 0.4 mg/kg/day,
intravenous, according to TBM grade at presentation and tapered over 6 to 8 weeks;
274 participants) or placebo (271 participants).
• Mannitol was given in 199 participants.
• None of the participants received antiretroviral drugs.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse (defined by the study authors as re-treatment for TB).
• Death from any cause.
• Clinical cure.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Coma-clearance time.
• Fever-clearance time.
• Time to discharge from the hospital.
• Treatment failure and time to treatment failure (the term “relapse” is used in the
article instead of treatment failure, defined by the onset of new focal neurological signs
or a fall in the Glasgow coma score of 2 points or more for 2 or more days after more
than 7 days of clinical stability or improvement at any time after randomization).
• Presence of focal neurologic deficit 9 months after randomization.
• Disability status at 5 years of follow-up.
Notes Country: Vietnam.
Setting: Pham Ngoc Thach Hospital (tertiary referral centre for patients with severe TB)
and the Hospital for Tropical Diseases (tertiary referral centre for patients with infectious
diseases) in Ho Chi Minh City
Study dates: from 4 April 2001 to 29 March 2003.
Study sponsor: the Wellcome Trust, UK.
Risk of bias
Bias Authors’ judgement Support for judgement
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Detection bias
Relapse
Low risk Participants were contacted by letter or tele-
phone, or both, and attended clinic for as-
sessment 5 years after randomization into
the original study. If the participant had
died prior to the follow-up assessment, the
date and cause of death was requested from
the relatives. Participants were assessed us-
ing a standard questionnaire and neurolog-
ical examination. Four survivors who were
unable to attend the hospital gave verbal
consent and were assessed by telephone in-
terview
The accomplished length of follow-up was
5.2 years (median) with an interquartile
range of 4.7 to 5.5 years after randomiza-
tion
Detection bias
Clinical cure and default
Low risk During ATT, participants were assessed at
1, 2, 6, and 9 months after randomization.
At each point, disability was assessed and
scored
Attrition bias
Relapse
High risk 40/336 (11.9%) participants were lost to
follow-up during the follow-up period
Attrition bias
Clinical cure and default
Low risk 10/545 (1.8%) participants were lost to fol-
low-up during ATT
Performance bias Unclear risk 143 participants received altered ATT reg-
imen due to adverse events. It is not stated
whether the regimen was prolonged for
these participants
Confounding bias Unclear risk Adherence to treatment is not reported.
274/545 participants were randomized to
receive either corticosteroids or placebo, but
it is unclear how this would affect the results
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Methods Study objective: to demonstrate non-inferiority of a 6-month intensive ATT regimen
compared with other published ATT regimens for TBM
Study design: prospective observational study.
Length of follow-up: at least 2 years after completing ATT.
Follow-up method: during ATT, home-based participants were reviewedmonthly; relapse
rate was determined by telephonic contact with the child’s caregiver at least 2 years after
therapy completion or if the participant was reviewed in our neurology outpatient clinic
after this time
Losses to follow-up: 29 children after completing ATT (they completed treatment in
hospital but caregivers could not be traced)
Participants Number: 184; median age 58 months (range 3 to 156 months); 49% male
Target treatment groups: children from 0 to 13 years.
Inclusion criteria: TBM was classified as follows.
• Definite TBM: when M. tuberculosis was cultured from CSF or polymerase chain
reaction (PCR), or both, for M. tuberculosis tested positive in CSF.
• Probable TBM: based on clinical signs of meningitis in the presence of
characteristic CSF findings (macroscopically clear, pleocytosis usually with lymphocyte
predominance, elevated protein, and reduced glucose). In addition, 2 of the following
criteria were required: other clinical specimens culture positive for M. tuberculosis or
positive TB histology or both, a positive tuberculin skin test, a chest radiograph
compatible with TB, a cranial CT or magnetic resonance imaging (MRI) compatible
with TBM, growth failure with crossing of weight-for-age percentiles or finally,
household contact with sputum smear-positive PTB.
Exclusion criteria: multidrug-resistant TB (defined as resistance to at least isoniazid and
rifampicin)
Bacteriologically confirmed TBM cases: 16/184.
Site of TB other than CNS: not reported.
Other clinical features: 12 TB mass lesion which refers to either large tuberculoma(s) or
TB abscesses; 72 communicating hydrocephalus, 37 non-communicating hydrocephalus
Clinical severity of the disease: 22 in stage I; 98 in stage II; 64 in stage III
HIV status: 128 HIV-negative, 22 HIV-positive, 5 exposed HIV-negative, 29 not tested
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: 6 months - 6HRZEth, single daily dosage
• Isoniazid: 20 mg/kg, maximum 400 mg (6 months).
• Rifampicin: 20 mg/kg, maximum 600 mg (6 months).
• Pyrazinamide: 40 mg/kg, maximum 2g (6 months).
• Ethionamide 20 mg/kg, maximum 750 mg (6 months).
24 children received prolonged ATT up to 18 months for different reasons (antitubercu-
lous drug-induced hepatotoxicity, poor adherence, TB mass lesions, TB-immune recon-
stitution inflammatory syndrome)
Prolonged-course ATT: 9 months
• 22 HIV-infected children were treated for 9 months because of perceived slower
response to treatment.
• 3 additional children with isoniazid-monoresistant TB were treated with the
addition of a fluoroquinolone and terizidone for 9 months.
Other interventions
• Prednisone (2 mg/kg/day, maximum 60 mg/day) given to all children for the first
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month of treatment and gradually discontinued over the next 2 weeks.
• Ventriculo-peritoneal shunt to 34 children and endoscopic third ventriculostomy
to 3 children to treat non-communicating hydrocephalus.
• Acetazolamide (50 mg/kg/day) and furosemide (1 mg/kg/day) for communicating
hydrocephalus.
• Combination antiretroviral therapy consisting of stavudine, lamivudine and
efavirenz initiated as soon after HIV diagnosis as possible.
Outcomes Outcomes included in this review (directly reported or deductible from reported data)
• Relapse.
• Death from any cause.
• Death after 6 months of ATT.
• Clinical cure.
• Default.
• Poor adherence.
• All adverse effects related to the ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
Notes Country: South Africa.
Setting: Tygerberg Children’s Hospital, a referral hospital in the Western Cape province
Study dates: from 1 January 2006 to 31 December 2009.
Study sponsor: none.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Low risk Relapse rate was determined by telephonic
contact with the child’s caregiver at least 2
years after therapy completion
Detection bias
Clinical cure and default
Low risk During the duration of the treatment, 1
group of participants was hospital-based.
The other group of participants was home-
based and were reviewed monthly
Attrition bias
Relapse
High risk 29/184 (15.8%) children were lost to fol-
low-up.
Attrition bias
Clinical cure and default
Low risk No losses of follow-up during the duration
of the treatment.
Performance bias High risk 28/177 (15.8%) children received pro-
longed ATT up to 18 months for differ-
ent reasons (antituberculous drug-induced
hepatotoxicity, poor adherence, TBmass le-
sions, TB-immune reconstitution inflam-
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matory syndrome)
Confounding bias Unclear risk All children received prednisone. 3 children
are reported to poorly adhere to treatment,
but it is unclear how this would affect the
results
Visudhiphan 1989
Methods Study objective: to evaluate the results of treating TBM with isoniazid and rifampicin
Study design: prospective observational study.
Length of follow-up: 1½ to 7 years after finishing the course of ATT
Follow-up method: not described.
Losses to follow-up: 4 participants lost during ATT, none after completing ATT
Participants Number: 51; 26/51 children were less than 4 years (range 7 months to 14 years); 47%
male
Target treatment groups: children with TBM.
Inclusion criteria: all TBM cases were diagnosed according to the characteristic clinical
features and typical CSFfindings (that is, lymphocytic pleocytosis, decreased glucose level,
and elevation of protein content). At least 3 of the following supporting criteria had to
be present
• A history of contact with a known TB patient.
• A positive skin test result.
• Radiological evidence of PTB.
• The characteristic change of large intracranial vessels, as seen in a cerebral
angiogram.
• Typical basal arachnoiditis and dilation of the ventricles, as seen in CT of the brain.
Participants who had characteristic clinical features with the presence of M. tuberculosis
in the CSF but without typical CSF findings were also included in this study
Exclusion criteria: none mentioned.
Bacteriologically-confirmed TBM cases: 13/51. Partial resistance to H in 2 participants,
and to R in 2 other participants
Site of TB other than CNS: not reported.
Other clinical features: 1 non-communicating hydrocephalus, 43 increased intracranial
pressure
Clinical severity of the disease: 5 in stage I; 25 in stage II; 21 in stage III
HIV status: not reported.
Duration of symptoms prior to admission and time to treatment initiation: not reported
Interventions Short-course ATT: none.
Prolonged-course ATT: 12 months - 12 HR.
Daily, 1 to 2 hours before breakfast, either orally or by nasogastric tube:
• Isoniazid 10 to 15 mg/kg.
• Rifampicin 15 mg/kg.
Other interventions
• Dexamethasone 0.3 to 0.5 mg/kg/day in the first week of ATT, then prednisolone
2 mg/kg/day for 2 to 3 weeks, followed by gradually tapered dose, to all participants.
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• Ventriculostomy to 3 participants who had a high CSF pressure (> 200 mmH20)
and whose condition deteriorated rapidly after the initial lumbar puncture.
• Ventriculoperitoneal shunt to 1 participant with obstructive hydrocephalus.
• Acetazolamide (25 to 50 mg/kg/day in 3 or 4 divided doses) and repetitive lumbar
puncture for management of increased intracranial pressure to 41 participants.
Outcomes Outcomes included in this review, directly reported (directly reported or deductible from
reported data)
• Relapse.
• Death from any cause.
• Clinical cure.
• All adverse effects related to ATT.
• Drug toxicity leading to discontinuation of regimen.
Outcomes not included in this review
• Neurological sequelae.
Notes Country: Thailand.
Setting: Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok
Study dates: from January 1979 to December 1985.
Study sponsor: none mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Detection bias
Relapse
Unclear risk Survivors were followed-up for a period
ranging from 1.5 to 7 years after finishing
the course of ATT. No details are given on
the methods of follow-up
Detection bias
Clinical cure and default
Unclear risk It is not stated how participants were given
antituberculous drugs and the way they
were followed-up during the 12-month
treatment
Attrition bias
Relapse
Low risk No participants were lost to follow-up after
completing treatment for at least 1.5 years
Attrition bias
Clinical cure and default
Unclear risk 4/51 (7.8%) participants were lost to fol-
low-up during ATT.
Performance bias Low risk There were 44 survivors at the time of com-
pleting ATT. The study authors stated that
“44 patients who received the full course of
treatment with isoniazid and rifampicin for
12 months were followed for 1.5 to 7 years
after finishing the course of treatment.” No
extended treatment is described
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Confounding bias Unclear risk Adherence to treatment was not assessed or
reported. All participants received corticos-
teroids
ADA: adenosine deaminase activity; AFB: acid-fast bacilli; ATT: antituberculous treatment, BCG: Bacillus Calmette-Guérin; CNS:
central nervous system; CSF: cerebrospinal fluid; CT: computerized tomography; DOT: directly observed therapy; E: ethambutol;
ELISA: enzyme-linked immunosorbent assay; EPTB: extra-pulmonary tuberculosis; Eth: ethionamide; H: isoniazid; HIV: human
immunodeficiency virus; PCR: polymerase chain reaction; PPD: purified protein derivative; PTB: pulmonary tuberculosis; R:
rifampicin; RCT: randomized controlled trial; RDT: Rural Development Trust; RNTCP: Revised National Tuberculois Control
Programme; S: streptomycin; TB: tuberculosis; TBM: tuberculous meningitis; UK: United Kingdom; VFHCS: Vicente Ferrer HIV
Cohort Study; Z: pyrazinamide.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Acharya 1985 There was no data on relapse.
Agrawal 1989 There was no data on length of antituberculous treatment (ATT), it is unlikely that there was follow-up of
participants after completing ATT and there was no data on relapse
Alarcón 2013 There was no follow-up of participants after completing ATT.
Alvarez-Uria 2013 There was no follow-up of participants after completing ATT.
Anuradha 2010 There was no follow-up of participants after completing ATT.
Bandyopadhyay 2009 There was no follow-up of participants after completing ATT.
Bhagwati 1986 There was no data on length of ATT, and no follow-up of participants after completing ATT
Bokade 2014 There was no data on length of ATT, and no follow-up of participants after completing ATT
Cardozo 1976 Retrospective collection of data.
Chan 1988 Study examined prolonged therapeutic external ventricular drainage, and included four participants with
TBM
Chan 2005 No follow-up of participants after completing ATT.
Chandra 1976 There was no data on length of ATT, and no follow-up of participants after completing ATT
Chugh 2009 There was no data on length of ATT, and no follow-up of participants after completing ATT
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Cotton 1991 There was no data on follow-up of participants after completing ATT
Cotton 1993 There was no data on length of ATT, and no follow-up of participants after completing ATT
de March-Ayuela 1994 There was no data on length of ATT and no data on relapse.
Degefie 2003 There was no data on relapse.
Dikshit 1976 The ATT regimen did not include rifampicin.
Donald 1986 There was no data on length of ATT, and no follow-up of participants after completing ATT
Donald 1996 There was no data on length of ATT, and no follow-up of participants after completing ATT
Do anay 1989 There was no follow-up of participants after completing ATT.
Eintracht 2000 Diagnostic test accuracy study, and there was no data on length of ATT and outcomes
Elliott 1993 We contacted the authors: there was no disaggregated data for tuberculous meningitis (TBM)
Elliott 1995a Duplicated cohort of participants from Elliott 1993.
Elliott 1995b Duplicated cohort of patients from Elliott 1993.
Erdös 1974 Retrospective study.
Escobar 1975 The ATT regimen did not include rifampicin.
Ganiem 2009 There was no data on length of ATT, and no follow-up of participants after completing ATT
Garg 2010 There was no follow-up of participants after completing ATT.
Girgis 1978 There was no follow-up of participants after completing ATT.
Girgis 1991 The ATT regimen did not include rifampicin.
Girgis 1993 Retrospective analysis of records.
Goyal 2014 There was no data on length of ATT not reported, and no follow-up of participants after completing ATT
Guillen 1993 Retrospective analysis of hospital records.
Gujjar 2009 This study examined the efficacy of hypervolemia-hypertension-hemodilution (HHH) regime in partici-
pants with TBM with arteritis. The study authors reported outcomes during ATT but there was no follow-
up after completing ATT
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Gupta 2013 There was no follow-up of participants after completing ATT.
Gupta 2015 There was no follow-up of participants after completing ATT.
Heemskerk 2016 There was no follow-up of participants after completing ATT.
Hoose 1990 Retrospective cohort.
Immanuel 1990 There was no data on relapse.
Irfan 1995 It is unclear whether this is a prospective or retrospective analysis. The study authors did not describe the
ATT regimen, and did not report relapse outcome
Jain 2011 There was no follow-up of participants after completing ATT.
Jain 2013 We contacted the study authors: there was unknown duration of ATT and no follow-up after completing
treatment
Jakka 2005 Study looking at prognostic implication of cerebrospinal fluid (CSF) adenosine deaminase activity (ADA)
; there was no data on relapse
Jubelt 2006 Duplicate cohort of patients from Török 2011a.
Julka 1998 There was no data on length of ATT, and no data on relapse.
Kalita 1999 There was no data on length of ATT, and no follow-up of participants after completing ATT
Kalita 2001 Duplicate cohort of patients from Kalita 1999.
Kalita 2007 There was no follow-up of participants after completing ATT.
Kalita 2009 There was no follow-up of participants after completing ATT.
Kalita 2014 There was no follow-up of participants after completing ATT.
Karande 2005a There was no follow-up of participants after completing ATT.
Karande 2005b There was no follow-up of participants after completing ATT.
Kingkaew 2009 There was no follow-up of participants after completing ATT.
Koh 2007 There was no follow-up of participants after completing ATT.
Kumarvelu 1994 There was no data on length of ATT, and no follow-up of participants after completing ATT
Lamprecht 2001 Retrospective study.
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Lardizabal 1998 There was no follow-up of participants after completing ATT.
Malhotra 2009 There was no data on relapse, and maximum 1 month of follow-up of participants after completing ATT
Marais 2006 There was no data on relapse.
Marais 2013 There was no follow-up of participants after completing ATT.
Maree 2007 There was no follow-up of participants after completing ATT.
Mathew 1998 This study assessed the predictive value of the response to external ventricular drainage on long term
outcome in the poor grade patients with TBM and hydrocephalus
We contacted the study authors: there was no data on relapse during the follow-up period
Misra 1996 There was no follow-up of participants after completing ATT.
Misra 2000 There was no follow-up of participants after completing ATT.
Misra 2010 There was no follow-up of participants after completing ATT.
Moreira 2008 There was no follow-up of participants after completing ATT.
Nadvi 2000 There was no follow-up of participants after completing ATT.
Narayanan 1982 The ATT regimen did not include rifampicin.
Panigatti 2014 There was no follow-up of participants after completing ATT.
Pardasani 2008 There was no data on length of ATT and no data on relapse.
Park 2014 There was no data on length of ATT and no data on relapse.
Patwari 1996 We contacted the study authors contacted: there was no data on relapse
Pepper 2009 There was no follow-up of participants after completing ATT.
Phuapradit 1990 There was no data on relapse.
Porkert 1997 Retrospective analysis from hospital records.
Radhakrishnan 1990 There was no data on length of ATT, and no follow-up of participants after completing ATT
Raghu Raman 1997 Prospective study that recruited non-consecutive cases of tuberculosis (TB) in children, and looked at the
pattern of TB in children vaccinated with Bacillus Calmette-Guérin (BCG). There was no data on relapse
Rahajoe 1979 There was no follow-up of participants after completing ATT.
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Rai 2014 There was no follow-up of participants after completing ATT.
Ramzan 2013 There was no follow-up of participants after completing ATT.
Ranjan 2003 There was no follow-up of participants after completing ATT.
Rao 1982 Retrospective study.
Rao 2013 There was no follow-up of participants after completing ATT.
Raut 2013 There was no data on relapse.
Rojas-Echeverri 1996 There was no data on relapse.
Ruslami 2013 There was no follow-up of participants after completing ATT.
Saleem 2011 There was no data on length of ATT, and no data on relapse.
Saleem 2015 Duplicated cohort of patients from Saleem 2011 with no data on relapse.
Salekeen 2013 We contacted the study authors: no follow-up of participants after completing ATT
Savula 1975 Retrospective study.
Schoeman 1990 Duplicated cohort of patients from Schoeman 1997a.
Schoeman 1991 There was no follow-up of participants after completing ATT.
Schoeman 1997a The aim of this study was to evaluate cognitive and motor impairment of children surviving TBM. The
study reported findings on 19 children from a cohort of 75 participants, with no details on eligible criteria
Schoeman 1997b There was no follow-up of participants after completing ATT.
Schoeman 2000a There was no follow-up of participants after completing ATT.
Schoeman 2000b There was no follow-up of participants after completing ATT.
Schoeman 2002 Retrospective study.
Schoeman 2004 There was no follow-up of participants after completing ATT.
Schoeman 2011 There was no follow-up of participants after completing ATT.
Shah 2014 We contacted the study authors: there were 7 participants with TBM followed-up for more than 6 months
after completing ATT (other participants had shorter length of follow-up). The study authors identified
these 7 participants as treatment failure with multidrug resistant (MDR) TB or extensively drug resistant
(XDR) TB (according to our outcome definitions)
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Shahbaz 2011 There was no follow-up of participants after completing ATT.
Sharma 2013b There was no data on length of ATT, and no follow-up of participants after completing ATT
Shor 1973 Retrospective study.
Simmons 2006 Duplicated cohort of patients from Török 2011a.
Singh 1994 There was no data on length of ATT, and no follow-up of participants after completing ATT
Singh 1998 There was no follow-up of participants after completing ATT.
Springer 2009 There was no data on length of ATT, and no follow-up of participants after completing ATT
Swamy 1987 This paper presented findings from three studies (no study identifiers) with no data on relapse
Te Brake 2015 There was no follow-up of participants after completing ATT.
Thwaites 2002 There was no follow-up of participants after completing ATT.
Thwaites 2003a We contacted the author of this PhD thesis: findings on the cohort of participants have been published
elsewhere (duplicated data), such as Thwaites 2003b.
Thwaites 2003b There was no follow-up of participants after completing ATT.
Thwaites 2005b Duplicated cohort of patients from Török 2011b.
Thwaites 2005c Duplicated cohort of patients from Török 2011b.
Thwaites 2007 Duplicated cohort of patients from Török 2011b.
Thwaites 2011 There was no follow-up of participants after completing ATT.
Torok 2008 There was no follow-up of participants after completing ATT.
Török 2011b The trial reported outcomes at time of completing ATT and three months after completing ATT
van der Merwe 2009 Retrospective study.
van Toorn 2012 There was no follow-up of participants after completing ATT.
Wait 2010 Duplicated cohort of patients from Schoeman 2002.
ADA: adenosine deaminase activity; ATT: antituberculous treatment; BCG: Bacillus Calmette-Guérin; CSF: cerebrospinal fluid; MDR:
multidrug resistant; TB: tuberculosis; TBM: tuberculous meningitis; XDR: extensively drug resistant.
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Caliman-Sturdza 2010
Methods Study objective: to investigate the particularities of the clinical manifestation and evolution of tuberculous meningitis
(TBM) in children
Study design: prospective observational study.
Participants 169 children with TBM.
Interventions Antituberculous treatment (ATT) regimen not mentioned in abstract
Outcomes Socioeconomic conditions, clinical presentation, time of initiating ATT, and evolution under ATT including neu-
rological complications and deaths. There are no data in the abstract about follow-up of the participants after ATT
completion and, if so, whether relapse was reported
Notes Country: Romania.
Setting: Clinical infectious diseases Iasi and Emergency County Hospital ’Sf. Ioan cel Nou’
Study dates: from January 2000 to December 2008.
Reason for awaiting classification: no access to full-text paper
Carrasco 1988
Methods Unknown.
Participants Unknown.
Interventions Unknown.
Outcomes Unknown.
Notes We did not have access to the abstract and the full-text paper
Das Gupta 2005
Methods Unknown.
Participants Unknown.
Interventions Unknown.
Outcomes Unknown.
Notes We did not have access to the abstract and the full-text paper
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Methods Study objective: to describe the demographic profile, clinical features, laboratory, and imaging results of a cohort of
adults with TBM
Study design: prospective observational study.
Participants 89 adults with TBM.
Interventions ATT consisted of rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin in 62 participants and without
streptomycin in 17 participants. Duration of ATT is not reported
Outcomes It is unclear whether there is any follow-up after completing ATT
Notes Country: Sri Lanka.
Study dates: from 1 January 2010 to 31 December 2011.
We attempted to contact the study author, and await a reply.
Kilincoglu 2009
Methods Study objective: to evaluate the results of shunt function in cases having high concentrations of cerebrospinal fluid
(CSF) proteins
Study design: prospective observational study.
Mean follow-up period: 45 months.
Participants 32 children with TBM hydrocephalous.
Interventions ATT regimen unknown.
Outcomes There was no data on relapse.
Notes Country: Turkey.
Study dates: from January 1995 to January 2001.
We attempted to contact the study author for data on relapse during the 45 month follow-up period; we await a reply
Mahadevan 2002
Methods Study objective: to identify the various factors that affect the outcome in childhood TBM
Study design: prospective observational study.
Follow-up period: from 9 to 18 months, but it is unclear whether it is from starting or after completing ATT
Participants 50 children with TBM.
Interventions ATT consisted of rifampicin, isoniazid, pyrazinamide, and either ethambutol or streptomycin, for unknown duration
Outcomes There was no data on relapse.
Notes Country: India.
Study dates: from May 1999 to July 2000.
We attempted to contact the study author for clarification of the length of follow-up and whether they have data on
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Mahadevan 2002 (Continued)
relapse during this follow-up period; we await a reply
Mahajan 2005
Methods Unknown.
Participants Unknown.
Interventions Unknown.
Outcomes Unknown.
Notes We did not have access to the abstract and the full-text paper
Nair 2005
Methods Unknown.
Participants Unknown.
Interventions Unknown.
Outcomes Unknown.
Notes We did not have access to the abstract and the full-text paper
Rahman 2009
Methods Study objective: to assess whether corticosteroids improve the clinical outcome in patients with CNS TB
Study design: prospective observational study.
Participants 13 participants with central nervous system tuberculosis (CNS TB) (7 TBM and 6 tuberculoma)
Interventions ATT regimen unknown.
Outcomes There was no data on death, recovery, and residual neurological deficits in the abstract
Notes Country: Bangladesh.
Reason for awaiting classification: no access to full-text paper to determine duration of follow-up and relapse
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Yadav 2004
Methods Study objective: to evaluate the lumboperitoneal shunt procedure
Study design: prospective observational study.
Follow-up period: 45.34 months in average, but it is unclear whether it is from starting or after completing ATT
Participants 285 participants with TBM-related hydrocephalus.
Interventions ATT not described.
Co-intervention: lumboperitoneal shunt.
Outcomes There was no data on relapse in the abstract.
Notes Country: India.
Study dates: from March 1992 to February 2002.
Reason for awaiting classification: no access to full-text paper to obtain data on ATT regimens administered and
whether data on relapse were collected
Yadav 2011
Methods Study objective: to evaluate the role of endoscopic third ventriculostomy in TBM hydrocephalus
Study design: prospective observational study.
Follow-up period: not stated.
Participants 59 participants with TBM and obstructive hydrocephalus.
Interventions ATT not described.
Co-intervention: endoscopic third ventriculostomy.
Outcomes There was no data on relapse in the abstract.
Notes Country: India.
Study dates: not reported.
Reason for awaiting classification: no access to full-text paper to inquire data on ATT regimens administered, duration
of follow-up, and data on relapse
ATT: antituberculous treatment; CNSTB: central nervous system tuberculosis; CSF: cerebrospinal fluid; TBM: tuberculousmeningitis.
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Description of cohort studies that administered six months ATT
Study Setting Participants ATT
regimens
Duration of
FU af-
ter ATT, in
months
Mean
(range)
Country Centre Number Adults/
children
HIV status MRC stages
of the dis-
ease
Alarcón
1990
Ecuador Tertiary cen-
tre
28 Adults and
adolescents
NR I: 4/28
II: 10/28
III: 14/28
2HRZ/
4HR
(18 to 30)
Biddulph
1990
Papua New
Guinea
Tertiary cen-
tre
43 Children NR NR 2HRZS/4
(HR)2
(up to 24)
Chot-
mongkol
1991
Thailand Tertiary cen-
tre
29 Adults NR I: 7/29
II: 12/29
III: 10/29
2HRZS/
4HR
16.3
(4 to 33)
Chot-
mongkol
1996
Thailand Tertiary cen-
tre
59 Adults NR I: 9/59
II: 40/59
III: 10/59
2HRZS/
4HR
30
(16 to 45)
Donald
1998
South Africa Tertiary cen-
tre
95 Children NR I: 4/95
II: 52/95
III: 39/95
6HRZEth 12
Jacobs 1992
a
Thailand Tertiary cen-
tre
45 Children NR I: 8/45
II: 25/45
III: 12/45
2HRZS/
4HR
At least 6
months: 27/
38
Less than 6
months: 7/
38
van Toorn
2014b
South Africa Tertiary cen-
tre
159 Children HIV-neg-
ative or un-
known
I: 22/184c
II: 98/184
III: 84/184
6HRZEth At least 24
Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow-up; H: isoniazid; HIV: human immun-
odeficiency virus; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide.
aIn this prospective cohort study, data are reported for three successive cohorts in the same centre over time. The first cohort received a
12-month regimen with 2/4 participants receiving rifampicin, the second a 9-month regimen with all participants receiving rifampicin,
and the third received a 6-month regimen with all participants receiving rifampicin and pyrazinamide.
bHIV-positive children were treated with a 9-month regimen due to a perceived slower response to treatment.
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cThere were no diaggregated data for clinical severity of the disease between the cohort of HIV-negative participants receiving 6 months
of treatment and the cohort of HIV-positive participants receiving 9-month ATT.
Table 2. Diagnosis of TBM: clinical and radiological characteristics in cohorts that received six months ATT
Study Previous history of
TB
Known contact
with TB patient
PPD skin test pos-
itive
Neuroimaging Abnormal chest X-
ray
Alarcón 1990 5/28 9/28 8/28 Done in all partici-
pants.
Abnormal findings
in 19/28.
17/28
Biddulph 1990 NR 5/38 25/38 (≥ 15 mm or
≥ 10mmwithBCG
scar)
Myelogram in par-
ticipants with par-
tial spinal block.
14/43
Chotmongkol 1991 NR NR NR CT scan in 18 par-
ticipants.
10/29
Chotmongkol 1996 NR NR NR CT scan: abnormal
findings in 31/37.
Myelogram for par-
ticipants with para-
paresis
23/59
Donald 1998 NR 55/95 2/95 between 10
mm and 15 mm,
84/95 ≥ 15 mm
CT scan 41/95
Jacobs 1992a NR 45/53 25/53 NR 35/53
van Toorn 2014a NR NR NR CT scan on admis-
sion: bilateral basal
ganglia infarction in
all 7 cases who
died before com-
pleting ATT
Done, NR
Abbreviations: ATT: antituberculous treatment; BCG: Bacillus Calmette-Guérin; CT: computed tomography; NR: not reported; PPD:
purified protein derivative.
aJacobs 1992 and van Toorn 2014 also reported cohorts of participants treated for longer than 6 months, but no disaggregated data
are provided on clinical features between both cohorts.
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Table 3. Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts that received six months ATT
Study CSF Other diag-
nostic meth-
ods for TB
Diagnostic classification
Cell count,
pro-
tein and glu-
cose content
Positive AFB
smear
Positive cul-
ture
Other tests
performed in
CSF
Bacterio-
logically con-
firmed
Clinically di-
agnosed
Alarcón 1990 Reported 15/28 16/28 ELISA
for BCG anti-
bodies,
ADA
Bacteri-
ological analy-
ses of sputum,
gastric aspi-
rate, and urine
1 lymph node
biopsy, 1 cul-
ture from ab-
scess drainage.
Autopsy find-
ings
22/28 6/28
Biddulph
1990
Reported Done but NR 5/36 None Sputum spec-
imens, fasting
gastric
aspirates, and
pleural
fluid for mi-
croscopy and
culture
Lymph node
biopsy for his-
tology and
culture.
Abdominal ul-
trasound.
BCG vaccine
scar.
5/43 38/43
Chotmongkol
1991
Reported NR 6/29 None None 6/29 23/29
Chotmongkol
1996
Reported 1/59 5/59 Pyogenic bac-
terial and fun-
gal culture, la-
tex agglutina-
tion test for
bacterial and
cryptococcal
Ag and cyto-
logic study for
None 5 or 6/59a 53 or 54/59a
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Table 3. Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts that received six months ATT
(Continued)
malignancy;
results NR
Donald 1998 Reported NR 18/95 DST
Air encephalo-
gram
Gastric as-
pirate for mi-
croscopy and
culture
18/95 77/95
Jacobs 1992b NR 2/33 5/35 None Presence of a
BCG vaccine
scar in 28/53
7/53 46/53
van Toorn
2014b
NR NR 16/136 PCR for MTB
in CSF 2 spec-
imensc
Culture of gas-
tric washings:
43/155
16/184 168/184
Abbreviations: ADA: adenosine deaminase activity; AFB: acid-fast bacillus; Ag: antigen; BCG: Bacillus Calmette-Guérin; CSF: cere-
brospinal fluid; DST: drug sensitivity tests; ELISA: enzyme-linked immunosorbent assay; NR: not reported; MTB: Mycobacterium
tuberculosis; PCR: polymerase chain reaction; PPD: purified protein derivative.
aUnclear whether the specimens with positive stain were also culture positive.
bJacobs 1992 and van Toorn 2014 also reported cohorts of participants treated for longer than 6 months, but no disaggregated data
are provided on CSF characteristics and diagnosis classification between the cohorts.
cThe study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2
positive PCR specimens were also culture positive.
Table 4. Description of cohort studies that administered more than six months ATT
Study Setting Participants ATT regi-
mens
Duration
of ATT
(months)
Dura-
tion of FU
after ATT,
in months
Mean
(range)
Country Centre Number Adults/c
hildren
HIV
status
Severity of
the disease
Anastasatu
1993
Romania Tertiary
centre
44 Children NR NR 3HRZ/
6HR2
(19 cases)a
9 51
3HR/
3HR2/
6H2
(25 cases)a
12
Do anay
1995
Turkey Multicen-
tre; univer-
sity hospi-
tals
72 Adults NR I: 7/72
II: 34/72
III: 31/72
2HRZS/
6HR
(37 cases)
8 Median 10
(6 to 24)
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Table 4. Description of cohort studies that administered more than six months ATT (Continued)
HRZE
(19 cases)
HRES
(6 cases)
HRZS
(6 cases)
HRZES
(3 cases)
HRE
(1 case)
12 to16 Median 13
(4 to 36)
Iype 2014 India Tertiary
centre
47 Adults HIV
positive ex-
cluded
I: 15/43
II: 24/43
III: 4/43
2(HRZS)
3/7(HR)3
(41 cases)
9 Median 5.
2
(IQ 3.4 to
9.8)
2
(HREZS)
3/1
(HREZ)3 /
7(HR)3 (2
cases)
10
Jacobs
1992b
Thailand Tertiary
centre
8 Children NR I: 0/8
II: 4/8
III: 4/8
2HRS/
7HR
(4 cases)
9 NR
2HSE/
10HE
(2 cases)
2RSE/
10RE
(2 cases)
12 NR
Lau 2005 China
(Hong
Kong)
Multicen-
tre; tertiary
and
secondary
hospitals
166 Adults and
children
2HIV pos-
itive
I: 91/166
II: 69/166
III: 6/166
HRZES
(66 cases)
HRZE
(63 cases)
HRZS
(24 cases)
HRZ
(8 cases)
HRE
(2 cases)
SHRE
(1 case)
HZE
(1 case)
HR
(1 case)
11.53
(mean)
24
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Table 4. Description of cohort studies that administered more than six months ATT (Continued)
Phuapra-
dit
1987
Thailand Tertiary
centre
28 Adults NR I: 4/28
II: 18/28
III: 6/28
2HRZS/
7HR
9 19.8
(12 to 29)
Ra-
machan-
dran
1989
India Multicen-
tre; tertiary
hospitals
180 Children NR I: 24/180
II: 139/
180
III: 17/180
2SHR/
4S2EH/
6EH
(77 cases)
2SHRZ/
10EH
(29 cases)
2R2 SHZ/
10EH
(74 cases)
12 (42 to 84)
Ra-
machan-
dran
1997
India Multicen-
tre; tertiary
hospitals
215 Children NR I: 45/215
II: 160/
215
III: 10/215
2SHE
(RZ)3/7
(RH)2
(89 cases)
2SHE
(RZ)2/7
(RH)2
(96 cases)
9 51
Sharma
2013a
India Tertiary
centre
42 Adults HIV
positive ex-
cluded
I: NDD
II: NDD
III: 21/42
2(HREZ)
3/7(HR)3
9 6
Török
2011a
Vietnam Multicen-
tre; tertiary
hospitals
545 Adults and
adoles-
cents
436 HIV
negative
98 HIV
positive
11
unknown
I: 176/545
II: 247/
545
III: 122/
545
3RHZS/
6RHZ
(399 HIV
negative)
3RHZE/
6RHZ
(98 HIV
positive)
3RHZES/
6RHZ
(43 previ-
ously
treated)
HZE
(2 cases)
SE
(1 case)
9 Median
53.4
(IQ 47.4
to 57)
van Toorn
2014
South
Africa
Tertiary
centre
25 Children 22 HIV
positive;
3
I: 22/184 c
II: 98/184
III: 84/184
9HRZEth
d
9 At least 24
87Six months therapy for tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 4. Description of cohort studies that administered more than six months ATT (Continued)
unknown
Visud-
hiphan
1989
Thailand Tertiary
centre
51 Children NR I: 5/51
II: 25/51
III: 21/51
12HR 12 (18 to 84)
Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow-up; H: isoniazid; HIV: human immun-
odeficiency virus; IQ: interquartile range; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide
aIt is unclear whether streptomycin twice weekly was also administered in both regimens in the first 3 months.
bIn this prospective cohort study, data are reported for 3 successive cohorts in the same centre over time. The first cohort received a 12-
month regimen with 2/4 participants receiving rifampicin, the second a 9-month regimen with all participants receiving rifampicin,
and the third received a 6-month regimen with all participants receiving rifampicin and pyrazinamide.
cThere were no diaggregated data for clinical severity of the disease between the cohort of HIV-negative participants receiving 6 months
of treatment and the cohort of HIV-positive participants receiving 9-month ATT.
dThe 22 HIV-positive children were treated with a 9-month regimen due to a perceived slower response to treatment, as well as the 3
children with M. tuberculosis isoniazid-monoresistance.
Table 5. Diagnosis of TBM: clinical and radiological characteristics in cohorts receiving more than six months ATT
Study Previous history of
TB
Known contact
with TB patient
PPD skin test pos-
itive
Neuro-imaging Abnormal chest X-
ray
Anastasatu 1993 NR NR NR NR 0/39
Do anay 1995 3/72 NR NR NR (although 1 in-
tracerebral tubercu-
loma is reported)
NR (although 22
PTB are reported)
Iype 2014 NR 14/43 NR Done in all partici-
pants.
5 tuberculoma,
9 hydrocephalus, 14
arteritis, 3 spinal
arachnoiditis.
11/43
Jacobs 1992a NR 45/53 25/53 NR 35/53
Lau 2005 NR 50/166 NR 50/155
had meningeal en-
hancement, ventric-
ular dilatation, tu-
berculoma or space
occupying lesion
63/158
Phuapradit 1987 NR NR NR CT scan in 21 par-
ticipants with in-
creased intracranial
18/28
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Table 5. Diagnosis of TBM: clinical and radiological characteristics in cohorts receiving more than six months ATT (Con-
tinued)
pressure:
10 communicating
hydrocephalus
3 diffuse cerebral
oedema with small
lateral ventricles
1 associated tuber-
culoma
Ramachandran
1989
NR 84/180 90/180 (≥10mm) NR 99/180
Ramachandran
1997
NR 137/215 73/215 (≥10mm) CT scans to 68 par-
ticipants
with suspected hy-
drocephalus
111/215
Sharma 2013a NR NR NR CT scan in 30 par-
tici-
pants (14 with mul-
tiple lacunar infarct,
hydrocephalus,
basal meningeal en-
hancement)
MRI performed in
11 participants.
9/42
Török 2011a NR NR NR NR Active non-miliary
TB: 214/545
Miliary TB: 155/
545
van Toorn 2014a NR NR NR CT scan on admis-
sion: bilateral basal
ganglia infarction in
all 7 cases who
died before com-
pleting ATT
Done, NR
Visudhiphan 1989 NR NR NR NR NR
Abbreviations: ATT: antituberculous treatment; CT: computed tomography; MRI: magnetic resonance imaging; NR: not reported;
PPD: purified protein derivative; PTB: pulmonary tuberculosis.
aJacobs 1992 and van Toorn 2014 also reported cohorts of participants treated for 6 months, but did not provide disaggregated data
on clinical features between both cohorts.
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Table 6. Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts receiving more than six months
ATT
Study CSF Other diag-
nostic meth-
ods for TB
Diagnostic classification
Cell count,
pro-
tein and glu-
cose content
Positive AFB
smear
Positive cul-
ture
Other tests
performed in
CSF
Bacterio-
logically con-
firmed
Clinically di-
agnosed
Anastasatu
1993
NR NR NDDa None None NDDa NDDa
Do anay
1995
NR NR NR None None NR NR
Iype 2014 NR 0/43 0/43 PCR: 2/4 Abdominal ul-
trasound, spu-
tum smearmi-
croscopy.
Findings not
reported
2/43 41/43
23 probable,
18 possible
Jacobs 1992b NR 2/33 5/35 None Presence of a
BCG vaccine
scar in 28/53
7/53 46/53
Lau 2005 Reported 82/
166 had AFB
smear or cul-
ture positive
68/166 None None 68/166 98/166
14 presump-
tive, 84 proba-
ble
Phuapradit
1987
Reported NR 12/28 None Discharge
of otitis media
with AFB
12/28 16/28
Ramachan-
dran
1989
Reported 36/180 59/180 DST None 83/180 97/180
Ramachan-
dran
1997
NR 74/215c 88/215c DST None 101/215 114/215
Sharma 2013a Reported 4/42 NR ADA in 29
cases; PCR in
2 samples
Histology of 2
axillary lymph
nodes
4/42 38/42
Török 2011a Reported 65/545 166/545 DST 187 posi-
tive cultures of
samples other
187/545 352/545
261 probable,
91 possible
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Table 6. Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts receiving more than six months
ATT (Continued)
than CSF
van Toorn
2014b
NR NR 16/136 PCR for MTB
in CSF 2 spec-
imensd
Culture of gas-
tric washings:
43/155
16/184 168/184
Visudhiphan
1989
NR NR 13/40 DST None 13/51 38/51
Abbreviations: ADA: adenosine deaminase activity; AFB: acid-fast bacillus; BCG: Bacillus Calmette-Guérin; CSF: cerebrospinal fluid;
DST: drug sensitivity tests; NDD: no disaggregated data; NR: not reported; MTB: Mycobacterium tuberculosis; PCR: polymerase
chain reaction; PPD: purified protein derivative; TBM: tuberculous meningitis.
aThere were 30 positive cultures among 60 participants with severe forms of TB, with no disaggregated data for the 44 TBM cases.
bJacobs 1992 and van Toorn 2014 also reported cohorts of participants treated for 6 months, but did not provide disaggregated data
on CSF characteristics and diagnosis classification between the cohorts.
cNumbers of smear- and culture-positive participants seem to be incorrectly reported.
dThe study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2
positive PCR specimens were also culture positive.
Table 7. Findings from the Alvarez-Uria 2012 cohort
Duration of ATT All < 6 months 6 monthsa > 6 months
Participant characteristics
Number of participants 217 122 20 75
Mean age (years) 38.0 37.7 37.3 38.6
HIV-positive 217 122 20 75
Previous TB 45 25 1 19
Real duration of ATT re-
ceived
In those who received
6 months or more: 8.6
months
(259 days)
1.2 months
(34.9 days)
6 months
(196 days)
9.2 months
(276 days)
Range from 212 to 501
days
Outcomes at the end of ATT
Cure 94 (43.3%) 0 (0%) 19 (95%) 75 (100%)
Default 30 (13.8%) 29 (23.8%) 1b (5%) 0 (0%)
Death 94 (43.3%) 93 (76%) 1 (5%) 0 (0%)
FU in survivors (from end of ATT)
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Table 7. Findings from the Alvarez-Uria 2012 cohort (Continued)
Lost to FU (0 days of FU
after completing ATT)
7/123 (5.7%) 2/29 (6.9%) 1/19 (5.3%) 4/75 (5.3%)
Length of FU among
survivors, mean (range)
22.9 months
687 days (9 to 1539
days)
12.4 months
372 days (9 to 1272
days)
30.5 months
915 days (66 to 1539
days)
25 months
750 days (30 to 1511
days)
Relapse 7/89 (7.9%) NAc 0/18 (0%) 7/71d (9.9%)
Death 37/116 (31.6%) 18/27 (66.7%) 3/18 (16.7%) 16/71 (22.5%)
Total number of deaths 131/217 (60.4%) 111/122 (91%) 4/20 (20%) 16/75 (21.3%)
Note: we have presented the results based on complete-case analysis.
Abbreviations: ATT: antituberculous treatment; FU: follow-up; HIV: human immunodeficiency virus; NA: not applicable; TB: tuber-
culosis; TBM: tuberculous meningitis.
aWe considered those participants treated between 180 and 209 days.
bOne participant had previous TB, thus the planned ATT was 8-month regimen. The investigators classified this participant as a
defaulter as he stopped ATT at 6 months.
cRelapse is defined as the number of participants who have new symptoms and signs of TBM after resolution of disease and completion
of ATT. None of the participants receiving less than 6-month ATT completed their treatment. Therefore, we could not apply the term
relapse to these participants. However, 5/27 participants who were defaulters and could be followed-up, presented new symptoms and
signs of TBM after stopping ATT, and were retreated.
dWe have presented the profile of these participants in Table 12.
Table 8. Six months ATT: relapse, death, and clinical cure
Study Number
of partic-
ipants
Pro-
longed
ATT
Losses to FU Length
of FU af-
ter ATT,
in
months
Mean
(range)
Relapse Death
from any
cause
Death af-
ter
6months
ATT
Clinical
cure
During
ATT
After
ATT
Number Out-
come
Alarcón
1990
28 0/20 0/28 0/20 (18 to 30) 1/20 Death 9/28
(32.1%)
1/28
(3.6%)
20/28
(71.4%)
Biddulph
1990
43 NR NDD NDD (up to 24) 1/38 Recovery 7/43
(16.3%)
2/43
(4.7%)
38/43
(88.4%)
Chot-
mongkol
1991
29 1/25 0/29a 0/29 16.3
(4 to 33)
0/25 NA 4/29
(13.8%)
0/29
(0%)
25/29
(86%)
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Table 8. Six months ATT: relapse, death, and clinical cure (Continued)
Chot-
mongkol
1996
59 0/52 0/59 0/59 30
(16 to 45)
0/52 NA 7/59
(11.9%)
0/59
(0%)
52/59
(88.1%)
Donald
1998
95 3/82 0/95 12/82 12b 1/70 Recovery 15/95
(15.8%)
2/95
(2.1%)
82/95
(86.3%)
Jacobs
1992
45 NR 0/45 4/38 NDDc 0/34 NA 7/45
(15.6%)
0/45
(0%)
38/45
(84.4%)
van
Toorn
2014
159 24/153 0/159 23/153 At least
24
0/130 NA 9/159
(5.7%)
3/159
(1.9%)
153/159
(96%)
Total 458 28/332
(8.4%)
0/415
(0%)
39/381
(10.2%)
Range
4 to 45
3/369
(0.8%)
1 death
2 recov-
eries
58/458
(12.7%)
8/458
(1.7%)
408/458
(89.1%)
Abbreviations: ATT: antituberculous treatment; FU: follow-up; NA: not applicable; NDD: no disaggregated data; NR: not reported.
Note: we have presented these results based on complete-case analysis.
aThe study authors reported 4 participants lost to follow-up and excluded them from their analyses. However, the study authors
reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period
of 16.5 months indicated that all had fully recovery.
bAttempted length of follow-up. No data reported on the real follow-up of the survivors.
cFollow-up was available for at least 6 months after completion of ATT in 27/38 survivors, and for less than 6 months in 7/38.
Table 9. Six months ATT: default, poor adherence, treatment failure, and adverse effects
Study Num-
ber of par-
ticipants
Prolonged
ATT
Losses
to FU dur-
ing ATT
Default Poor adher-
ence
Treatment
failure
All ad-
verse effects
(number of
events)
Drug toxi-
city leading
to ATT dis-
continua-
tion
or modifi-
cation
Alarcón
1990
28 0/28 0/28 0/28 NR 0/28 24 6/28
Biddulph
1990
43 NR NDD NDD NR NR NDD NDD
Chot-
mongkol
1991
29 0/25 0/29a 4/29a NR NR 1 1/29
93Six months therapy for tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 9. Six months ATT: default, poor adherence, treatment failure, and adverse effects (Continued)
Chot-
mongkol
1996
59 0/52 0/59 0/59 NR NR NR NR
Donald
1998
95 3/82 0/95 0/95 NR NR 32 6/95
Jacobs 1992 45 NR 0/45 NR NR NR NR 0/45
van Toorn
2014
159 24/153 0/159 0/159 3/159 NR NDDb NDDc
Total 458 28/332
(8.4%)
0/415
(0%)
4/370
(1.1%)
3/159
(1.9%)
0/28
(0%)
57 13/197
(6.6%)
Abbreviations: ATT: antituberculous treatment; FU: follow-up; NDD: no disaggregated data; NR: not reported.
Note: we have presented these results based on complete-case analysis.
aThe study authors reported that 4 participants were lost to follow-up and excluded them from their analyses. However, the study
authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean
period of 16.5 months indicated that all had fully recovered. All four participants fit the definition of defaulter.
b51 adverse effects were reported among the 184 participants recruited, without disaggregated data between those receiving 6 and 9
months of ATT.
cATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT.
Table 10. More than six months ATT: relapse, death, and clinical cure
Study Dura-
tion of
ATT
(months)
Number
of par-
tici-
pants
Pro-
longed
ATT
Losses to FU Length
of
FU after
ATT, in
months
Mean
(range)
Relapse Death
from
any
cause
Death
after 6
months
ATT
Clinical
cure
During
ATT
After
ATT
Number Out-
come
Anas-
tasatu
1993
9 19 NR 2/19a 0/17a 60b 0/17 NA 0/19
(0%)
0/19
(0%)
17/17
(100%)
12 25 NR 3/25a 0/22a 60b 0/22 NA 0/25
(0%)
0/25
(0%)
22/22
(100%)
Do
anay
1995
8 37 2/25 7/37 7/55 Median
10
(6 to 24)
0/48 NA 5/37
(13.5%)
0/37
(0%)
25/30
(83.3%)
12 to 16 35 0/30 3/35 Median
13
(4 to 36)
2/35
(5.7%)
0/35
(0%)
30/32
(93.8%)
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Table 10. More than six months ATT: relapse, death, and clinical cure (Continued)
Iype
2014
9 47 2/35 2/47 0/35 Median
5.2
(3.4 to 9.
8)
1/35 Recov-
ery
10/47
(21.3%)
1/47
(2.1%)
35/45
(77.8%)
Jacobs
1992
9 4 NR 0/4 NR NR NR NA 2/4
(50%)
NDDc 2/4
(50%)
12 4 NR 0/4 NR NR NR NA 2/4
(50%)
NDDc 2/4
(50%)
Lau
2005
Mean
11.53
166 Individ-
ualised
for all
10/166 0/133 At least
24
0/133 NA 26/166
(15.7%)
NDDd 133/156
(85.3%)
Phuapra-
dit
1987
9 28 1/23 3/28e 1/23 19.8
(12 to
29)
0/22 NA 2/28
(7.1%)
2/28
(7.1%)
23/25
(92%)
Ra-
machan-
dran
1989
12 180 23/119 14/180 2/119 (42 to
84)
0/117 NA 64/180
(35.6%)
19/180
(10.6%)
119/166
(71.7%)
Ra-
machan-
dran
1997
9 215 9/137 29/215f 0/137 51b 3/128 1 death
2 recov-
eries
69/215
(32%)
12/215g
(5.6%)
137/186
(73.7%)
Sharma
2013a
9 42 0/35 0/42 0/35 6b 0/35 NA 7/42
(16.7%)
NR 35/42
(83%)
Török
2011a
9 545 NRh 10/545 40/336 Median
53.4
(IQR
47.4 to
57)
3/296i 3 recov-
eries
249/545
(45.7%)
NDDj 336/535
(62.8%)
van
Toorn
2014
9 25
HIV-
positive
and iso-
niazid-
resistant
4/24 0/25 6/24 At least
24
0/18 NA 6/25
(24%)
5/25
(20%)
24/25
(96%)
Visud-
hiphan
1989
12 51 0/44 4/51 0/44 (18 to
84)
0/44 NA 3/51
(5.9%)
0/51
(0%)
44/47
(93.6%)
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Table 10. More than six months ATT: relapse, death, and clinical cure (Continued)
Total 8 to 16 1423 32/472
and 166
individ-
ualized
ATT
87/
1423
(6.1%)
56/985
(5.7%)
Range
6 to 84
7/915
(0.8%)
1 death
6 recov-
eries
447/
1423
(31.4%)
39/662
(5.9%)
984/
1336
(73.7%)
Abbreviations: ATT: antituberculous treatment; FU: follow-up; HIV: human immunodeficiency virus; IQR: interquartile range; NA:
not applicable; NDD: no disaggregated data; NR: not reported.
Note: we have presented these results based on complete-case analysis.
aThere were 5 participants (2 in the 9-month group, 3 in the 12-month group) lost to follow-up at the end of the 5 years follow-up.
No results were reported for these 5 participants, and it is unclear when they left the trial and what their outcomes were.
bAttempted length of follow-up. No data reported on the real follow-up of the survivors.
cData could not be disaggregated by time until death. There were 7 deaths in the 6-month group, 2 in the 9-month group, and 2 in
the 12-month group; the study authors stated that over 90% of deaths occurred within the first 3 months of treatment in this study.
dThere were at least 3 deaths after six months of ATT. Indeed, three participants died in the second year from the start of ATT,
due to nasopharyngeal carcinoma, acquired immune deficiency syndrome and chronic obstructive pulmonary disease. There were no
disaggregated data among the deaths occuring within the first 12 months to report those occuring between the sixth and twelfthmonths
from the start of ATT.
eThree participants with poor compliance dropped out during the early stage of ATT and could not be followed-up. One participant
developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was
lost to follow-up afterwards.
fTen out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from
analysis.
gTen participants discharged against medical advice died.
h143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged
ATT.
iThese 3 participants were re-treated for TB. It is unclear whether they were re-treated because of TBM relapse or because of presenting
another form of TB.
jThere were 50 deaths reported among the 296 survivors who completed the 9-month treatment. We do not know if there were
additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. The study authors could not
determine how many of these deaths could be attributed to relapse.
Table 11. More than six months ATT: default, poor adherence, treatment failure, and adverse effects
Study Duration
of ATT
(months)
Num-
ber of par-
ticipants
Prolonged
ATT
Losses to
FU during
ATT
Default Poor
adherence
Treatment
failure
All
adverse ef-
fects
(number
of events)
Drug toxi-
city
leading to
ATT dis-
continua-
tion
or modifi-
cation
Anastasatu
1993
9 19 NR 2/19a NR NR 0/17 NR NR
12 25 NR 3/25 NR NR 0/22 NR NR
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Table 11. More than six months ATT: default, poor adherence, treatment failure, and adverse effects (Continued)
Do anay
1995
8 37 2/25 7/37 0/30 NR 1/30b 6 12/62
12 to 16 35 0/30 3/35 2/32 NR 1/32 8
Iype 2014 9 47 2/35 2/47 2/45 NR 4/45c 4 1/45
Jacobs
1992
9 4 NR 0/4 NR NR NR NR 0/4
12 4 NR 0/4 NR NR NR NR 0/4
Lau 2005 Mean 11.
53
166 Individ-
ualised for
all
10/166 0/156 0/156 NR 58 0/156
Phuapra-
dit
1987
9 28 1/23 3/28d 4/25 NR NR 21 1/25
Ra-
machan-
dran
1989
12 180 23/119 14/180 NR NR NR 37 37/174
Ra-
machan-
dran
1997
9 215 0/137 29/215e NR NR NR 18 18/205
Sharma
2013a
9 42 0/35 0/42 0/42f NR NR 3 0/42
Török
2011a
9 545 NRg 10/545 NR NR 89/535 400 143/535
van Toorn
2014
9 25
HIV-
pos and H-
resistant
4/24 0/25 0/25 0/25 NR NDDh NDDi
Visud-
hiphan
1989
12 51 0/44 4/51 NR NR NR 12 4/47
Total 8 to 16 1423 32/472
and
166 indi-
vidualized
ATT
87/1423
(6.1%)
8/355
(2.3%)
0/181
(0%)
95/681
(14.0%)
567 216/1299
(16.6%)
Abbreviations: ATT: antituberculous treatment; FU: follow-up; H: isoniazid; HIV: human immunodeficiency virus; mo: months;
NDD: no disaggregated data; NR: not reported.
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Note: we have presented these results based on complete-case analysis.
aThere were 5 participants (2 in the 9-month group, 3 in the 12-month group) lost to follow-up at the end of the 5 years follow-up.
No results were reported for these five participants, and it is unclear when they left the trial and what their outcomes were.
bThis study described 1 participant in the 8-month ATT group as having treatment modified due to “inadequate clinical response”,
and 1 participant in the 12- to 16-month ATT group as dying in the fifth month of treatment due to “therapeutic failure”.
cFour participants developed treatment failure, 3 during the fourth month of ATT, and 1 during the ninth month (who had concurrent
pulmonary TB with proven isoniazid resistance). Three of these 4 participants died.
dThree participants with poor compliance dropped out during the early stage of ATT and could not be followed-up. One participant
developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was
lost to follow-up afterwards.
eTen out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from
analysis.
fThe study authors stated that out of the 42 participants, 35 completed ATT, and 7 died. It is very likely that there was no defaulters,
although this outcome was not clearly stated.
g143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged
ATT.
h51 adverse effects are reported among the 184 participants, without disaggregated data between participants receiving 6 or 9 months
of ATT.
iATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT.
Table 12. Profile of participants who relapsed after completing ATT
Studies Gender, age (years) Duration of ATT
received (months)
Time between end
of ATT and relapse
Outcome Comments
Six months ATT
Alarcón 1990 Female, 34 6 3 months Death Disease severity: stage III
when first diagnosed
Biddulph 1990 Male, 1 6 2 months Recovery Disease severity: stage I at re-
lapse
It is unclear whether or not
this participant missed doses
in the continuation phase of
treatment, but the study au-
thors reported that missed
doses were made up in all par-
ticipants
Donald 1998 Female, 11 6 3 weeks Recovery Disease severity: stage I when
first diagnosed, and stage II at
relapse
During the first course of
ATT, Ethwas stopped and the
dosage of H and R halved to
10 mg/kg and Z halved to 20
mg/kg due to poor appetite
and nausea after 3 months of
treatment
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Table 12. Profile of participants who relapsed after completing ATT (Continued)
More than six months ATT
Iype 2014 Male, adult 9 3 months Recovery -
Ramachandran
1997
Child 9 3 months Death Positive CSF culture, fully
sensitive on DST at initial di-
agnosis and relapse
Mild sequelae at the end of
first course of ATT. Treated
with ‘intensive therapy’ for 9
months, died 10 months after
completing the second ATT
regimen despite having nor-
mal CSF analysis and negative
CSF cultures
Child 9 2 months Recovery Positive CSF culture, fully
sensitive on DST at initial di-
agnosis and relapse
Mild sequelae at the end of
first course of ATT.
Child 9 13 months Recovery Abnormal CSF and positive
CSF culture, resistant to H
and S on DST at initial diag-
nosis and relapse
Moderate sequelae at the end
of first course of ATT.
Török 2011a Adult 9 NR Recovery At five-year follow-up, these
three participants self-
reported re-treatment for TB.
It is unclear whether this was
for TBM or another form of
TB
Adult 9 NR Recovery
Adult 9 NR Recovery
Additional cohort
Alvarez-Uria 2012 Male, 32, HIV-pos-
itive
8.4 10 months Recovery This participant had previous
TB
Male, 65, HIV-pos-
itive
9.1 24 months Death -
Male, 31, HIV-pos-
itive
9.6 8 months Recovery This participant was cure after
completing ATT for relapse.
However, he died 12 months
after completing the second
ATT regimen
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Table 12. Profile of participants who relapsed after completing ATT (Continued)
Male, 32, HIV-pos-
itive
9.8 31 months Recovery This participant had previous
TB
Male, 32, HIV-pos-
itive
9.9 5 days Recovery This participant had previous
TB
Male, 45, HIV-pos-
itive
10 20 months Death -
Male, 13, HIV-pos-
itive
10.9 16 months Recovery -
Abbreviations: ATT: antituberculous treatment; CSF: cerebrospinal fluid; DST: drug sensitivity tests; Eth: ethinamide; H: isoniazid;
HIV: human immunodeficiency virus; R: rifampicin; TB: tuberculosis; Z: pyrazinamide.
Table 13. Causes of deaths after six months ATT
Study Length of treat-
ment (months)
Deaths after 6
months ATT
Number of these deaths attributed to:
Relapse Complications
of TBMa
Non TB causes Unknown
Six months ATT
Alarcón 1990 6 1 1 0 0 0
Biddulph 1990 6 2 0 2 0 0
Donald 1998 6 2 0 2 0 0
van Toorn 2014 6 3 0 2 0 1
More than six months ATT
Iype 2014 9 1 0 0 0 1
Phuapradit 1987 9 2 0 2 0 0
Ramachandran
1997
9 12 1 6 4 1
Török 2011a 9 50b 0 0 0 50
van Toorn 2014 9 5 0 4 (HIV infectionor post-TBMcom-
plications)
1
Lau 2005 11.53 (mean) 3c 0 0 3 0
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Table 13. Causes of deaths after six months ATT (Continued)
Ramachandran
1989
12 19 0 12 7 0
Abbreviations: ATT: antituberculous treatment; HIV: human immunodeficiency virus; mo: months; TB: tuberculosis; TBM: tuber-
culous meningitis.
aDeath due to TBM complications can occur at any point in the course of treatment regardless of treatment duration, even after
microbiological cure has been achieved. The complications leading to deaths reported in the included studies were all related to severe
neurological sequelae.
bThere were 50 deaths reported among the 296 survivors who completed the nine-month treatment. We do not know if there were
additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. Authors could not determine
how many of these deaths could be attributed to relapse.
cThree participants died in the second year from the start of ATT, due to nasopharyngeal carcinoma, acquired immune deficiency
syndrome, and chronic obstructive pulmonary disease. There were no disaggregated data among the deaths occuring within the first
12 months to report those occuring between the sixth and twelfth months from the start of ATT.
Table 14. Adverse events
Study ID Number of adverse events Description of adverse events
Related to ATT (events) Leading to ATT discontinuation
(participants)
Six months ATT
Alarcón 1990 24 6/28 • Elevation in ALT/AST/alkaline
phosphatase/bilirubin: 15, leading to
discontinuation of treatment with H/
R and substitution with S for 3 to 7
days in 4 participants.
• Hyperuricaemia leading to 3-
day suspension of Z in 2 participants.
• Gastrointestinal symptoms 3
participants.
• Arthralgia 2 participants.
• Dizziness with nystagmus 1
participant.
• Rash 1 participant.
Biddulph 1990 NDD NDD 15/639 TB cases had problems with
the drug prescribed, but NDD for
TBM
Chotmongkol 1991 1 1/29 • 1 severe hepatitis due to H.
ATT was continued with R and E for
18 months with full recovery.
• No other adverse events
reported.
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Table 14. Adverse events (Continued)
Chotmongkol 1996 NR NR • Gastrointestinal bleeding or
hyperglycemia was not observed as
complications of prednisolone
therapy.
• Adverse events were assessed and
recorded; but results not reported.
Donald 1998 32 6/95 • Nausea and vomiting leading to
stopping of Eth and reduction of RH
doses. This case relapsed and was
successfully re-treated with HRZEth
at full doses.
• Hepatotoxicity:
◦ 10 mild elevation of
bilirubin leading to substitution of
HRZEth with SE in 5 children, who
were then re-started on HRZEth
when liver function normalised in 2
to 3 weeks;
◦ 13 mild and transient
elevation of ALT/AST, without
treatment interruption.
Six and more than six months ATT
Jacobs 1992 NR 0/45 NR
NR 0/4 NR
NR 0/4 NR
van Toorn 2014 51 17/184 • Anti-TB drug-induced
hepatotoxicity (ADIH):
◦ Grade 1 (mild) ALT 51 to
125 U/L: 18/184;
◦ Grade 2 (mild) ALT 126
to 250 U/L: 6/184; ATT changed to
liver-friendly regimens;
◦ Grade 3 (moderate) ALT
251 to 500 U/L: 6/184; ATT
changed to liver-friendly regimens;
◦ Grade 4 (severe) ALT >
500 U/L: 2/184; ATT changed to
liver-friendly regimens.
In all ADIH cases from grade 2 sever-
ity, change to liver-friendly regimens
resulted in normalization of liver en-
zymes (mediumduration7days, range
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Table 14. Adverse events (Continued)
3 to 16 days) and the original regimen
was restarted (stepwise) without recur-
rence
• Significant nausea and
vomiting: 19/184
Eth was substituted with E in 3 cases,
solving the problem. In the remain-
ing 16 cases, administration of Eth at
night solved the problem
Of these 19 participants, 8 had drug-
induced hepatotoxicity and 11 had
normal liver function. In these 11 ei-
ther substituting Eth for E or giving
Eth at night resolved the nausea and
vomiting
More than six months ATT
Anastasatu 1993 NR NR NR
Do anay 1995 6 12/72 • 2 nausea and vomiting.
• 10 toxic hepatitis with a
moderate increase in hepatic enzyme
levels. HR were discontinued in these
cases for a short time (3 to 5 days)
and after recovery, reinstituted.
• 2 hearing loss. S was stopped.8
Iype 2014 12 1/43 • 8 paradoxical reactions
(increased size of tuberculoma or
development of new tuberculoma, 2
died)
• 4 hepatitis: 1 at the end of 1st
month; 2 at 4 months; 1 at 7
months. One case of hepatitis led to
discontinuation of ATT at 124 days.
Lau 2005 58 0/166 Skin rash, hearing difficulty, impaired
liver function with elevated ALT, and
blurring of vision
Phuapradit 1987 21 1/28 • 6 participants with 2 to 3-fold
elevation of ALT/AST ± alkaline
phosphatase level (no
discontinuation of ATT) during the
early weeks of treatment.
• 14 participants with
asymptomatic hyperuricemia (90 to
140 mg/L) during the first 2 months
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Table 14. Adverse events (Continued)
of ATT when Z was given, 8 received
probenecid.
• 1 erythema multiforme from Z.
All drugs were discontinued. After
rashes healed, ATT was continued
with HRS with full recovery.
Ramachandran 1989 37 (36*) 37 (36*)/180 • 4 cases according to the 1989
publication (*3 cases according to the
1986 publication) with ocular
complications: ethambutol was
discontinued and PAS substituted,
even though it was clear that the
problem was unrelated to drugs.
• 30 jaundice: R (first study) or
both RZ (second and third studies)
were discontinued while the other
drugs were continued.
• 2 skin reactions: R was stopped
in 1 participant and the participant
recovered completely; all anti-
tuberculosis drugs were withheld for
1 week in the other participant and
the participant recovered fully. The
treatment was resumed uneventfully.
• 1 arthralgia: Z was stopped and
the swelling diminished during the
next 3 weeks. He could not be
followed up further as he died of
TBM.
Ramachandran 1997 18 18/215 13 participants developed jaundice
with abnormal liver function tests
5 participants had an increase in hep-
atic enzymes levels without clinical
jaundice
For these 15 participants: R and Z
were terminated and other drugs were
continued
Sharma 2013a 3 0/42 • 1 drug-induced hepatitis
causing death.
• 2 participants with clinical
jaundice and persistent vomiting who
were converted to daily regimen.
• No other adverse events
reported.
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Table 14. Adverse events (Continued)
Török 2011a 400 155/545 329 non-severe; 71 severe
• Subclinical hepatitis: 92 non-
severe; 0 severe.
• Clinical hepatitis: 9 non-severe;
8 severe.
• Gastrointestinal bleeding: 10
non-severe; 5 severe.
• Bacterial sepsis: 12 non-severe;
7 severe.
• Septic shock: 0 non-severe; 3
severe.
• Brain herniation syndrome: 0
non-severe; 5 severe.
• Decrease in visual acuity: 16
non-severe; 14 severe.
• Hyponatremia: 11 non-severe; 7
severe.
• Hyperglycaemia: 5 non-severe;
0 severe.
• Hypertension: 5 non-severe; 0
severe.
• Vertigo: 39 non-severe; 0 severe.
• Deafness: 8 non-severe; 6 severe.
• Cushing’s features: 12 non-
severe; 0 severe.
• Pruritus: 12 non-severe; 0
severe.
• Polyarthralgia: 5 non-severe; 0
severe.
• Streptomycin reaction: 4 non-
severe; 0 severe.
• Rifampin flu: 7 non-severe; 0
severe.
• Rash: 13 non-severe; 1 severe.
• Other (other events that were
reported fewer than 4 times): 76
non-severe; 15 severe.
ATT was stopped or modified in 143
participants.
Visudhiphan 1989 12 4/51 • 4 participants: elevation of
serum AST/ALT levels à rifampicin
dose decreased to 10 mg/kg/day in 3
participants, and to 8 mg/kg/day in
the 4th participant.
• 8 participants with mild
gastrointestinal disturbances.
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Abbreviations: ALT: alanine transaminase; AST: aspartate transaminase; ATT: antituberculous treatment, E: ethambutol; Eth: ethion-
amide; H: isoniazid; HIV: human immunodeficiency virus; NDD: no disaggregated data; NR: not reported; R: rifampicin; Z:
pyrazinamide
A P P E N D I C E S
Appendix 1. Recommendations of antitubercular regimens for TBM according to different
guidelines
Guidelines and local
practices
Intensive phase Continuation phase
Drugs Duration
(months)
Drugs Duration
(months)
WHO Guidelines.
Treatment of tuberculo-
sis (WHO 2010a)
HRZS 2 HR 7 to 10
WHO
Rapid advice. Treatment
of tuberculosis for chil-
dren (WHO 2010b)
HRZE 2 HR 10
TB CARE I 2014a HRZE 2 HR 4
European Union Stan-
dards for Tuberculosis
Care (Migliori 2012)a
HRZE 2 HR 4
British Infectious Soci-
etyGuidelines (Thwaites
2009)
HRZE 2 HR 10
NICE 2011 HRZ + 4th drug (for ex-
ample, E)
2 HR 10
Clinical Practical Guide-
line on the Diagnosis,
Treatment and Preven-
tion of Tuberculosis
The Spanish Guideline (
CPG 2009)
HRZE 2 HR 10
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(Continued)
SEIP 2008 HRZE
(or HRZS or HRZA)
2 HR 10
American Thoracic
Society 2003
HRZE 2 HR 7 to 10
Technical and Opera-
tional Guidelines for Tu-
berculosis Control, India
(RNTCP 2005)
HRZS 2 HR 6 to 7
National Guidelines on
diagnosis and treatment
of pediatric tuberculosis,
India (RNTCP 2012)
HRZE 2 HR 7b
Department of Health
South Africa 2014
HRZE 2 HR 7
Local official practice
in Cape Town, South
Africa (van Toorn 2014)
HRZEth 6 - 0
IUATLD 2010a HRZE 2 HR 4
Abbreviations: A: amikacin; E: ethambutol; Eth: ethionamide; H: isoniazid; R: rifampicin; S: streptomycin, Z: pyrazinamide; WHO:
World Health Organization; TB: tuberculosis; TBM: tuberculous meningitis.
aGeneral recommendations for TB treatment. There is no specific mention regarding TBM treatment.
bA further extension may be done for 3 more months on a case-to-case basis in case of delayed response and as per the discretion of the
treating physician.
Appendix 2. Detailed search strategy
Medline (Pubmed)
Search Query
#26 Search (#25) AND #12 Field: Title/Abstract
#12 Search (#11) OR #9 Field: Title/Abstract
#25 Search (#24) OR #23 Field: Title/Abstract
#23 Search “Prospective Studies”[mesh] Field: Title/Abstract
#24 Search ((((#20) OR #19) OR #18) OR #15) OR #14 Field: Title/Abstract
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(Continued)
#14 Search “Cohort Studies”[Mesh] Field: Title/Abstract
#18 Search “Controlled Clinical Trial” [Publication Type] Field: Title/Abstract
#15 Search cohort Field: Title/Abstract
#19 Search “Randomized Controlled Trial” [Publication Type] Field: Title/Abstract
#20 Search Random* or placebo* or “single blind*” or “double blind*” or “ triple blind* ” Field: Title/Abstract
#22 Search “Prospective Studies”[Majr] Field: Title/Abstract
#9 Search (#8) AND #7 Field: Title/Abstract
#11 Search “Tuberculosis, Meningeal”[Majr] Field: Title/Abstract
#8 Search Brain OR mening* OR cerebral OR neurological Field: Title/Abstract
#7 Search (#6) OR “Tuberculosis”[Majr] Field: Title/Abstract
#6 Search tubercul* Field: Title/Abstract
#3 Search “Tuberculosis”[Majr]
Embase (OVID)
Search Query
1 tuberculosis/
2 limit 1 to human
3 tubercul*.ab. or tubercul*.ti.
4 limit 3 to human
5 2 or 4
6 (Brain or mening* or cerebral or neurological).ab. or (Brain or mening* or cerebral or neurological).ti
7 5 and 6
8 tuberculous meningitis/
9 limit 8 to human
10 7 or 9
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(Continued)
11 cohort analysis/
12 prospective study/
13 controlled clinical trial/
14 randomized controlled trial/
15 11 or 12 or 13 or 14
16 (Random* or placebo* or single blind* or double blind* or triple blind*).ab. or (Random* or placebo* or single blind* or
double blind* or triple blind*).ti
17 15 or 16 )
18 10 and 17
Cochrane library
ID Search Hits
Search Query
#1 tubercul* ti,ab,kw (Word variations have been searched)
#2 MeSH descriptor: [Tuberculosis] explode all trees
#3 Brain or mening* or cerebral or neurological:ti,ab,kw (Word variations have been searched)
#4 #1 or #2
#5 #3 and #4
#6 MeSH descriptor: [Tuberculosis, Meningeal] explode all trees
#7 #5 or #6
LILACS, INDMED, South Asian Database of controlled trials, WHO ICTRP, Clinicaltrials.gov, ProQuest Dissertations and theses,
openSigle:
Tuberculosis AND meningitis
Tuberculosis AND brain
Tuberculosis AND cerebral
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We included studies when most of the participants were followed-up for at least six months after completing antituberculous treatment
(ATT).
We reported on drug toxicity leading to discontinuation or modification of the treatment regimen rather than to discontinuation only.
We anticipated in our protocol that there would be no studies with a direct comparison between short and prolonged ATT, and that it
would therefore be inadequate to assess the risk of bias of the included studies with the Cochrane ’Risk of bias’ assessment tool (Higgins
2011), and the Downs and Black checklist for assessment of methodological quality (Downs 1998). We mentioned in the protocol that
instead, to assess the risk of bias of the single-arm cohort studies, we would assess different items for each outcome: study design, how
the participants were selected, the way the participants were selected, etc. In our review, we have devised a ’Risk of bias’ assessment tool
to appraise the reliability of the outcome data from each study, based on the domains included in the ACROBAT-NSRI tool (Sterne
2016). We believe that this was a more reliable way to assess risk of bias, and the used tool actually includes the items we mentioned
in our protocol.
We stated in our protocol that we would calculate the risk ratio (RR) for dichotomous outcomes and the rate ratio for count data
outcomes, and that we would present the effect estimates with 95% confidence intervals (CIs). This was not possible, as we did not
find any trials that directly compared short versus prolonged course regimens. Therefore, we presented the findings separately from
each group of cohorts.
We did not use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles to assess the quality
of the evidence as originally planned, because this was not possible as already explained in the review. Instead, we assessed the quality
of the evidence descriptively.
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